EpiPedia of HLA - epregistry.com.br · 17RS (preliminary) on HLA-ABC El-Awar et al, Transplantation...

EpiPedia of HLA by

Rene Duquesnoy and Marilyn Marrari University of Pittsburgh Medical Center

First Edition (September 2016)

The EpiPedia of HLA represents a compendium of information about antibody-verified HLA epitopes. It covers the HLA-ABC, DR, DQ, DP and MICA loci and includes reviews of more than 100 publications about HLA epitopes. This document is posted on the International HLA Epitope Registry website http://www.epregistry.com.br which has also detailed information for each antibody-verified epitope. In many cases, these epitopes were experimentally determined with monospecific antibodies either monoclonal antibodies or eluates of allosera absorbed with selected HLA alleles. Such epitopes often can be defined by eplets but there are also variations that correspond to eplets paired with other residue configurations, most of them are self because they are on one or more alleles of the antibody producer. Ideally, epitopes should be defined by monospecific antibodies produced by individuals with known high-resolution HLA types in induced by known mismatched HLA alleles. However, a given epitope can also be identified with sera with two or more antibody specificities provided that the single allele panel has informative alleles that can explain the reactivity with such epitope. The EpiPedia of HLA includes descriptions of epitopes identified with informative antibody reactivity patterns of sera provided by investigators worldwide who had participated in published collaborative studies. Many serum reactivity patterns have been re-analyzed with the updated HLAMatchmaker Antibody Analysis Version 02 which distinguishes between immunizer-specific and third-party antibody-verified eplets and pairs and “other” eplets as candidates for antibody verification. Version 02 which can be downloaded from the HLAMatchmaker website www.epitopes.net has also amino acid residue information helpful in the interpretation of reactivity differences between alleles in the panel. The educational page of the HLAMatchmaker website has now also “Five Maps of HLA Epitopia” that can be downloaded. Antibody verifications of epitopes consider three levels: Confirmed (the data are convincing), Provisional (the data are promising but we would like to see more experimental support) and Preliminary (the evidence is not sufficient enough and more studies are needed). The HLA Epitope Registry will list only antibody-verified epitopes that are classified as Confirmed or Provisional. Classifications will be updated after more experimental evidence has been obtained from histocompatibility testing laboratories willing to share their data. This EpiPedia describes the experimental evidence collected for antibody-verified epitopes corresponding to (1) eplets including a few cases whereby residue variations reflect the so-called Landsteiner-type cross-reactivity and (2) eplet pairs that as shown with molecular models represent combinations of eplets with other amino acid configurations within a radius of about 15 Angstroms, a sufficient distance for making contact with the CDRs of antibody. There are also literature references about antibody-verified epitopes. The EpiPedia represents a work-in-progress as of the issue date. Updates with new information will replace this version on a regular basis.

http://www.epregistry.com.br/

http://www.epitopes.net/

EpiPedia of HLA-ABC

6K2 (provisional) on HLA-ABC

Duquesnoy et al Int J Immunogenetics In press, 2016

Data provided by Stefan Schaub, Basel, Switzerland

First Pregnancy Serum 1stP#186

Antibody Producer A*11:01 A*24:02 B*07:02 B*39:06 C*07:02 C*07:02

Immunizing Haplotype A*03:02 B*27:05 C*01:02

MFI Ep

C*01:02 Immunizer,Inf 7245 6K2

Other HLA-C 68+173 weak rx with 76VRN pair

Positive Control 7002

Negative Control 0

17RS (preliminary) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Alloserum 2005-02583 positive with HLA-A*30:01 (no information on HLA types of antibody producer/immunizer) Equivalent to TerEp #36.

21H (provisional) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Two serum eluates (absorbed with HLA-C*02:02, C*03:03 cells) positive with HLA-C*02:02, C*03:02, C*03:03, C*03:04, C*15:02 (no information on HLA types of antibody producers/immunizers) Equivalent to TerEp #39. Epitope shared also by C*04:03, which was not tested.

41T (confirmed) on HLA-ABC

Duquesnoy R, Marrari M, Mulder A, Claas F, Mostecki J, Balazs I. 2012. Structural Aspects of HLA Class I Epitopes Detected by Human Monoclonal Antibodies. Human Immunology 73: 267-77 Human monoclonal antibody ROU9A6 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A1, A25; B8, B18; Cw7. Immunizer types as HLA-A2; B44, B60; Cw5, w10.

El-Awar et al, Human Immunology 68: 170-180, 2007: Serum eluate W7248.BO (absorbed with B*44:02 cells, no information on HLA types of antibody producer/immunizer) Equivalent to TerEp #21

Fernandez-Vina et al, in Immunobiol of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: ROU9A6 (13-WS 0120) positive with HLA-B*13:01, *13:02, *13:04, *40:01, *40:02, *40:04, *40:06, *40:11, *40:19, *40:30, *41:01, *41:02, *44:02, *44:03, *44:04, *44:21, *45:01, *47:01, *47:02, *47:03, *49:01, *50:01, *50:02 in CDC assays in 13th IHWS.

Post 1st pregnancy serum #233 (Schaub, Basel)

Mother A*02:01 A*23:01 B*15:18 B*51:01

Allele MFI Epitope Epitope

B*40:02 IMM 9647 41T 163EW+66I/N

B*40:06 10787 41T 163EW+66I/N

B*40:01 10547 41T 163EW+66I/N

B*13:02 8552 41T 163EW+66I/N

B*47:01 5358 41T 163EW+66I/N

B*13:01 5221 41T 163EW+66I/N

B*45:01 Informative 10001 41T






B*27:05 7995 163EW+66I/N

A*66:02 7976 163EW+66I/N

B*07:02 11608 163EW+66I/N

B*27:08 9459 163EW+66I/N

B*73:01 8410 163EW+66I/N

B*81:01 7533 163EW+66I/N

B*48:01 5159 163EW+66I/N

73 remaining alleles 171+182

43Q pair on HLA-ABC

43Q+62GER (provisional) Hahn A et al, Transplant Immunology 32: p. 141-143, 2015: A patient on the waiting list for a second transplant had received a kidney from a zero-HLA-A, -B, -DR antigen mismatch deceased donor and the Luminex single antigen assay detected anti-HLA-A2 antibody. Molecular typing showed the patient type as HLA-A*02:02, while the A2 alleles in the Luminex panel consisted of A*02:01, A*02:03 and A*02:06. Epitope-based antibody specificity analysis using the nonself-self paradigm suggested an antibody towards a new eplet pair, 43Q+62GER. Both configurations are self for the patient but each is present on different alleles. The combination is nonself. Please note: This epitope pair is shared by most HLA-A*02 alleles, but not A*02:05, which is included on some Luminex single antigen bead panels.

The two configurations that make up this eplet pair are 10 Ångstroms apart, sufficient distance for contact by two different complementarity determining regions (CDRs).

44KM3 (confirmed) on HLA-ABC

Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibody 8714.TO (12w002) positive with HLA-A1, A36 (r=0.82) in CDC assays in 12th IHWS. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibody Z6879 and human monoclonal antibody VDK 1D12 (13-WK 0003) positive with HLA-A*01:01, *01:03, *36:01 in CDC assays in 13th IHWS. El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody positive with HLA-A*01:01, A*36:01 Equivalent to TerEp #1.

44RMA (confirmed) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting

with antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print], 201

El-Awar NR et al, Human Immunology 71: 456-61, 2010:Mouse monoclonal antibody Z3633.T0 (IgM) reacts with HLA-B13, B46, B57, B62, B63, B75, B76, B77 in Luminex single antigen assay. Immunizing cells typed as HLA-A2, A11; B35, B62; Cw4, Cw9. Equivalent to TerEp 43.


Mother A*26:01 A*30:01 B*18:01 B*38:01

MFI Epitope Epitope

B*15:01 Imm 12245 44RMA 163LW

B*15:02 11877 44RMA 163LW

B*15:13 9703 44RMA 163LW

B*15:11 5869 44RMA 163LW

B*46:01 5794 44RMA 163LW

B*15:16 9345 44RMA 163LW

B*57:03 8781 44RMA 163LW

B*57:01 9117 44RMA 163LW

B*13:01 Informative 6347 44RMA



B*15:03 10973 163LW

B*15:10 8885 163LW

B*35:01 4976 163LW

B*49:01 9776 163LW

B*50:01 9496 163LW

B*51:01 1072 163LW

B*51:02 5101 163LW

B*52:01 4356 163LW

B*53:01 3911 163LW

B*56:01 4091 163LW

B*58:01 2721 163LW

B*78:01 2005 163LW

C*03:03 3075 163LW

C*03:04 2848 163LW

C*03:02 4268 163LW

41 remaining HLA-B,C alleles 76+117

44RT (provisional) on HLA-ABC

l-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Mouse monoclonal antibody FN3814-3E1G4 positive with HLA-B*18:01, B*35:01, B*37:01, B*51:01, B*51:02, B*52:01, B*53:01, B*58:01, B*78:01 Equivalent to TerEp #35.

44RT pair on HLA-ABC

44RT+65QIT (provisional) Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting

with antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print], 2016

El-Awar et al, Clinical Transplants 2007, pp 169-188: Serum eluate X6101 (absorbed with B*18:01 recombinant single allele cell line) positive with HLA-B18, B35, B37, B51, B52, B53, B78 (no information on HLA types of antibody producer/immunizer) Reacts with 44RT-positive alleles that share also epitope 69TNT, located 11 Ångstroms away. Equivalent to Terasaki epitope #219

Post 1st pregnancy serum #87 (Schaub. Basel)

Mother A*01:01, A*68:01 B*40:01 B*44:02 C*03:04' C*07:04

MFI Epitope Epitope

3 65QIT

1 65QIT

B*35:01 Imm 6814 44RT+65QIT 163LW+65QIT

B*51:01 4787 44RT+65QIT 163LW+65QIT

B*51:02 6951 44RT+65QIT 163LW+65QIT

B*52:01 3266 44RT+65QIT 163LW+65QIT

B*53:01 6097 44RT+65QIT 163LW+65QIT

B*78:01 5893 44RT+65QIT 163LW+65QIT

B*18:01 Informative 3618 44RT+65QIT

B*37:01 Informative 2759 44RT+65QIT

B*58:01 Informative 566 44RT+65RNA 163LW+65RNA

B*15:01 1843 163LW+65QIT

B*15:02 3444 163LW+65QIT

B*15:03 2260 163LW+65QIT

B*15:10 1803 163LW+65QIT

B*15:11 1257 163LW+65QIT

B*15:13 1597 163LW+65QIT

B*49:01 1861 163LW+65QIT

B*50:01 2006 163LW+65QIT

B*56:01 704 163LW+65QIA

B*57:01 593 163LW+65RNA

B*57:03 504 163LW+65RNA

B*15:16 689 163LW+65RNA

C*03:02 9 163LW+65QKR

C*03:03 7 163LW+65QKR

C*03:04 self 2 163LW+65QKR

29 remaining HLA-B alleles 149+350


Mother A*32:01 A*32:01 B*15:01 B*38:01

Allele MFI Epitope

Pos cont 7861

Neg cont 1

B*51:01 IMM 8272 44RT+65QIT

B*51:02 8190 44RT+65QIT

B*78:01 7870 44RT+65QIT

B*35:01 6967 44RT+65QIT

B*53:01 6354 44RT+65QIT

B*18:01 3711 44RT+65QIT

B*52:01 3309 44RT+65QIT

B*37:01 1967 44RT+65QIT

B*58:01 9 44RT+65RNA

41 HLA-B alleles 128+333

56R (confirmed) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with

antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print], 2016

El-Awar N et al, Transplantation 84: 532-540, 2007 (no MFI values): Alloserum 2002-01731 positive with HLA-A*30:01, A*31:01 (no information on HLA types of antibody producer/immunizer) Equivalent to TerEp #31. El-Awar N et al, Human Immunology 71: 456-461, 2010 (no MFI values): Mouse monoclonal antibody 0273HA (IgM) produced by immunization with cells that type as HLA-A31; B62; Cw1, Cw10 is positive with HLA-A30:01, A*30:02, A*31:01 in Luminex single bead assay. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibody CHL-129.11 (12w038) positive with HLA-A30, A31 (r=0.85) in CDC assays in 12th IHWS. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibody TER.M.A3031 (10w2050) positive with HLA-A30, A31 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody shows extra reactions with lymphoblastoid cell lines. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibody TER.M.A3031 (10w2050) positive with HLA-A30, A31 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.


Mother A*01:01 A*02:01 B*35:03 B*40:01

Epitope Epitope*

A*30:01 IMM 5769 56R

A*30:02 5784 56R

A*31:01 5572 56R

A*23:01 2609 82LR

A*24:02 3760 82LR

A*24:03 3633 82LR

A*25:01 8024 82LR

A*32:01 5050 82LR

23 remaining HLA-A allleles 15+11

* On Immunizing B*51:01

62EE (provisional) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Mouse monoclonal antibody Z5571.I0 positive with HLA-A*23:01, A*24:02, A*24:03, A*80:01 Equivalent to TerEp #28. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Human monoclonal antibody BVK5C4 (13-WS 0047) reacts with HLA-A*23:01, *24:02, *24:06, *24:07, *24:17, *24:20, *24:27, *80:01 in CDC assays in 13th IHWS. Only one of four informative HLA-A*24:03 cells was positive in CDC assays.

62GE (confirmed) on HLA-ABC

Human monoclonal antibodies from Arend Mulder (Leiden): (See Mulder et al, J Immunology 175: 5950-5957, 2005)

ROU2D3 (IgM): Antibody producer A1, A25; B8, B18; Cw7. Immunizer A2; B*44, B60; Cw5, Cw10

SN230G6 (IgG) Antibody producer A24, A29; B7, B44, Cw7. ImmunerA2; B57.

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X4632 (absorbed with B*58:01 cells) positive with HLA-A*02:01, A*02:03, A*02:06, B*57:01, B*57:03, B*58:01 (no information on HLA types of antibody producer/immunizer) Equivalent to TerEp #17. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: ROU2D3 (13-WS 0025), SN230G6 (13-WS 0024), WIM1B3 (13-WS 0026) positive with HLA-A**02:01, *02:02, *02:03, *02:04, *02:05, *02:06, *02:07, *02:11, *02*12, *02:17, *02:35, *02:36, *02:49, B*57:01, *58:02 in CDC assays in 13th IHWS. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: mAb HO-2 (12w043) positive with HLA-A2, B57, B58 (r=0.86) in CDC assays in 12th IHWS.

ROU2D3 tested in Luminex-C1q assay WIM1B3 (IgM): Antibody producer A3; B47, B51; Cw6. Immunizer unknown

62GK2 (confirmed) on HLA-ABC

Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibody MAD.148 (10w2030) positive with HLA-A2 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody is weak with PBL and has extra reactions with A3-, A29- and A32-positive lymphoblastoid cell lines. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibody MAD148 (10w2030) positive with HLA-A2 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Reacts also with A3-, A29- and A31-positive lymphoblastoid cell lines. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibody 8710.TO (12w007) positive with HLA-A2 in CDC assays in 12th IHWS. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibodies X7849, Z1165 positive with HLA-A*02:01, *02:02, *02:03, *02:04, *02:05, *02:06, *02:07, *02:11, *02:12, *02:17, *02:35, *02:36, *02:49 in CDC assays in 13th IHWS. El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody S8043 positive with HLA-A*02:01, A*02:03, A*02:06 Equivalent to TerEp #201.

62GRN (confirmed) on HLA-ABC

Human monoclonal antibody SEE5G7 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy (no information on HLA types of antibody producer/immunizer).

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Multiple mouse monoclonal antibodies and one alloserum positive with HLA-B*57:01, B*57:03, B*58:01 (no information on HLA types of antibody producer/immunizer) Equivalent to TerEp #236. Mulder et al, Human Immunology 56: 106-113, 1997: Human monoclonal antibody VN2F1 positive with HLA-B57, B58 in ELISA and CDC assays (no information on HLA types of antibody producer/immunizer). Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Antibody VN2F1 (12w062) positive with HLA-B57, B58 (r=0.78) in CDC assays in 12th IHWS.

62LQ (confirmed) on HLA-ABC

Human monoclonal antibody DK1G8 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A1, A2; B8, B27; Cw2, Cw7. Immunizer types as HLA-A29, A34; B38, B45; Cw6.

Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibody LA3 2F5 (12w036) positive with HLA-A29, A43 (r=0.80) in CDC assays in 12th IHWS. El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody X5518.TO positive with HLA-A*29:01, A*20:02, A*43:01. Equivalent to TerEp #5.

62LQ pair on HLA-ABC

62LQ+163T (preliminary) Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on

HLA class I alleles reacting with antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print], 201



Second Pregnancy 2ndP#95


Immunizing Allele A*29:02

MFI

Allele RX Enter Ep

A*29:01 2788 62LQ+s163T 163T is self for A*03:01 and 7.5 Ang away

A*29:02 Imm 2480 62LQ+s163T

A*43:01 78 (62LQ+163R)

Self alleles 3+5

Other alleles N=86 3+4

Pos Cont 9008

Neg cont 0

62QE pair on HLA-ABC

62QE+s56G (confirmed) Human monoclonal antibody OK2H12 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A28; B7, B27; Cw2, Cw7. Immunizing haplotype is HLA-A3; B70. See also Duquesnoy et al, Human Immunology 66: 749-761, 2005. Reacts only with 62QE-positive alleles that also share self residue 56G, located 8 Ångstroms away.

Antibody has unexplained weak positive reactions with HLA-B*57:01, B*57:03 and B*58:01 (MFI range 1123-1999). Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, John A. Hansen (Ed), pp 890-931, 2006: OK2H12 (13-WS 0063) reacts with HLA-A*01:01, *01:03, *03:01, *03:02, *03:05, *03:06, *03:09, *11:01, *11:02, *11:03, *32:01, *32:04, *36:01, *74:01, *74:03, *74:06 in CDC assays in 13th IHWS. Mulder et al, Human Immunology 56: 106-113, 1997: OK2H12 reacts with HLA-A1, A3, A11, A32 in ELISA assays (no A36 tested, unknown if A74 was tested); reacts with HLA-A1, A3, A11, A32, A36 in CDC assays (unknown if A74 was tested).

62QE+151H (preliminary) El-Awar et al, Human Immunology 71: 456-461, 2010 (no MFI values): Mouse monoclonal antibody X8342.H0 (IgM) produced by immunization with cells that type as HLA-A1; B13, B64; Cw6, Cw8 is positive with HLA-A*01:01, A*03:01, A*11:01, A*11:02, A*36:01 Reacts with 62QE-positive alleles that share also epitope 151H. Equivalent to TerEp #248.

62RNR (preliminary) on HLA-ABC

El-Awar N et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate Z3044 (absorbed with A*69:01 cells) positive with HLA-A*25:01, A*26:01, A*33:01, A*33:03, A*34:01, A*66:01, A*66:02, A*68:01, A*68:02, A*69:01. Equivalent to TerEp #214.

62RR (provisional) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Mouse monoclonal antibody FC1043-6B4D1B9 (absorbed with A*25:01 cells) positive with HLA-A*25:01, A*26:01, A*33:01, A*33:03, A*34:01, A*66:01, A*66:02, A*68:01, A*68:02, A*69:01, B*15:16 Equivalent to TerEp #243.

Post allograft nephrectomy serumZ Atwi, Nehlsen-Cannarella (Detroit, Mich)

Patient A*02:05 A*32:01 B*07:06 B*40:02

Allele MFI Ep

A*68:01 Imm 2415 62RR

A*68:02 3513 62RR

A*66:01 2546 62RR

A*66:02 1872 62RR

A*34:02 1823 62RR

A*33:03 1649 62RR

A*25:01 1487 62RR

A*69:01 1426 62RR

A*26:01 1394 62RR

A*34:01 1325 62RR

A*33:01 919 62RR

B*15:16 1081 62RR

A*30:01 Imm 1519 56R

A*30:02 512 56R

A*31:01 564 56R

A*32:01 Self 119

All self alleles 176+70

15 remaining HLA-A 305+197

Neg Cont 93

Pos Cont 15288

Post allograft nephrectomy serum KE, Chrenova (Bratislava, Slovakia)

Patient: A*01:01A*02:01 B*08:01 B*27:05 C*02:02 C*07:01

Allele MFI Ep Comment

A*68:01Imm 10811 62RR has 63N

A*25:01 4232 62RR has 63N

A*26:01 3954 62RR has 63N

A*33:01 8131 62RR has 63N

A*33:03 7106 62RR has 63N

A*34:02 8603 62RR has 63N

A*66:01 8722 62RR has 63N

A*66:02 7413 62RR has 63N

A*68:02 8216 62RR has 63N

A*69:01 8951 62RR has 63N

B*15:16 2444 62RR has 63E

A*01:01 Self 344

A*02:01 Self 242


18 Remaining HLA-A 318+89

Neg Cont 224

Pos Cont 13272

65GK (confirmed) on HLA-ABC

Human monoclonal antibody from Arend Mulder (Leiden):

IND3H3 (IgG) Antibody producer types as HLA-A1, A32; B8, B51; Cw1, Cw7. Immunizer types as HLA-A3, A23; B35, B50; Cw4, Cw6.

VIE6C10 (IgG) Antibody producer types as HLA-A2, A33; B7, B62; Cw7, Cw10. Immunizer unknown

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody Z1238.TO positive with HLA-A*23:01, A*24:02, A*24:03. Equivalent to TerEp #3. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies HA9 (10w2060) and HU49 (10w2061) positive with HLA-A9 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody HA9 is very weak with PBL. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies HA9 (10w2060) and HU49 (10w2061) positive with HLA-A23, A24 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.

65QIA (confirmed) on HLA-ABC

Human monoclonal antibody VTM4D9 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A25, A29; B44, B62; Cw5. Immunizing haplotype is HLA-A1; B7; Cw7.

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate Z6331.00 (absorbed with B*81:01 cells) positive with HLA-B*07:02, B*27:05, B*27:08, B*42:01, B*54:01, B*55:02, B*56:01, B*67:01, B*73:01, B*81:01, B*82:01 (no information on HLA types of antibody producer/immunizer). Equivalent to TerEp #229.Epitope is not shared by HLA-B*07:03. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibody K53 (12w046) positive with HLA-B7, B27, B42, B54, B55, B56, B67, B73, B81 (r=0.85) in CDC assays in 12th IHWS. No B*07:03 cells tested.

Post 2nd pregnancy serum #364 (Schaub, Basel)

Mother A*02:01 A*02:01 B*44:02 B*49:01


B*27:05 Imm 11790 65QIA 163EW+66I/N

B*07:02 10299 65QIA 163EW+66I/N

B*27:08 12034 65QIA 163EW+66I/N

B*81:01 7882 65QIA 163EW+66I/N

B*73:01 5323 65QIA 163EW+66I/N

B*67:01 Informative 9343 65QIA






B*40:02 10246 163EW+66I/N

B*40:06 8080 163EW+66I/N

B*40:01 7795 163EW+66I/N

B*13:02 7301 163EW+66I/N

B*48:01 3716 163EW+66I/N

B*13:01 3508 163EW+66I/N

B*47:01 1558 163EW+66I/N

A*66:02 11032 163EW+66I/N


65QIA pairs on HLA-ABC

65QIA+s76ESN (provisional) Human monoclonal antibody MUL9F4 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A25; B18, B51; Cw12, Cw15. Immunizer types as HLA-A11; B55; Cw1.

Additional moderate positive reaction (MFI=3233) with B*39:01 on OL kit only. Reacts only with 65QIA-positive alleles that also share self epitope 76ESN, located 13 Ångstroms away.

PANEL OL MFI GP MFI

Positive control nt nt

Negative control 1 10

65QIA+/76ESN+ B*07:02 8267 2548

65QIA+/76ESN+ B*27:08 10474 2036

65QIA+/76ESN+ B*42:01 10079 2212

65QIA+/76ESN+ B*54:01 8499 2793

Immunizing allele: 65QIA+/76ESN+ B*55:01 9157 2041

65QIA+/76ESN+ B*56:01 9840 1874

65QIA+/76ESN+ B*67:01 9318 nt

65QIA+/76ESN+ B*81:01 11072 1731

65QIA+/76ESN+ B*82:01 11026 nt

65QIA+/76ESN+ B*82:02 nt 2563

65QIA+ B*27:03 nt 7

65QIA+ B*27:05 117 21

65QIA+ B*73:01 4 11

Self Alleles 14 ± 20 12 ± 16

Other 65QIA-negative Alleles 71 ± 374 11 ± 4

65QKR+76VS (provisional) Human monoclonal antibody WK4C11 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A1; B8; Cw7. Immunizer types as HLA-A*02, A*11; B*14:02, B*27:05; C*01, C*08.

PANEL OL MFI GP MFIPositive control nt ntNegative control 1 9 B*46:01 11780 3944 65QKR+76VS

C*01:02 Imm 12898 7179 65QKR+76VS

C*03:02 11126 nt 65QKR+76VS

C*03:03 13265 10082 65QKR+76VS

C*03:04 14200 10269 65QKR+76VS

C*07:02 5681 108 65QKR+76VS

C*08:01 11291 11005 65QKR+76VS

C*08:02 nt 9021 65QKR+76VS

C*12:02 nt 10827 65QKR+76VS

C*12:03 11187 nt 65QKR+76VS

C*14:02 10367 8492 65QKR+76VS

C*16:01 10029 1975 65QKR+76VS

C*02:02 1028 9 65QKR+76VN

C*04:01 83 4 65QKR+76VN

C*04:03 nt 11 65QKR+76VN

C*05:01 1794 11 65QKR+76VN

C*06:02 337 3 65QKR+76VN

C*17:01 158 10 65QKR+76VN

C*18:01 nt 10 65QKR+76VN

C*18:02 582 nt 65QKR+76VN

Self Alleles 29 ± 32 261 ± 446

Other Alleles 369 ± 1262 25 ± 61

65RNA pairs on HLA-ABC

65RNA+80I (provisional) .Human monoclonal antibody HDG41B1 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A24; B7, B60; Cw7, Cw10. Immunizer types as HLA-A2, A32; B7, B35; Cw4, Cw7. See also Mulder et al, Human Immunology 56: 106-113, 1997.

Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, John A. Hansen (Ed), pp 890-931, 2006: HDG41B1 (13-WS 0149) reacts with HLA-A*25:01, A*25:02, A*32:01, A*32:04, B*15:16, B*15:17, B*57:01, B*57:02 B*57:03, B*58:01, B*58:02 in CDC assays in 13th IHWS.

Allele OL MFI GP MFI Epitope

Positive control 10144 10718

Negative control 10 334

A*32:01 Imm 20157 12337 65RNA+80I

A*25:01 20769 8715 65RNA+80I

B*15:16 18565 14272 65RNA+80I

B*57:01 10931 8210 65RNA+80I

B*57:03 15821 nt 65RNA+80I

B*58:01 10006 12586 65RNA+80I

23 Alleles 96+425 328+26 65RNA+80T

Self Alleles 12 ± 5 335 ± 53Other alleles 14 ± 7 351 ± 53

66IF pairs on HLA-ABC

66IF+163TEW (provisional) Reacts with 66IF-positive alleles that share also epitope 163TEW, located 15 Ångstroms away. Equivalent to TerEp #225.

El-Awar et al, Human Immunology 71: 456-461, 2010 (no MFI values): Mouse monoclonal antibody 0059HA produced by immunization with cells that type as HLA-A26; B8; Cw7 is positive with HLA-B*08:01, B*59:01. El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate RGF38 (absorbed with B*08:01 cells) positive with HLA-B*08:01, B*59:01 (no information on HLA types of antibody producer/immunizer)

66NV on HLA-ABC (provisional)


Data provided by Stefan Schaub, Basel, SwitzerlandSecond Pregnancy Serum #102


Immunizing Allele A*03:01 Serum has antibodies against 161Dand 76VDT and the newly antibody-defined 66NV

Allele Im MFI Ep 1 Ep 2 Ep 3

A*03:01 Imm 13090 161D 76VDT 66NV

A*02:01 1935 76VDT

A*02:03 2616 76VDT

A*02:06 2541 76VDT

A*11:01 4117 76VDT 66NV

A*11:02 3481 76VDT 66NV

A*68:01 4313 76VDT 66NV

A*68:02 3036 76VDT 66NV

A*69:01 522 76VDT 66NV

A*30:01 2777 76VDT 66NV

A*31:01 4982 76VDT 66NV

A*33:01 2229 76VDT 66NV

A*33:03 4077 76VDT 66NV

A*34:02 4218 76VDT 66NV

A*66:01 1000 76VDT 66NV

A*66:02 3264 76VDT 66NV

A*74:01 4769 76VDT 66NV

A*34:01 1208 76VDT

A*25:01 1177 66NV informative








Self 1+0

Others N=68 26+78

Pos Cont 10347

Neg Cont 0


Data provided by Stefan Schaub, Basel, SwitzerlandSecond PregnancySerum #364

Antibody Producer A*02:01 A*02:01 B*44:02 B*49:01 C*05:01


Allele MFI Ep1 Ep2 Ep Ep

A*11:01IMm 9136 144KR 163R 138MI 66NV

A*11:02 9283 144KR 163R 138MI 66NV

A*03:01 7442 144KR 138MI 66NV

A*80:01 5743 144KR 138MI 66NV

A*36:01 10391 144KR 138MI

A*01:01 9670 144KR 163R 138MI

A*24:03 9755 144KR 138MI

A*24:02 9085 144KR 138MI

A*66:01 11036 163R 138MI 66NV

A*43:01 10327 163R 138MI 66NV

A*26:01 10171 163R 138MI 66NV

A*25:01 9439 163R 138MI 66NV

A*29:01 6713 138MI 66NV

A*29:02 6731 138MI 66NV

A*30:01 7820 138MI 66NV

A*30:02 7680 138MI 66NV

A*31:01 9529 138MI 66NV

A*32:01 8769 138MI 66NV

A*33:01 8268 138MI 66NV

A*33:03 8926 138MI 66NV

A*66:02 11032 138MI 66NV

A*74:01 6620 138MI 66NV

A*23:01 6265 138MI

A*34:01 10944 138MI

A*34:02 9970 138MI

A*68:02 10510 66NV Informative



A*02:06 304

A*02:01 58

A*02:03 42

Self Alleles 15+29


Negative Control 65

69AA (confirmed) on HLA-ABC

El-Awar N et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X0786.00 (absorbed with B*58:01 and B*55:02 cells) positive with HLA-B*07:02, B*15:16, B*27:05, B*27:08, B*42:01, B*54:01, B*55:02, B*56:01, B*57:01, B*57:03, B*58:01, B*67:01, B*73:01, B*81:01, B*82:01 Equivalent to TerEp #224.

69AA pairs on HLA-ABC

69AA+65QI (provisional)

69AA+76E (provisional)

6

Human mAb VTM9A1C from Arend Mulder (Leiden)

Ab Prod A*2501 A*2902 B*4402 B*15:01

Allele OL MFI GP MFI Epitope

Neg cont 5 87

Pos cont 11034 15687

B*07:02 Imm 10674 17798 69AA+65QI

B*27:05 11837 17072 69AA+65QI

B*27:08 14587 17655 69AA+65QI

B*42:01 15186 18440 69AA+65QI

B*54:01 8944 17210 69AA+65QI

B*55:01 15124 17984 69AA+65QI

B*56:01 7397 13257 69AA+65QI

B*67:01 10752 nt 69AA+65QI

B*73:01 9252 1763 69AA+65QI

B*81:01 12193 15465 69AA+65QI

B*82:01 11026 11123 69AA+65QI

B*15:16 306 1003 69AA+65RN

B*57:01 809 263 69AA+65RN

B*57:03 490 nt 69AA+65RN

B*58:01 366 781 69AA+65RN

69AA-neg alleles 26+11 82+28

Human mAb MUL9E11 from Arend Mulder (Leiden)

Ab producer A*02:01 A*25:01 B*18:01 B*51:01

Allele OL GP Epitope

Neg Cont 3 138

Pos Cont 7002 15102

B*55:01 Imm 14378 18201 69AA+76E

B*07:02 10286 17103 69AA+76E

B*15:16 13067 12306 69AA+76E

B*27:05 3242 2348 69AA+76E 80T effect?

B*27:08 12928 12130 69AA+76E

B*42:01 13463 17868 69AA+76E

B*54:01 14807 18050 69AA+76E

B*56:01 14770 17386 69AA+76E

B*57:01 10091 10466 69AA+76E

B*57:03 13218 nt 69AA+76E

B*58:01 8121 14141 69AA+76E

B*67:01 9611 nt 69AA+76E

B*81:01 14536 10489 69AA+76E

B*82:01 15919 18267 69AA+76E

B*73:01 NEG 43 110 69AA+76V

69AA-neg alleles 57+156 89+33

69TNT (provisional) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate Z7227.00 (absorbed with B*13:01 cells) positive with HLA- B*08:01, B*13:01, B*14:01, B*14:02, B*15:01, B*15:02, B*15:03, B*15:10, B*15:12, B*15:13, B*18:01, B*35:01, B*37:01, B*38:01, B*39:01, B*39:05, B*40:01, B*40:02, B*40:05, B*41:01, B*44:02, B*44:03, B*45:01, B*47:01, B*48:01, B*49:01, B*50:01, B*51:01, B*51:02, B*52:01, B*53:01, B*59:01, B*78:01 Equivalent to TerEp # 22

69TNT pairs on HLA-ABC

69TNT+80N (provisional) El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X4715.D0 (absorbed with B*45:01 cells) positive with HLA-B*08:01, B*14:01, B*14:02, B*15:01, B*15:02, B*15:03, B*15:10, B*15:12, B*18:01, B*35:01, B*39:01, B*39:05, B*40:01, B*40:02, B*40:05, B*41:01, B*45:01, B*48:01, B*50:01, B*78:01 (no information on HLA types of antibody producer/immunizer) Reacts with 69TNT-positive alleles that share also epitope 80N, located 16 Ångstroms away. Equivalent to TerEp #227

70IAQ (provisional) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate Z9009.A0 (absorbed with B*82:01 cells) positive with HLA-B*07:02, B*42:01, B*54:01, B*55:02, B*56:01, B*67:01, B*81:01, B*82:01 Equivalent to TerEp #402.


Mother A*01:01 A*02:01 B*40:02 B*57:01

C*02:02"C*06:02

Allele MFI Epitope Effect of

B*07:02 IMM 3379 70IAQ 143T147W

B*55:01 9334 70IAQ 143T147W

B*54:01 9008 70IAQ 143T147W

B*82:01 5246 70IAQ 143T147W

B*56:01 3810 70IAQ 143T147W

B*42:01 2968 70IAQ 143T147W

B*67:01 2606 70IAQ 143T147W

B*81:01 966 70IAQ 143S147L

73 other HLA-A,B alleles 23+63

Serum reacted also with 73VRN on HLA-C and B46, B73

71ATD (confirmed) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Multiple mouse monoclonal antibodies positive with HLA-B*27:05. Equivalent to TerEp #406

71SA (provisional)

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody Z1203.TO positive with HLA-B*15:16, B*57:01, B*57:03, B*58:01. Equivalent to TerEp #207

71TTS (provisional) on HLA-ABC

Human monoclonal antibody DMS4G2 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Mother types as HLA-A3, A68; B7, B51; Cw7. Father types as HLA-A2, A29; B35, B62; Cw4.I it not known whether B*15:01 or B35:01 ids the immunizing allele

Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: DMS4G2 (13-WS 0137) reacts with HLA-B*08:04, *15:01, *15:02, *15:03, *15:04, *15:05, *15:07, *15:10, *15:12, *15:18, *15:20, *15:25, *15:27, *15:30, *15:31, *15:32, *15:35, *15:39, *15:65, *15:70, *18:01, *18:02, *18:03, *18:04, *18:05, *35:20, *39:01, *39:02, *39:08, *40:01, *40:02, *40:02, *40:06, *40:10, *40:11, *40:30, *41:01, *41:02, *45:01, *47:02, *48:01, *48:07, *50:01, *50:02 in CDC assays in 13th IHWS, but weak/negative CDC reactions with cells bearing Luminex-positive alleles B*08:01, *14:01, *14:02, *15:02, *15:11, *35:01, *35:08, *78:01 (B*07:03, *14:05, *14:06 not tested).

73AN (provisional) on HLA-ABC

Rejected kidney transplant serum ND11, Schoenemann(Berlin, Germany)

Patient type

A*24:08 A*30:01 B*08:01 B*44:02 C*07:01 Immunizing Allele: C*04:01

C*04:01 Imm 7454 73AN

C*18:02 8374 73AN

C*06:02 10172 73AN

C*17:01 9671 73AN

C*05:01 818

C*03:02 316

C*03:03 298

C*03:04 362

C*01:02 533

C*14:02 720

C*02:02 384

C*15:02 311

C*08:01 235

C*07:02 313

C*12:03 269

C*16:01 272

self-HLA - 204+15

73TVS (preliminary) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Serum eluate A6 (absorbed with C*01:02 cells) positive with HLA-B*46:01, C*01:02, C*03:02, C*03:03, C*03:04, C*08:01,C*14:02, C*16:01 Equivalent to TerEp#421.

73TVN (provisional) on HLA-ABC

This post-allonephrectomy serum came from a patient WOJ at UPMC who typed as A*25:01, A*68:01; B*35:01, B*53:01; C*04:01, C*06:02 had A*02:01-induced antibodies reacted with 62GE and B*04:01-induced antibodies reacted with 163EW+self-73TE (see 163EW+73TE report). The C*03:03-induced antibodies reacted with all 73TVN-carrying alleles. The 73AVN-carrying C*07:02 and C*12:03 were considered non-reactive. 73TVN is related to the well-defined 76VN epitope but it requires 73T which is 3 Angstroms from 76V as an essential component

Epitope

C*03:03 Imm 6705 73TVN

C*03:02 7621 73TVN

C*03:04 6390 73TVN

C*08:01 5134 73TVN

B*46:01 4907 73TVN

C*14:02 4662 73TVN

C*01:02 4384 73TVN

C*16:01 3450 73TVN

B*73:01 5960 73TVN

C*07:02 1077 73AVN

C*12:03 823 73AVN

C*04:01 self 482

C*06:02 self 369

C*05:01 460

C*18:02 368

C*15:02 341

Post-allograft nephrectomy serum Tagoy (Iniotaki, Athens, Greece)

HLA type of antibody producer

A*24:04 A*31:01 B*44:03 B*35:01 C*04:01

C*01:02 Imm 11799 73TVN 77S

C*03:02 10771 73TVN 77S

C*08:01 6935 73TVN 77S

C*03:03 6751 73TVN 77S

C*03:04 5969 73TVN 77S

B*46:01 5130 73TVN 77S

C*14:02 4564 73TVN 77S

C*16:01 3307 73TVN 77S

B*73:01 1187 73TVN 77G

C*12:03 945 73AVN

C*07:02 713 73AVN

C*04:01 self 281

C*15:02 505

C*05:01 430

C*17:01 361

C*18:02 346

C*06:02 345

C*02:02 318

76ANT (provisional) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X9288.OO (absorbed with A*29:02 cells) positive with HLA-A*01:01, A*26:01, A*29:01, A*29:02, A*36:01, A*43:01, A*80:01 Equivalent to TerEp#15.


Mother A*24:02' A*32:01 B*35:03 B*44:29

C*05:01; C*12:03 C*12:03


A*01:01 IMM 11998 90D 76ANT

A*26:01 13077 90D 76ANT

A*36:01 11871 90D 76ANT

A*43:01 12957 90D 76ANT

A*80:01 12508 90D 76ANT

A*11:01 12113 90D 76ANT

A*11:02 11764 90D

A*25:01 12680 90D

A*34:01 13187 90D

A*34:02 12487 90D

A*66:01 13734 90D

B*73:01 14956 90D

C*04:01 2145 90D

C*06:02 10851 90D

C*07:02 IMM 7107 90DC*18:02 8541 90D

A*29:01 Informative 8029 76ANT

A*29:02 Informative 7332 76ANT

14 informative 79GT alleles 814+562 (weak)

4 remaining HLA-A alleles 151+299

76EG (provisional) on HLA-ABC

In the MERFAT serum, note that the 76EG-specific antibody response to A*30:02 was made by a patient who typed as A*30:01. There were also A*11:01-induced antibodies were specific for 163RW

Post allograft nephrectomy serum GERPAU, Cesbron (Nantes, France)

Patient HLA type: A*02:01 A*24:02 B*15:01 B*27:05

Im Score MFI Ep

A*30:02 Imm 3863 76EG

A*30:01 347

A*31:01 Imm 267

A*24:02 self 185

A*02:01 self 146


Remaining HLA-A alleles (N=26) 212+107

Neg Cont 106

Pos Cont 10027

Post allograft nephrectomy serum MERFAT, Cesbron (Nantes, France)

Patient A*29:02 A*30:01 B*07:02 B*51:01C*07:02

Allele Self MFI Ep1 Ep2

A*30:02 Imm 8825 76EG

A*30:01 Self 706A*29:02 Self 703

A*11:01 Imm 3203 163RW

A*25:01 3780 163RW

A*26:01 2329 163RW

A*43:01 2180 163RW

A*66:01 2511 163RW

A*11:02 3140 163RW

All Self Alleles 646+72

Remaining HLA-A (N=22) 818+259

Neg Cont 611

Pos Cont 11611

76ESI (provisional) on HLA-ABC

Vilella R, Yauge J, Vives J. 1983. Monoclonal antibody against HLA-Aw32 + A25. Is HLA-Aw32 an allele with no unique antigenic determinant? Human Immunology 6: 53-62: Mouse monoclonal antibody CATA-1 produced by immunization of BALB/c mouse with lymphocytes from donor who typed as HLA-A1, A32; B7, B37. Antibody reacts with HLA-A25, A32 in CDC assays. Absorption with HLA-A32 platelets removed all reactivity. Nelson K, Bodmer J, Martin A, Navarette C, Strong DM. 1989. Micro EIA and monoclonal antibodies. In Immunobiology of HLA. Histocompatibility Testing 1987, vol I, ed B Dupont, pp. 292-301, New York, USA: Springer-Verlag: Monoclonal antibody TER.M.A2532 (10w2056) positive with HLA-A25, A32 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody has unexplained extra reactions. Kennedy L et al. 1989. In Immunobiology of HLA. Histocompatibility Testing 1987, vol I, ed B Dupont, pp. 301-305, New York, USA: Springer-Verlag: Monoclonal antibody TER.M.A2532 (10w2056) positive with HLA-A25, A32 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody reacts also with A23-, A24-, B27-positive lymphoblastoid cell lines. Fernandez-Vina M, Maiers M, Gutierrez M et al. 2006. In Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Conference, vol. I,ed JA Hansen, pp 890-931, Vogens, Denmark: P.J. Schmidt: Mouse monoclonal antibodies H172 (13-WS 0050), 307-33 (13-WS 0078) positive with HLA-A*25:01, *25:02, *32:01, *32:04 in CDC assays in 13th IHWS.

Post-allograft nephrectomy serum Tagoy (Iniotaki, Athens)

HLA type of antibody producer

A*24:04 A*31:01 B*44:03 B*35:01 C*04:01

Immunizer: unknown

Allele MFI Epitope

A*25:01 8267 76ESI

A*32:01 8204 76ESI

Neg Cont 145

Pos Cont 6029

self alleles 211+72

26 Neg HLA-A alleles 233+218

Epitope: 76ESN (confirmed) on HLA-ABC

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate Z3038 (absorbed with B*41:02 cells) positive with HLA-B*07:02, B*08:01, B*14:01, B*14:02, B*15:01, B*15:02, B*15:03, B*15:10, B*15:12, B*18:01, B*27:08, B*35:01, B*39:01, B*40:01, B*40:02, B*40:05, B*41:01, B*42:01, B*45:01, B*48:01, B*50:01, B*54:01, B*55:02, B*56:01, B*67:01, B*78:01, B*81:01, B*82:01 Equivalent to TerEp #216 Lutz CT, Smith KD, Greazel NS, Mace BE, Jensen DA, McCutcheon JA, Goeken NE. 1994. Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. Journal of Immunology 153: 4099-110 HLA-B7 transfected cells (721.221) with single-point mutations were tested in flow cytometry binding assays using three anti-Bw6 monoclonal antibodies: SFR8-B6 (x), BB7.6 (x), 126-39 (K. Gelsthorpe, Sheffield, England). The variants involving mutations 76E to 76V and 80N to 80T did not affect binding of any of the antibodies. A mutation of 79G to 79R diminished binding of SFR8-B6, but not the other two antibodies.

76VD (preliminary) on HLA-ABC

Post allograft nephrectomy serum

Day, Romano (Hershey, PA)Patient A*25:01 A*29:01 B*15:01 B*44:02

Allele MFI Ep1 Ep2 Ep3

A*11:01 Imm 11987 144K 62QE+s56G 76VD

A*02:03 12575 144K 76VD

A*02:06 12436 144K 76VD

A*11:02 12323 144K 62QE+s56G 76VD

A*69:01 11985 144K 76VD

A*02:01 11756 144K 76VD

A*24:03 8694 144K

A*68:02 7980 144K 76VD

A*03:01 7879 144K 62QE+s56G

A*24:02 7733 144K

A*68:01 7399 144K 76VD

A*01:01 4232 144K 62QE+s56G

A*36:01 3880 144K 62QE+s56G

A*80:01 1818 144K

A*74:01 Imm 6988 62QE+s56G 76VD

A*32:01 4653 62QE+s56G

A*30:01 6772 76VD

A*34:02 6579 76VD

A*31:01 5068 76VD

A*33:03 4962 76VD

A*34:01 4932 76VD

A*66:02 3574 76VD

A*66:01 3466 76VD

A*33:01 2591 76VD

A*43:01 1125

A*30:02 906

A*23:01 709

A*26:01 269

A*29:02 203

A*29:01 Self 118

A*25:01 Self 65


Neg Cont 48

Pos Cont 9996

Post allograft nephrectomy serum14709, Jaramillo (Chicago. IL)

Patient A*23:01 A*30:02 B*53:01 C*04:01

Allele MFI Ep1 Ep 2 Ep3 Ep4

A*02:01 Imm 15936 62GE 76VD 144K 253Q

A*02:03 13398 62GE 76VD 144K 253Q

A*02:06 16421 62GE 76VD 144K 253Q

B*57:01 6889 62GE

B*57:03 8468 62GE

B*58:01 6921 62GE

A*68:01 13787 76VD 144K 253Q

A*68:02 12591 76VD 144K 253Q

A*69:01 9676 76VD 144K 253Q

A*03:01 4478 76VD 144K

A*11:01 6996 76VD 144K

A*11:02 11269 76VD 144K

A*24:03 8525 144K

A*24:02 6623 144K

A*01:01 1790 144K

A*36:01 1523 144K

A*80:01 1051 144K

A*31:01 4949 76VD 253Q

A*33:01 2826 76VD 253Q

A*33:03 5127 76VD 253Q

A*34:01 4615 76VD 253Q

A*34:02 5590 76VD 253Q

A*66:01 3830 76VD 253Q

A*66:02 4128 76VD 253Q

A*74:01 5105 76VD 253Q

A*30:01 3815 76VD

A*30:02 Self 278 (76EN)

A*32:01 2317 253Q

A*25:01 3551 253Q

A*26:01 2563 253Q

A*29:01 4003 253Q

A*29:02 3532 253Q

A*43:01 2556 253Q

B*73:01 2312 253Q

C*07:02 4181 253Q

C*17:01 4956 253Q

A*23:01 Self 345



Neg Cont 194

Pos Cont 10399

76VD pairs on HLA-ABC

76VD+90D (preliminary)

Post allgraft nephrectomy serum edmhb20 , Campbell (Edmonton, Alberta)

Patient type

A*01:01 A*02:01 B*39:01 B*08:01 C*07:01

MFI

A*11:01 Imm 2258 76VD+s90D

A*11:02 4605 76VD+s90D

A*66:01 3497 76VD+s90D

A*34:02 1657 76VD+s90D

Neg Cont 163

Pos Cont 13135

Self Alleles 371+114

24 HLA_A Alleles 267+52

76VRN (confirmed) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


Post 1st Pregnancy serum #177 (Schaub)

Mother A*01:01 A*02:01 B*40:02 B*57:01

C*02:02 C*06:02

MFI Epitope Epitope

C*07:02 IMM 3045 76VRN 267QE

B*46:01 9065 76VRN

B*73:01 13249 76VRN 267QE

C*01:02 8866 76VRN

C*03:02 10259 76VRN

C*03:03 7911 76VRN

C*03:04 7958 76VRN

C*08:01 11695 76VRN

C*12:03 9621 76VRN

C*14:02 9265 76VRN

C*16:01 4906 76VRN

C*17:01 606 267QE

C*02:02 Self 75

C*04:01 56

C*05:01 141

C*06:02 Self 90

C*15:02 82

C*18:02 116

El-Awar et al, Transplantation 84: 532-540, 2007: Alloserum 2002-00142 and serum eluate Z9016.00 (absorbed with C*18:02 cells). Equivalent to TerEp #246.

76VRN pairs on HLA-ABC

76VRN+s152E (preliminary) cross-reactivity with 76VRN+152T/V


Ayelet, Klein (PetaTikva, Israel)

Patient A*02:01 B*44:02 C*05:01

C*16:01 Imm 6163 76VRN

C*07:02 8293 76VRN

C*01:02 3831 76VRN

C*03:02 4408 76VRN

C*03:03 3683 76VRN

C*03:04 5656 76VRN

C*08:01 9662 76VRN

C*12:03 1986 76VRN

C*14:02 5332 76VRN

C*17:01 1429 76VRN

B*46:01 5779 76VRN

B*73:01 5743 76VRN

C*02:02 155

C*04:01 200

C*05:01 Self 197

C*06:02 196

C*15:02 3815

C*18:02 409

Self alleles 124+63

Neg Cont 53

Pos Cont 13365

Post 1st Pregnancy serum #177 (Schaub)

MFI Epitope Epitope

C*07:02 IMM 3045 76VRN 267QE

B*46:01 9065 76VRN

B*73:01 13249 76VRN 267QE

C*01:02 8866 76VRN

C*03:02 10259 76VRN

C*03:03 7911 76VRN

C*03:04 7958 76VRN

C*08:01 11695 76VRN

C*12:03 9621 76VRN

C*14:02 9265 76VRN

C*16:01 4906 76VRN

C*17:01 606 267QE

C*02:02 Self 75

C*04:01 56

C*05:01 141

C*06:02 Self 90

C*15:02 82

C*18:02 116



First Pregnancy 1stP#254


Immunizing allele C*01:02

Allele MFI Ep

C*01:02 Imm 3025 76VRN+s152E

C*03:02 Informative 2065 76VRN+s152E





B*46:01 Informative 2182 76VRN+s152E

C*08:01 Informative 3202 76VRN+152T

B*73:01 Informative 3061 76VRN+152V

Mean+SD 2168+709 76VRN+152E/T/V

C*07:02 Informative 92 (76VRN+152A)

C*16:01 Informative 210 (76VRN+152A)

Self 4+3

Other (N=81) 4+4

Positive control 8855

Negative control 1 HLA-C

76VS + 152RE pairs on HLA-ABC

76VS + s152RE (preliminary) cross-reactivity with 76VS+152RT Duquesnoy R and Marrari M, Transplant Immunology 24: 164-171, 2011:Serum MA submitted by S. Chrenova (Bratislava, Slovakia) to the 15th International Histocompatibility Workshop study on HLA epitope immunogenicity was obtained from a patient who typed as HLA-A3, 11; B35, 51; Cw4, and had rejected a kidney transplant from a one-haplotype mismatched related donor. The serum had antibody reactivity against all the HLA mismatched alleles, including two epitopes on the mismatched donor HLA-C*12:03. Reactivity towards the eplet pair consisting of the donor 76VS and patient self eplet 152RE was observed in the eluate obtained following absorption of the serum with HLA-C*08:02, which has this pair:

79GT (provisional) on HLA-ABC

Duquesnoy et al, International Journal of Immunogenetics,in press 2016:

80I (confirmed) on HLA-ABC

Human monoclonal antibody KAL3D5 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A1, A26; B8, B27; Cw1, Cw7. Immunizer types as HLA-A1, A2; B8, B49; Cw7. See also Duquesnoy et al, Human Immunology 73: 267-277, 2012.

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate RGF19 (absorbed with B*49:01) positive with HLA-A*23:01, A*24:02, A*24:03, A*25:01, A*32:01, B*15:13, B*15:16, B*38:01, B*49:01, B*51:01, B*51:02, B*52:01, B*53:01, B*57:01, B*57:03, B*58:01, B*59:01. Equivalent to TerEp #23.

80I pairs on HLA-ABC

80I+69TNT (provisional) El Awar N et al, Human Immunology 68: 170-180, 2007: Serum eluate Z2980.BO (absorbed with B*52:01 cells) was positive with a subgroup of HLA-B allele beads bearing B*38:01, B*49:01, B*51:01, B*51:02, B*53:01, B*15:13 in Luminex single antigen assay. Equivalent to TerEp #230.

80I+90A (provisional) El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X8059.C0 (absorbed with B*57:01 cells) positive with HLA-A*23:01, A*24:02, A*24:03, A*32:01, B*15:13, B*15:16, B*38:01, B*49:01, B*51:01, B*51:02, B*52:01, B*53:01, B*57:01, B*57:03, B*58:01, B*59:01 (no information on HLA types of antibody producer/immunizer) Reacts with 80I-positive alleles that share also residue 90A, located 13 Ångstroms away. Equivalent to TerEp #212

80I+152RE (preliminary) El Awar N et al, Transplantation 84: 532-540, 2007: Monoclonal antibody FC2121-5A4A1 was positive with beads bearing B*49:01, B*51:01, B*51:02, B*52:01, B*15:13, B*15:16 in Luminex single antigen assay. Equivalent to TerEp #419.Duquesnoy R, Marrari M, Tissue Antigens 74: 117-33, 2009:

80K (confirmed) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Serum eluate A113 (absorbed with C*17:01 cells) positive with HLA-C*02:02, C*04:01, C*05:01, C*06:02, C*15:02, C*17:01, C*18:02 Equivalent to TerEp #244. Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71 Bachelet T, Couzi L, Guidicelli G, Moreau K, Morel D, Merville D, Taupin J-L. 2011. Anti-Cw Donor-specific Alloantibodies Can Lead to Positive Flow Cytometry Crossmatch and Irreversible Acute Antibody-Mediated Rejection. Amer J Transplant 11: 1543-44: A previously sensitized patient with HLA type HLA-A2, A11; B44, B55; Cw3, Cw7 received a renal transplant from a donor mismatched for HLA-A3, B41, B57, Cw6 and Cw17. Serum from day 0 showed donor-specific antibody reactivity towards Cw6 and Cw17. The kidney was removed on day 30, and antibody eluted from a segment of the graft showed a pattern of positive reactions (MFI >3000) in Luminex testing with 80K+ alleles: HLA-Cw2, Cw4, Cw5, Cw6, Cw15, Cw17, Cw18.

Post Allograft nephrectomy serum pf28 Campbell (Edmonton)

Patient A*02:01, A*03:01 B*15:01 B*40:01 C*03:04

Allele MFI Epitope TP Epitope

C*04:01 Imm 10474 80K

C*04:03 15418 80K

C*05:01 13681 80K 138K

C*15:02 12164 80K

C*18:01 10372 80K

C*06:02 5851 80K

C*02:10 5255 80K

C*17:01 2944 80K

C*08:02 3015 138K

10 remaining HLA-C alleles 863+640

Post allograft nephrectomy serum MARGER, Cesbron (Nantes, France)

Patient: A*11:01 A*26:01 B*38:01 B*55:01

MFI Ep

C*04:01 Imm 6506 80K

C*02:02 7307 80K

C*05:01 6064 80K

C*06:02 7047 80K

C*15:02 6123 80K

C*17:01 9580 80K

C*18:02 10504 80K

C*01:02 275

C*03:02 310

C*03:03 302

C*03:04 250

C*07:02 923

C*08:01 359

C*12:03 371

C*14:02 637

C*16:01 916

Self Alleles 254+111

NegCont 123

Pos Cont 8848

80K pairs on HLA-ABC

80K+14R (Provisional) Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA

class I alleles reacting with antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print], 2016


Mother A*01:01 A*23:01 B*15:17

B*49:01 C*07:01 C*07:01

Allele MFI Epitope

C*06:02 IMM 5712 80K+14R

C*02:02 833 80K+14R

C*05:01 1303 80K+14R

C*15:02 7653 80K+14R

C*17:01 2218 80K+14R

C*18:02 3762 80K+14R

C*04:01 70 80K+14W

9 remaining HLA-C alleles 47+79

80N (confirmed) on HLA-ABC

Human monoclonal antibody KAM3H9 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A*02:01/02:06/02:07; B*27:03/27:05/27:09, B*37:01; C*02:02, C*06:02. Immunizing haplotype is HLA-A*02; B*07; C*07. See also Duquesnoy et al, Human Immunology 73: 267-277, 2012.

Duquesnoy R et al, Human Immunology 73: 267-77, 2012: Human IgG mAb OUW4F11from a woman who typed as HLA-A3, A68; B27, B44; Cw2 and was sensitized through pregnancy by the HLA-A1; B8; Cw7 child’s paternal haplotype. Similar to KAM3H9, the antibody reacted in Luminex single antigen assays with all 80N-carrying HLA-B and HLA-C alleles.

El-Awar N et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X1779.BO (absorbed with B*55:02 cells) positive with HLA-B*07:02, B*08:01, B*14:01, B*14:02, B*15:01, B*15:02, B*15:03, B*15:10, B*15:12, B*18:01, B*27:08, B*35:01, B*39:01, B*39:05, B*40:01, B*40:02, B*40:05, B*41:01, B*42:01, B*45:01, B*46:01, B*48:01, B*50:01, B*54:01, B*55:02, B*56:01, B*67:01, B*73:01, B*78:01, B*81:01, B*82:01 Equivalent to TerEp #25, but serum eluate X1779.BO was not tested for HLA-C reactivity.

80N pairs on HLA-ABC

80N+s73TY (preliminary)

Post allograft nephrectomy serum ECU-2, Rebellato (Greenville, NC)Patient A*03:01 A*66:01 B*42:02 B*49:01

MFI Ep1 Ep2

B*45:01 Imm 9048 163LS/G 80N+s73TY

B*15:12 7361 163LS/G 80N+s73TY

B*44:02 6523 163LS/G

B*44:03 4614 163LS/G

B*82:01 4444 163LS/G

B*15:01 2294 80N+s73TY

B*15:02 1817 80N+s73TY

B*15:03 2986 80N+s73TY

B*15:10 2137 80N+s73TY

B*18:01 1190 80N+s73TY

B*35:01 728 80N+s73TY

B*40:01 1735 80N+s73TY

B*40:02 3603 80N+s73TY

B*41:01 2970 80N+s73TY

B*48:01 4054 80N+s73TY

B*50:01 2535 80N+s73TY

15 HLA-B alleles 138+51 80N+73TD

9 HLA-C alleles 318+97 80N+73TD

B*57:01 2577 62GE induced by A*02:01

B*57:03 3193 62GE induced by A*02:01

B*58:01 2570 62GE induced by A*02:01

12 Remaining HLA-B 226+211

7 Remaining HLA-C 375+143

B*49:01 Self 128 (73TY)


Neg Cont 50

Pos Cont 4852

80TLR (provisional) on HLA-ABC

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate RGF41 (absorbed with B*44:03 cells) positive with HLA-B*13:01, B*27:05, B*37:01, B*44:02, B*44:03, B*47:01 Equivalent to TerEp #217.

82LR (confirmed) on HLA-ABC

Human monoclonal antibody MUS4H4 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A66; B39, B41. Immunizer types as HLA-A1, A9; B7, B39. See also Duquesnoy et al, Human Immunology 73: 267-277, 2012. MUS4H4 had identical reactivity pattern in CDC assays in 13th IHWS. The two pregnancy sera are often seen examples that show lower MFI values of 82LR-carrying alleles that have the nearby 80T residue rather than 80I.

El-Awar et al, Human Immunology 68: 170-180, 2007: Serum eluate RGF19 (absorbed with B*44:03 cells, Equivalent to TerEp #24

Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997:

Post 2nd pregnancy serum (Schaub, Basel)

Mother A*01:01 A*30:02 B*40:01 B*41:01

Note: A*32:01 is the immunizing 82LR-carrying allele

Allele MFI Epitope Residue

A*32:01 Imm 12533 82LR 80I

A*23:01 6612 82LR 80I

A*24:02 6418 82LR 80I

A*24:03 7332 82LR 80I

A*25:01 9714 82LR 80I

B*15:13 3111 82LR 80I

B*15:16 4204 82LR 80I

B*38:01 5729 82LR 80I

B*49:01 11147 82LR 80I

B*51:01 4638 82LR 80I

B*51:02 6876 82LR 80I

B*52:01 5997 82LR 80I

B*53:01 5380 82LR 80I

B*57:01 5238 82LR 80I

B*57:03 4667 82LR 80I

B*58:01 3765 82LR 80I

B*59:01 5755 82LR 80I

Mean+SD 5409+2076

B*27:05 3772 82LR 80T

B*13:02 3408 82LR 80T

B*37:01 3055 82LR 80T

B*44:03 2256 82LR 80T

B*44:02 2180 82LR 80T

B*47:01 916 82LR 80T

B*13:01 686 82LR 80T

Mean+SD 2325+1190


Effect of 80I and 80T on 82LR epitope


Mother A*01:01 A*02:01 B*35:03 B*40:01

Epitope Epitope

B*51:01 IMM 5500 82LR 80I

B*51:02 7297 82LR 80I

B*15:13 4490 82LR 80I

B*52:01 6674 82LR 80I

B*49:01 6682 82LR 80I

B*38:01 7165 82LR 80I

B*59:01 5093 82LR 80I

B*53:01 5699 82LR 80I

B*15:16 4836 82LR 80I

B*57:03 2969 82LR 80I

B*57:01 3217 82LR 80I

B*58:01 2380 82LR 80I

A*23:01 2609 82LR 80I

A*24:02 3760 82LR 80I

A*24:03 3633 82LR 80I

A*32:01 5050 82LR 80I

A*25:01 8024 82LR 80I

Mean+SD 5005+1751

B*13:01 670 82LR 80T

B*13:02 1081 82LR 80T

B*44:02 623 82LR 80T

B*44:03 685 82LR 80T

B*37:01 1062 82LR 80T

B*47:01 326 82LR 80T

B*27:05 779 82LR 80T

Mean+SD 747+263

A*30:01 IMM 5769 56R

A*30:02 5784 56R

A*31:01 5572 56R


Monoclonal antibody XIII120.7 (12w041) positive with HLA-A23, A24, A2403, A25, A32 and Bw4-positive alleles in CDC assays in 12th IHWS. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibody TER.M.A910 (10w2062) positive with HLA-A23, A24, A25, A32, Bw4 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Tahara et al, Immunogenetics 32: 351-360, 1990: Mouse monoclonal antibodies (IgG) 2A1, 17A10 and 17A12 produced by immunization of C57BL/6 transgenic HLA-B*13:02 mice with human lymphoblastoid cells (HOM-2) with HLA type HLA-A3, B27, Cw1. Antibodies reacted with all Bw4, A23, A24, A25 and A32-positive cells in CDC assays with PBL and lymphoblastoid cell lines. Reactivities of 2A1 (DUP TM915), 17A10 (DUP TM916), 17A12 (DUP TM917) were confirmed in 11th International Workshop CDC, ELISA and Flow cytometry assays (see Inoko et al, in HLA 1991, Tsuji K, Aizawa M, Sasazuki T (Eds), pp. 919-930, 1992). Lutz CT, Smith KD, Greazel NS, Mace BE, Jensen DA, McCutcheon JA, Goeken NE. 1994. Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. Journal of Immunology 153: 4099-110 HLA-B7 transfected cells (721.221) with mutations at specific amino acid positions were tested in flow cytometry binding using anti-Bw4 monoclonal antibodies and absorption studies using alloantisera. A simultanous substitution at positions 80, 82 and 83 (80N →T, 82R→L and 83R→G) created a B7 variant that could bind all six anti-Bw4 monoclonal antibodies tested. Similarly, the variant cells were able to absorb anti-Bw4 alloantibody reactivity. Both Bw4 and Bw6 monoclonal antibodies could bind to variant cells with a single mutation at either position 82 or 83.

82LR pairs on HLA-ABC

82LR+90A located 6 Ångstroms away not on the 82LR-carrying HLA-A25. Equivalent to TerEp #250. El-Awar et al, Human Immunology 71: 456-461, 2010:

Mouse monoclonal antibody 548HA1-4 (IgM) produced by immunization with cells that type as HLA-A1, A26; B27, B37; Cw2, Cw6 Müller et al, Human Immunology 5: 269-281, 1982: Mouse monoclonal antibody Tü48 (IgM) produced in BALB/c mouse after immunization with lymphocytes from two donors with HLA types HLA-A1, A2; B17, B27; Cw1 and HLA-A32; B14, B27; Cw2. Antibody reacts with all Bw4-positive cells, as well as HLA-A23, A24 and A32-positive cells in CDC assays. Absorptions with EBV-transformed B cell lines (HLA-A3, A24; B27; Cw2 / HLA-A3, A32; B7, B35; Cw3, Cw4 / HLA-A2; B44) removed reactivity Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, Domenique Charron (Ed), pp.7-11, 1997: Monoclonal antibody TOK45-3A (12w071) positive with HLA-A23, A24, A32 and all Bw4-positive alleles in CDC assays in 12th IHWS. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies TU48 (10w2057), TOK45.3A (10w2064) and TOK45.3B (10w2065) positive with HLA-A23, A24, A32, Bw4-positive alleles in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies TU48 (10w2057), TOK45.3A (10w2064) and TOK45.3B (10w2065) positive with HLA-A23, A24, A32, Bw4 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.

82LR + 138M (provisional) Tongio MM et al, in Charron D, ed. HLA: Genetic Diversity of HLA Functional and Medical Implication. Paris: EDK, 1997, p 7-11: Mouse IgM monoclonal antibody 7008.TO (12W033, One Lambda, Canoga Park, USA) reacted with HLA-A23, A24, A2403, A25, A32 in complement-dependent lymphocytotoxicity assays in 12th International Histocompatibilty Workshop studies.

82LR + 138T (provisional) Lutz CT, Smith KD, Greazel NS et al: J Immunology 153: p. 4099-4119, 1994: Tongio MM et al, in Charron D, ed. HLA: Genetic Diversity of HLA Functional and Medical Implication. Paris: EDK, 1997, p 7-11: Mouse IgG monoclonal antibody 116-5-28 (12W070, K. Gelsthorpe, Sheffield, England) reacted with all Bw4+ HLA-B antigens, but not HLA-A23, A24, A2403, A25, A32, in complement-dependent lymphocytotoxicity assays in 12th International Histocompatibility Workshop studies (r=0.88).

82LR+144QR (provisional) El-Awar et al, Human Immunology 71: 456-461, 2010: Mouse monoclonal antibody Z1153 (IgM) produced by immunization with cells that type as HLA-A3; B65; Cw8

Reacts with 82LR-positive alleles that share residues 144Q and 145R, located 15 Ångstroms away. Equivalent to TerEp #423.

82LR + 145R (provisional) El-Awar et al, Human Immunology 71: 456-461, 2010: Reacts with 82LR-positive alleles that share also residue 145R, located 15 Ångstroms away. Equivalent to TerEp #249.

Marrari M et al, Human Immunology 25: p. 217-220, 2011:

Two patients awaiting renal transplant (sera contributed by R. Conca, Torino, Italy) have antibody reactivity towards all HLA-Bw4+ alleles except B13, which corresponds to the 145R+s82LR epitope pair. Both are women who type as HLA-B13 and were sensitized during pregnancy by exposure to a HLA-B*44:02 mismatch

These results of a nonself-self algorithm based analysis suggest that 145R+82LR-specific antibodies in these two patients originated from B-cells with low avidity immunoglobulin receptors specific for the structurally defined 145L epitope on self B*13:02. Such receptors might interact though their CDRs with different portions of the B*13:02 molecular surface but the binding strength is so weak that B-cell activation and antibody production cannot occur. In contrast, a substitution of 145L by 145R within this structural epitope would trigger the activation of these B-cells and antibody responses in these patients. The immunizing B*44:02 has this 145R difference with B*13:02, whereas all other surface residues in the structural epitope are identical. In particular, the self 82LR eplet on B*13:02 and shared with B*44:02 is critical for antibody binding.

82LR+s145R+s149A (provisional) Human monoclonal antibody VDK8F7 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A3, A31; B35; Cw4. Immunizer types as HLA-A1, A3; B7, B37; Cw7. See also Marrari et al, Transplantation 90: 1468-1472, 2010

Very low MFI values with B*15:13, B*51:01 and B*52:01 on GP kit only.

82LR+144Q (preliminary) on all 82LR-carrying alleles except A*24:02/03 Duquesnoy, Hönger, Hösli , Marrari and

Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with antibodies induced during

pregnancy. Int J Immunogenetics. [Epub ahead of print], 2016

.


Mother A*24:02, A*31:01 B*15:01 B*15:18 C*03:03,-

Allle MFI Epitope Epitope

Pos cont 9135

Neg cont 63

A*11:01 Imm 11078 90D+14R

Fifteen 90D+14R alleles 7295+3505 90D+14R

B*51:01 Imm 11747 82LR+144Q

A*23:01 6034 82LR+144Q

A*25:01 9805 90D+14R 82LR+144Q

A*32:01 8152 82LR+144Q

B*13:01 3105 82LR+144Q

B*13:02 9477 82LR+144Q

B*15:13 10692 82LR+144Q

B*15:16 12649 82LR+144Q

B*18:01 8324 82LR+144Q

B*27:05 9062 82LR+144Q

B*35:01 11175 82LR+144Q

B*37:01 8905 82LR+144Q

B*38:01 10949 82LR+144Q

B*44:02 5006 82LR+144Q

B*44:03 6607 82LR+144Q

B*47:01 3505 82LR+144Q

B*49:01 8487 82LR+144Q

B*51:02 9666 82LR+144Q

B*52:01 11146 82LR+144Q

B*53:01 10288 82LR+144Q

B*57:01 10308 82LR+144Q

B*57:03 10172 82LR+144Q

B*58:01 9179 82LR+144Q

B*59:01 11402 82LR+144Q

B*78:01 9230 82LR+144Q

A*24:03 211 82LR+144K

A*24:02 Self 1 82LR+144K


90D (provisional) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate W6409 (absorbed with A*80:01 cells) positive with HLA-A*01:01, A*11:01, A*11:02, A*25:01, A*26:01, A*34:01, A*36:01, A*43:01, A*66:01, A*80:01, B*73:01 Equivalent to TerEp #16


Mother A*02:01 A*31:01 B*27:02 B*51:01 C*02:02 C*15:02

Alllele MFI Epitope Epitope Effect of Epitope

Pos cont 9840

Neg cont 1

B*07:02 Imm 9641 80N

39 80N alleles 8995+2296

C*07:02 Imm 4490 80N 90D 14R

B*73:01 13961 80N 90D 14R

A*01:01 Informative 5822 90D 14R










C*04:01 Informative 837 90D 14W

C*06:02 Informative 3403 90D 14R


A*80:01 Informative 9130 90D 14R 62EE

A*24:02 Imm 2714 62EE

A*23:01 2061 62EE

A*24:03 892 62EE



Mother A*24:02' A*32:01 B*35:03 B*44:29 C*05:01 C*12:03

Allele MFI Epitope Effect of Epitope

A*01:01 IMM 11998 90D 14R 76ANT

A*26:01 13077 90D 14R 76ANT

A*36:01 11871 90D 14R 76ANT

A*43:01 12957 90D 14R 76ANT

A*80:01 12508 90D 14R 76ANT







B*73:01 Informative 14956 90D 14R

C*04:01 Informative 2145 90D 14W


C*07:02 IMM 7107 90D 14R

C*18:02 8541 90D 14RA*29:01 8029 76ANT

A*29:02 7332 76ANT

14 informative 79GT alleles 814+562 (weak)


90D pairs on HLA-ABC

90D +79GT (provisional) El Awar N et al, Transplantation 84: 532-540, 2007: Alloserum AS264 (absorbed with A*36:01 cells) was positive with beads bearing A*01:01, A*11:01, A*11:02, A*25:01, A*26:01, A*34:01, A*36:01, A*43:01, A*66:01, A*80:01 in Luminex single antigen assay. The eluate did not react with A*66:02. Equivalent to TerEp #241. Laundy GJ et al, Transfusion 44: 814-25, 2004: Serum from patient SR145, with acquired aplastic anemia following multiple transfusions of WBC-poor red blood cells and single-donor platelets, showed pattern of IgM reactivity towards HLA-A1, A11, A25, A26, A34, A36, A43, A*66:01 and A*80:01. No reactivity was seen with HLA-B73, Cw4, Cw6, Cw7 or Cw18, which share eplet 90D but without 79GT

90A+14R (preliminary) Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I

alleles reacting with antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print], 2016

Post 2nd Pregancy serum #222 (Schaub, Basel)

Mother A*02:01,- B*35:03 B*51:01 C*04:01, C*14:02

Allele MFI Epitope Residue influence?

Pos cont 8419

Neg cont 1

A*01:01 3043 90D+14R 69A,73T

A*36:01 3525 90D+14R 69A,73T

A*25:01 4178 90D+14R 69A,73T

A*26:01 2388 90D+14R 69A,73T

A*43:01 2606 90D+14R 69A,73T

A*66:01 2729 90D+14R 69A,73T

A*11:01 4447 90D+14R 69A,73T

A*11:02 3235 90D+14R 69A,73T

A*34:01 2670 90D+14R 69A,73T

A*34:02 4041 90D+14R 69A,73T

A*80:01 3865 90D+14R 69A,73T

B*73:01 3531 90D+14R 69A,73T

C*06:02 1472 90D+14R 69R, 73A

C*07:02 1351 90D+14R 69R, 73A

C*18:02 1256 90D+14R 69R, 73A

C*04:01 Self 1 90D+14W 69R, 73A


107W (confirmed) on HLA-ABC

Human monoclonal antibody JOK3H4 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A1, A24; B8, B35; Cw4. Immunizing haplotype is HLA-A32; B*40:01, C*03:04 (see Mulder et al, J Immunology 175: 5950-5957, 2005)

This post-allonephrectomy serum came from patient ND7 (C Schoenemann, Berlin) who typed as A26; B27, B44; Cw2, Cw3 and received a transplant from a donor mismatched for A2. A2-induced antibodies reacted with alleles sharing 107W:

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody X3653.AP positive with HLA-A*02:01, A*02:03, A*02:06, A*69:01 Equivalent to TerEp #2. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibodies Z5018 and BB7.2 (13-WS 0016) positive with HLA-A*02:01, *02:02, *02:03, *02:04, *02:05, *02:06, *02:07, *02:11, *02:12, *02:17, *02:35, *02:36, *02:46, *02:49, *69:01 in CDC assays in 13th IHWS. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibodies 211-122 (12w016), BB7.2 (12w018) and 8661.TO (12w019) positive with HLA-A2, A69 in CDC assays in 12th IHWS, with r values of 0.87, 0.94 and 0.96, respectively. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989:

Monoclonal antibodies BB7.2 (10w2037) and GSP20.1 (10w2039) positive with HLA-A2, A69 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody GSP20.1 reacts also with A31-, A34-, A68-positive lymphoblastoid cell lines. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies BB7.2 (10w2037) and GSP20.1 (10w2039) positive with HLA-A2, A69 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody GSP20.1 reacts also with A31-, A34-, A68-positive lymphoblastoid cell lines. Layet C, Kahn-Perles B, Pontarotti P, Ferrier P, Sire J, Lemonnier FA. 1987. Creation of an HLA-A2/HLA-Aw69 alloantigenic determinant on an HLA-A3 molecule by site-directed mutagenesis. Journal of Immunology 138: 2197-201 Site-directed mutagenesis of the HLA-A3 molecule was performed by substituting tryptophan (W, shared by A2, A69) for glycine (G) at position 107, then measuring binding of mouse monoclonal antibodies BB7.2 and PA2.1, both HLA-A2, A69-specific. Binding was measured by cell surface radioimmunoassay. Both antibodies reacted with transfected cells, indicating the epitope that is recognized involves the presence of tryptophan at this position. This mutation did not prevent binding of A3-specific antibodies to the transfected cells, but the A2, A69-specific and A3-specific antibodies can each block the binding of the other in criss-cross inhibition studies.

113H (provisional) on HLA-ABC


Data provided by Stefan Schaub, Basel, Switzerland Serum has antibodies against the high frequency 80N Second Pregnancy Serum #93 and 163LW eplets and the newly defined 113H eplet

Antibody Producer A*02:01 A*03:01 B*37:01 B*44:02 C*05:01C*06:02

Immunizing Allele B*35:01

MFI Ep 2 Ep 2 Ep 3 Allele MFI Ep 1 Ep 2

B*35:01 Imm 13824 80N 163LW 113H C*03:02 9862 80N 163LW

B*15:11 7937 80N 163LW 113H C*03:03 7512 80N 163LW

B*46:01 10453 80N 163LW 113H C*03:04 7041 80N 163LW

B*56:01 11251 80N 163LW 113H C*01:02 6874 80N

B*15:03 12812 80N 163LW 113H C*07:02 930 80N negative effect of 66N?

B*15:01 13327 80N 163LW 113H C*08:01 7814 80N

B*15:10 13392 80N 163LW 113H C*12:03 7724 80N

B*78:01 14269 80N 163LW 113H C*14:02 8406 80N

B*15:12 15466 80N 163LW 113H C*16:01 3648 80N

B*50:01 12000 80N 163LW

B*45:01 12950 80N 163LW

B*15:02 14028 80N 163LW

B*67:01 14949 80N 113H

B*18:01 14824 80N 113H B*27:05 neg 684

B*42:01 14761 80N 113H B*47:01 neg 421

B*40:02 14613 80N 113H B*37:01 self 208

B*82:01 14430 80N 113H B*44:02 self 114

B*41:01 14356 80N 113H B*44:03 neg 108

B*55:01 14222 80N 113H

B*07:02 14039 80N 113H C*02:02 neg 263

B*40:06 13939 80N 113H C*04:01 Imm 659

B*40:01 13303 80N 113H C*05:01 Self 268

B*54:01 13129 80N 113H C*06:02 Self 148

B*39:01 12943 80N 113H C*17:01 neg 136

B*08:01 12890 80N 113H C*18:02 neg 219

B*48:01 10959 80N 113H

B*81:01 10135 80N 113H Self 131+98

B*27:08 14094 80N

B*14:02 13375 80N Pos cont 8803

B*14:01 12651 80N Neg Cont 0

B*73:01 10554 80N

B*51:02 14115 163LW 113H

B*53:01 12926 163LW 113H

B*52:01 10672 163LW 113H

B*15:16 10621 163LW 113H

B*51:01 9636 163LW 113H

B*57:01 8721 163LW 113H

B*57:03 7931 163LW 113H

B*58:01 6839 163LW 113H

B*49:01 13099 163LW

B*15:13 9527 163LW

B*13:01 1660 113H informative




C*15:02 1275 113H informative



Second Pregnancy 2ndP#348

Antibody Producer A*02:01 A*68:01 B*44:02 B*50:01 C*06:02C*07:04


Allele MFI Ep1 Ep2 Ep3 New Ep Allele MFI

B*57:01 Imm 9163 82LR 44RMA 69AA 113H B*14:01 500

B*15:16 10994 82LR 44RMA 69AA 113H B*14:02 1537

B*57:03 8956 82LR 44RMA 69AA 113H B*44:02 self 1

B*15:13 3730 82LR 44RMA B*44:03 1

B*58:01 7230 82LR 69AA 113H B*45:01 1

B*27:05 12576 82LR 69AA B*50:01 self 150

B*38:01 9392 82LR 113H

B*59:01 8404 82LR 113H C*01:02 825

B*51:02 11741 82LR 113H C*02:02 16

B*52:01 11574 82LR 113H C*03:02 13

B*51:01 11563 82LR 113H C*03:03 20

B*53:01 10131 82LR 113H C*03:04 21

B*49:01 6485 82LR C*04:01 1

B*37:01 4454 82LR C*05:01 1

B*47:01 7043 82LR C*06:02 self 1

B*15:01 5482 44RMA 113H C*07:02 1

B*46:01 5454 44RMA 113H C*08:01 5

B*15:02 2915 44RMA C*12:03 6

B*15:11 1751 44RMA 113H C*14:02 101

B*13:02 11126 44RMA 113H C*16:01 1

B*13:01 4940 44RMA 113H C*17:01 1

B*15:12 7802 44RMA 113H C*18:02 1

B*82:01 12370 69AA 113H

B*56:01 7075 69AA 113H

B*42:01 11706 69AA 113H

B*54:01 11320 69AA 113H Self 34+65

B*55:01 11018 69AA 113H

B*67:01 10813 69AA 113H PosCont 8743

B*27:08 12474 69AA NegCont 26

B*81:01 12414 69AA 113H

B*07:02 11861 69AA 113H

B*73:01 4467 69AA

B*08:01 9095 113H Informative












C*15:02 9259 113H Informative

127K (confirmed) on HLA-ABC Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


El-Awar N et al, Human Immunology 68, 170-180, 2007 (no MFI values): Serum eluate (absorbed with A*69:01 cells) positive with HLA-A*02:01, *02:03, *02:06, *23:01 *24:02, *24:03, *68:01, *68:02, *69:01 Equivalent to TerEp #19. El-Awar N et al, Human Immunology 71: 456-461, 2010 (no MFI values): Mouse monoclonal antibody 0189HA (IgM) produced by immunization with cells that type as HLA-A2, A24; B54, B67; Cw1, Cw7 is positive with HLA-A*02:01, A*02:03, A*02:06, B*23:01, A*24:02, A*24:03, A*68:01, A*68:02, A*69:01. De Vito LD et al, Human Immunology 37: 165-77, 1993: Human sera with high-titer anti-HLA-A2 reactivity induced by pregnancy and/or transfusion were tested on a series of affinity columns to isolate anti-HLA-A2-specific antibodies and then tested in an inhibition radioimmunoassay against native HLA-A2 or recombinant A2 proteins that had been generated by site-specific mutations. Purified antibodies from antibody producers DOUV and LC reacted only with A2 variants with lysine (K) at position 127; substitution of asparagine (N) for lysine abolished binding. Substituting lysine for asparagine at position 127 in an A3 molecule also led to binding of the purified antibody. Laundy GJ et al, Transfusion 44: 814-25, 2004: Serum from multiparous female patient KG186, with acquired aplastic anemia following transfusions of WBC-poor red blood cells, showed pattern of IgG reactivity towards HLA-A2, A23, A24, A68 and A69.


Mother A*03:01, A*33:01 B*14:02 B*15:18 C*07:04 C*08:02

Allele MFI Epitope Epitope Epitope

Pos cont 8644

Neg cont 9

A*24:02 IMM 6122 127K 82LR 167DG

A*23:01 8354 127K 82LR 167DG

A*24:03 6704 127K 82LR

A*02:01 Informative 3246 127K






A*25:01 7549 82LR

A*32:01 7947 82LR

A*01:01 5319 167DG

A*80:01 8625 167DG

B*15:12 11983 167DG


131S (confirmed) on HLA-ABC

Two post-pregnancy sera Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-

defined epitopes on HLA class I alleles reacting with antibodies induced during pregnancy. Int J

Immunogenetics. [Epub ahead of print], 2016

Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class

I alleles reacting with antibodies induced during pregnancy. Int J Immunogenetics. [Epub ahead of print],

2016 Below is another example of a highly reactive post allograft nephrectomy serum with antibodies induced by two HLA-B mismatches. Informative alleles for four epitopes are highlighted in color

Duquesnoy et al Int J Immunogenetics In press, 2016 Data provided by Stefan Schaub, Basel, Switzerland

First Pregnancy Serum #228 Second PregnancySerum #124

Antibody Producer A*01:01 A*24:02 Antibody Producer A*01:01 A*30:01

Antibody Producer B*08:01 B*40:02 Antibody Producer B*07:02 B*08:01

Antibody Producer C*02:02 C*07:01 Antibody Producer C*07:02 C*07:01

Immunizing Allele B*15:01 Immunizing Allele B*35:01

MFI Ep 1 Ep 2 New Ep MFI Ep 1 New Ep

B*15:01 Imm 9061 163LW 44RMA 131S B*35:01 Imm 6534 44RT 131S

B*15:16 12947 163LW 44RMA 131S B*51:01 1879 44RT 131S

B*57:01 11647 163LW 44RMA 131S B*51:02 3445 44RT 131S

B*57:03 12306 163LW 44RMA 131S B*52:01 2860 44RT 131S

B*15:02 11902 163LW 44RMA 131S B*53:01 3975 44RT 131S

B*15:11 7151 163LW 44RMA 131S B*58:01 2830 44RT 131S

B*15:13 12512 163LW 44RMA 131S B*78:01 2418 44RT 131S

B*46:01 11621 163LW 44RMA 131S B*18:01 5805 44RT 131S

B*58:01 11660 163LW 131S B*37:01 3952 44RT 131S

B*15:03 10383 163LW 131S B*13:01 2520 131S Informative











B*15:12 8924 44RMA 131S B*15:16 2106 131S Informative



B*14:01 12244 131S Informative B*38:01 2010 131S Informative

















B*07:02 299 131R B*07:02 44 131R

B*08:01 297 131R B*08:01 26 131R

B*40:01 3 131R B*40:01 1 131R

B*40:02 1 131R B*40:02 31 131R

B*40:06 629 131R B*40:06 61 131R

B*41:01 487 131R B*41:01 7 131R

B*42:01 758 131R B*42:01 4 131R

B*48:01 362 131R B*48:01 69 131R

B*73:01 477 131R B*73:01 1 131R

B*81:01 17 131R B*81:01 1 131R

Self Alleles 117+131 Self Alleles 15+20

Positive Control 7311 Positive Control 9263

Negative Control 0 Negative Control 0

Post allgraft nephrectomy serum GUIMAR, Cesbron (Nantes, France)

Patient A*01:01 A*02:01 B*07:02 B*08:01 C*07:02 C*07:01

Immunizer B*44:02 B*27:05

MFI Ep1 Ep2 Ep3 Ep4

B*44:02 Imm 13793 41T 82LR 131S 163LS/G

B*44:03 12154 41T 82LR 131S 163LS/G

B*45:01 13872 41T 131S 163LS/G

B*49:01 13387 41T 82LR 131S

B*13:02 13562 41T 82LR 131S

B*47:01 14149 41T 82LR 131S

B*50:01 9585 41T 131S

B*40:01 5587 41T

B*40:02 5277 41T

B*41:01 4688 41T

B*27:05 Imm 13771 82LR 131S

B*15:13 14263 82LR 131S

B*15:16 15619 82LR 131S

B*38:01 11939 82LR 131S

B*51:01 15197 82LR 131S

B*51:02 8521 82LR 131S

B*52:01 11539 82LR 131S

B*53:01 14562 82LR 131S

B*57:01 14048 82LR 131S

B*57:03 13506 82LR 131S

B*58:01 15021 82LR 131S

B*59:01 9856 82LR 131S

B*37:01 10069 82LR 131S

A*23:01 13810 82LR

A*24:02 14444 82LR

A*24:03 14896 82LR

A*25:01 13240 82LR

A*32:01 16023 82LR

A*32:01 16023 82LR

A*24:03 14896 82LR

A*24:02 14444 82LR

A*23:01 13810 82LR

A*25:01 13240 82LR

B*15:12 10359 131S 163LS/G

B*82:01 9609 131S 163LS/G

B*14:01 4143 131S

B*14:02 2971 131S

B*15:01 5631 131S

B*15:02 5215 131S

B*15:03 2833 131S

B*15:10 2578 131S

B*18:01 5738 131S

B*27:08 9285 131S

B*35:01 5288 131S

B*39:01 3333 131S

B*46:01 3293 131S

B*54:01 3155 131S

B*55:01 2497 131S

B*56:01 5416 131S

B*67:01 5610 131S

B*78:01 3740 131S

B*07:02 self 105

B*08:01 self 101

B*42:01 108

B*48:01 137

B*73:01 387

B*81:01 111

Self alleles 176+20

24 other HLA-A alleles 168+272

131S pairs on HLA-ABC

131S+163T (provisional) El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate Z6331.00 (absorbed with B*39:05 cells) positive with HLA-B*14:01, B*14:02, B*18:01, B*37:01, B*38:01, B*39:01, B*39:05, B*54:01, B*55:01, B*59:01, B*67:01 (no information on HLA types of antibody producer/immunizer) Reacts with 131S-positive alleles that share also epitope 163T, located 15 Ångstroms away. Equivalent to TerEp #228.

138K (provisional) on HLA-ABC

Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71

Antibody reactivity towards this eplet was seen in six renal transplant patients whose post-nephrectomy sera were submitted to the 15th International Histocompatibility Workshop study on HLA epitope immunogenicity. The very high antibody frequency (>50%) observed in this small study leads us to believe that eplet 138K has a relatively high immunogenicity among HLA-C eplets.

138MI (provisional) on HLA-ABC


Data provided by Stefan Schaub, Basel, SwitzerlandSecond Pregnancy Serum #364

Antibody Producer A*02:01 A*02:01 B*49:01 B*44:02 C*05:01


Allele MFI Ep1 Ep2 Ep Ep

A*11:01IMm 9136 144KR 163R 66NV 138MI

A*11:02 9283 144KR 163R 66NV 138MI

A*03:01 7442 144KR 66NV 138MI

A*80:01 5743 144KR 66NV 138MI

A*36:01 10391 144KR 138MI

A*01:01 9670 144KR 163R 138MI

A*24:03 9755 144KR 138MI

A*24:02 9085 144KR 138MI

A*66:01 11036 163R 66NV 138MI

A*43:01 10327 163R 66NV 138MI

A*26:01 10171 163R 66NV 138MI

A*25:01 9439 163R 66NV 138MI

A*29:01 6713 66NV 138MI

A*29:02 6731 66NV 138MI

A*30:01 7820 66NV 138MI

A*30:02 7680 66NV 138MI

A*31:01 9529 66NV 138MI

A*32:01 8769 66NV 138MI

A*33:01 8268 66NV 138MI

A*33:03 8926 66NV 138MI

A*66:02 11032 66NV 138MI

A*74:01 6620 66NV 138MI

A*68:02 10510 66NV

A*68:01 9306 66NV

A*69:01 2831 66NV

A*23:01 6265 138MI Informative



A*02:06 304

A*02:01 58

A*02:03 42

Self Alleles 15+29


Negative Control 65

Post allograft nephrectomy serum ND9, Schonemann (Berlin, Germany)

Patient's HLA type

A*02:01 A*68:01 B*07:02 B*52:01 C*07:02 C*12:03

MFI AbVerEp New Ep?

A*01:01 Imm 12910 166DG 105PF 138MI

A*23:01 10801 166DG 138MI

A*80:01 10635 166DG 138MI

A*24:02 9784 166DG 138MI

B*15:12 9622 166DG

A*43:01 12769 105PF 138MI

A*26:01 12650 105PF 138MI

A*36:01 12422 105PF 138MI

A*11:02 9842 105PF 138MI

A*11:01 9497 105PF 138MI

A*25:01 9369 105PF 138MI

A*66:01 8107 105PF 138MI

A*66:02 4335 105PF 138MI

A*34:01 3468 105PF 138MI

A*68:02 weak 1691 105PF

A*03:01 Informative 8982 138MI












A*02:01 Self 346

A*68:01 Self 183

A*02:03 317

A*69:01 238

A*02:06 208

138MI pairs on HLA-ABC

138MI + s79GT (provisional) Duquesnoy R et al: Human Immunology 66: p. 749-761, 2005: Human monoclonal IgM antibodies OK4F9 and OK4F10 were obtained from a female with HLA type HLA-A2, 28; B7, 27; Cw2, w7 who developed antibodies during pregnancy to the paternal HLA-A3 of the child. Both antibodies reacted with a group of HLA-A alleles that shared eplet 138MI of the immunizing A3 in combination with eplet 79GT shared by the immunizer and HLA-A2 and A28 of the antibody producer. The sera were tested by complement-dependent lymphocytotoxicity, and in Flow cytotometry and ELISA antigen binding

assays:

143S pairs on HLA-ABC

143S+76ESN (provisional) Human monoclonal antibody Ha2C10B12 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A3; B62. Immunizer types as HLA-A2, A11; B7, B60; Cw5, Cw7.

Additional moderate reactions (MFI range 714-2189) with HLA-A*32:01, B*15:02, B*35:01 and B*46:01 on OL kit only. Ha2C10B12 has similar reactivity pattern in CDC assays in 13th IHWS (13WS 0175) and 12th IHWS (12W068)

.

144K (provisional) on HLA-ABC

This serum reacted with all HLA-A alleles except those two of the patient. Nevertheless, it was possible to four likely epitopes. One of them is defined by 144K. Informative alleles are highlighted in yellow. Please note lower MFI values when nearby residues were 150A or 151H. The other epitopes discussed in the EpiPedia are 76VD and 253Q

El-Awar et al, Human Immunology 68, 170-180, 2007 (no MFI values): Serum eluate (absorbed with A*01:01 cells) positive with HLA-A*01:01, *02:01, *02:03, *02:06, *03:01, *11:01, *11:02, *24:02, *24:03, *36:01, *68:01, *68:02, *69:01, *80:01. Equivalent to TerEp #13


Patient A*23:01 A*30:02 B*53:01 C*04:01 C*05:01

Allele MFI Ep1 Ep2 effect of Ep 3 Ep4

A*02:01 Imm 15936 62GE 144K 150A+151H 76VD 253Q

A*02:03 13398 62GE 144K 150A+151H 76VD 253Q

A*02:06 16421 62GE 144K 150A+151H 76VD 253Q

B*57:01 6889 62GE

B*57:03 8468 62GE

B*58:01 6921 62GE

A*68:01 13787 144K 150A+151H 76VD 253Q

A*68:02 12591 144K 150A+151H 76VD 253Q

A*69:01 9676 144K 150A+151H 76VD 253Q

A*03:01 4478 144K 150A+151H 76VD

A*11:01 6996 144K 150A+151H 76VD

A*11:02 11269 144K 150A+151H 76VD

A*24:03 8525 144K 150A+151H

A*24:02 6623 144K 150A+151H

A*01:01 1790 144K 150V+151H

A*36:01 1523 144K 150V+151H

A*80:01 1051 144K 150A+151R

A*31:01 4949 76VD 253Q

A*33:01 2826 76VD 253Q

A*33:03 5127 76VD 253Q

A*34:01 4615 76VD 253Q

A*34:02 5590 76VD 253Q

A*66:01 3830 76VD 253Q

A*66:02 4128 76VD 253Q

A*74:01 5105 76VD 253Q

A*30:01 3815 76VD

A*30:02 Self 278

A*32:01 2317 253Q

A*25:01 3551 253Q

A*26:01 2563 253Q

A*29:01 4003 253Q

A*29:02 3532 253Q

A*43:01 2556 253Q

B*73:01 2312 253Q

C*07:02 4181 253Q

C*17:01 4956 253Q

A*23:01 Self 345



Neg Cont 194

Pos Cont 10399

144K pairs on HLA-ABC Below is another example of a highly reactive post allograft nephrectomy serum with antibodies induced by two HLA-B mismatches. Informative alleles for four epitopes are highlighted in color

144K+127K (preliminary)

144K+76VDT (preliminary) El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate SE896 (absorbed with A*11:01 cells) positive with HLA-A*02:01, A*02:03, A*02:06, A*03:01, A*11:01, A*11:02, A*68:01, A*68:02, A*69:01 (no information on HLA types of antibody producer/immunizer) Reacts with 144K-positive alleles that share also epitope 76VDT, located 11 Ångstroms away. Equivalent to TerEp #210.

144KR (confirmed) on HLA-ABC

Human monoclonal antibody) from Arend Mulder (Leiden): Sensitization due to pregnancy.

MUL2C6 (IgG Antibody producer A2, A25; B18, B51; Cw12, Cw15. Immunizing haplotype A11; B55; Cw3.

OK5A3 (IgM) Antibody producer A2, A28; B7, B27; Cw2, Cw7. Immunizing haplotype is HLA-A3; B70.

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): . Equivalent to TerEp #208. Serum eluate (absorbed with A*80:01 cells) positive with A*01:01, *03:01, *11:01, *11:02, *24:02, *24:03, *36:01, *80:01 Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: OK5A3 (13-WS 0042) reacts with HLA-A*01:01, *01:03, *03:01, *03:02, *03:05, *03:06, *03:09, *11:01, *11:02, *11:03, *24:02, *24:03, *24:06, *24:07, *24:10, *24:17, *24:20, *24:22, *24:27, *24:33, *32:04, *36:01, *80:01 in CDC assays in 13th IHWS.

144KR pairs on HLA-ABC

144KR+s151H (confirmed) Human mAb from Arend Mulder (Leiden) Sensitization due to pregnancy. MUL4C8 (IgG) Antibody producer types as HLA-A2, A25; B18, B51; Cw12, Cw15. Immunizing haplotype is HLA-A11; B55; Cw3. BRO11F6 (IgG) Antibody producer types as HLA-A26, A68; B38, B44, Cw7. Immunizer HLA type is unknown.

144KR+127K (provisional) El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Multiple mouse monoclonal antibodies positive with HLA-A*24:02, A*24:03 Reacts with 144KR-positive alleles that share also epitope 127K, located 7 Ångstroms away. Equivalent to TerEp #407. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, John A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibody H1160 (13-WS 0048) positive with HLA-A*24:02, *24:03, *24:06, *24:07, *24:10, *24:17, *24:20, *24:22, *24:27, *24:33 in CDC assays in 13th IHWS. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, Domenique Charron (Ed), pp.7-11, 1997: Monoclonal antibody 8596.TO (12w034) positive with HLA-A24, A2403 (r=0.85) in CDC assays in 12th IHWS. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibody GS114.1 (10w2063) positive with HLA-A24 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibody GS114.1 (10w2063) positive with HLA-A24 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.

144Q pair

144Q+138M (preliminary) Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on



Mother A*02:01, A*11:01 B*35:03 B*35:01 C*04:01,-


A*29:01 Imm 8649 62LQ 144Q+138M

A*29:02 10276 62LQ 144Q+138M

A*43:01 7716 62LQ 144Q+138M

A*30:01 4947 144Q+138M

A*30:02 6065 144Q+138M

A*26:01 4778 144Q+138M

A*31:01 5635 144Q+138M

A*33:01 4566 144Q+138M

A*33:03 5845 144Q+138M

A*32:01 5327 144Q+138M

A*74:01 4604 144Q+138M

A*25:01 5374 144Q+138M

A*34:01 4095 144Q+138M

A*34:02 6944 144Q+138M

A*66:01 3595 144Q+138M

A*66:02 5114 144Q+138M

A*23:01 3685 144Q+138M


144QL (confirmed) on HLA-ABC

Human monoclonal antibody GK31F12 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA- A*02, A3; B62, 35; Cw4, Cw10. Immunizer types as HLA-A1, A30; B7, B13.

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): to TerEp #8. Mouse monoclonal antibody Z0693.TO positive with HLA-B*1301 Mulder et al, Human Immunology 56: 106-113, 1997: Antibody GK31F12 has identical reactivity pattern in ELISA and CDC assays. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Human monoclonal GK31F12 (13-WS 0130) and mouse monoclonal antibodies 11H4 (13-WS 0129), 375-1 (13-WS 0128), 276-5 (13-WS 0127), TU110 (13-WS 0126), H758 (13-WS 0132) positive with HLA-B*13:01, *13:02, *13:04 in CDC assays in 13th IHWS. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibodies 276-5 (12w054), GK31F12 (12w055), TU+110 (12w056) and IIH4DS (12w057) positive with HLA-B13 in CDC assays in 12th IHWS, with r values of 0.51, 0.72, 0.65 and 0.53, respectively. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies SY1 (10w1220), VE5 (10w1250), TER.M.B13 (10w2092), UL.39.10 (10w2094) positive with HLA-B13 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. VE5 weak with PBL. Ve5 and TER.M.B13 had extra reactions with lymphoblastoid cell lines. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies SY1 (10w1220), VE5 (10w1250), TER.M.B13 (10w2092) and UL.39.10 (10w2094) positive with HLA-B13 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.

Epitope: 144TKH (confirmed) on HLA-ABC

Human monoclonal antibodies SN607D8 (IgG) and SN66E3 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A24, A29; B7, B44; Cw7. Immunizing haplotype is HLA-A2; B57.

SN607D8 SN66E3

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate (absorbed with A*69:01 cells) positive with HLA-A*02:01, *02:03, *02:06, *68:01, *68:02, *69:01 Equivalent to TerEp #18. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: SN607D8 (13-WS 0010) and SN66E3 (13-WS 0022) react with HLA-A*02:01, *02:02, *02:03, *02:04, *02:05, *02:06, *02:07, *02:11, *02:12, *02:17, *02:35, *02:36, *02:46, *02:49, *68:01, *68:02, *68:03, *68:05, *68:10, *68:17, *69:01 in CDC assays in 13th IHWS, but both were negative with most A*02:03 cells. Mouse monoclonal antibodies X1438, 278-1 (13-WS 0021), 115-8-1 (13-WS 0020), MRE1 (13-WS 0019) positive with HLA-A*02:01, *02:02, *02:03, *02:04, *02:05, *02:06, *02:07, *02:11, *02:12, *02:17, *02:35, *02:36, *02:46, *02:49, *68:01, *68:02, *68:03, *68:05, *68:10, *68:17, *69:01 in CDC assays in 13th IHWS Mulder et al, Human Immunology 56: 106-113, 1997: SN607D8 and SN66E3 react with HLA-A2, A28 in ELISA and CDC assays. Müller et al, Human Immunology 6: 189-197, 1983: Mouse monoclonal antibody Tü101 (IgM) produced by immunization of BALB/c mouse against HLA-A2. Antibody reacts with HLA-A2- and A28-positive cells in CDC assays. Dessi et al, Human Immunology 27: 323-332, 1990: Human monoclonal antibody 91C2 (IgG) reacts with HLA-A2, A28 cells in indirect immunofluorescence assays. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibodies 151-8-1 (12w009) and 301338 (12w011) positive with HLA-A2 (including A*02:03), A68, A69 in CDC assays in 12th IHWS. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies 76.3.10 (10w2020), NFLD.M2 (10w2021), CBRI.M1.20.86 (10w2026), CBRI.M3.63.14 (10w2027), XV.17 (10w2029), 4B (10w2032), TU101 (10w2033), TU160 (10w2035) MTC301338 (10w2040) positive with HLA-A2, A28 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibodies XV.17, 4B and TU160 are weak with PBL. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies 76.3.10 (10w2020, NFLD.M2 (10w2021), 76.3.21 (10w2025), CBRI,M1.20.86 (10w2026), CBRI.M3.63.14 (10w2027), XV.17 (10w2029), TU101 (10w2033), TU152 (10w2034), MTC301338 (10w2040) positive with HLA-A2, A68, A69 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.

145KHA (confirmed) on HLA-ABC

Tongio et al, In HLA: Genetic Diversity of HLA Functional and Medical Implication, ed. D. Charron, pp 7-11. Paris, France: EDK, 1997: Monoclonal antibodies 278-1 (12w010), TU-101 (12w012), HO-1 (12w013) and MRE1 (12w015) positive with HLA-A2 (not A*02:03), A68, A69 in CDC assays in 12th IHWS, with r values of 0.85, 0.90, 0.94 and 0.87, respectively. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibodies Z1211, TU101 0245 (13-WS 0018) positive with HLA-A*02:01, *02:02, *02:04, *02:05, *02:06, *02:07, *02:11, *02:12, *02:17, *02:35, *02:36, *02:46, *02:49, *68:01, *68:02, *68:03, *68:05, *68:10, *68:17, *69:01 in CDC assays in 13th IHWS. Mulder et al, Tissue Antigens 42: 27-34, 1993: Human monoclonal antibody 5C2A2 induced by sensitization to A2 and/or A28 through transfusion and restimulated with in vitro immunization positive with A*02:01, A*02:02, A*02:04, A*02:05, A*02:06, A*02:07, A*02:08, A*02:09, A*02:10, A*68:01, A*68:02, A*69:01 EBV-transformed cell lines in microlymphocytotoxicity assays. Reactions with A*02:03 cells were negative. Hogan KT et al, Journal of Immunology 141: 2519-25, 1988: Monoclonal antibody CR11-351 binds to HLA-A2 molecules with the exception of HLA-A2.3, which differs from A*02:01 in 3 amino acid positions, 149, 152 and 156. The substitution of threonine (T) for alanine (A) at position 149 in transfected human cell line Hmy2.C1R completely eliminated binding of CR11-351. Substitutions of glutamic acid (E) for valine (V) at position 152 and/or tryptophan (W) for leucine (L) at position 156 had no effect on antibody binding. This showed that the presence of alanine at position 149 is critical for the antibody recognition of the epitope recognized by this monoclonal antibody. The authors proposed that the epitope recognized by antibody CR11-351 is made up of the amino acid positions 142T-145H-149A.

145RT (provisional) on HLA-ABC

Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with


El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody Z8855.TO positive with HLA-A*25:01, *26*01, *34:01, *43:01, *66:01, *66:02 Equivalent to TerEp #4.


Mother A*01:01 A*24:02 B*14:02

B*15:01 C*03:03 C*07:01

Allele MFI Epitope

Pos cont 8155

Neg cont 1

A*25:01 IMM 1249 145RT

A*26:01 125 145RT

A*34:01 503 145RT

A*34:02 1225 145RT

A*43:01 162 145RT

A*66:01 788 145RT

A*66:02 1320 145RT


149TAH (provisional) on HLA-ABC

MFI valuesEl-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Alloserum S33S positive with HLA-A*02:03, *25:01, *26:01, *34:01, *43:01, *66:01, *66:02 Equivalent to TerEp #27.

150AAH (confirmed) on HLA-ABC

El-Awar et al, Human Immunology 71: 456-461, 2010: Mouse monoclonal antibody X8032.H0 (IgM) produced by immunization with cells that type as HLA-A2, A3; B7, B62. Equivalent to TerEp #422.

149AH pair

149AH+161T (preliminary) Duquesnoy, Hönger, Hösli , Marrari and Schaub: Detection of newly antibody-defined epitopes on



Mother A*31:01 A*32:01 B*27:05 B*40:01

MFI Epitope

A*02:01 Imm 2947 149AH+161T

A*02:06 2954 149AH+161T

A*02:03 3949 149AH+161T

A*01:01 3722 149AH+161T

A*11:01 2675 149AH+161T

A*11:02 2682 149AH+161T

A*24:02 3375 149AH+161T

A*24:03 3734 149AH+161T

A*36:01 1772 149AH+161T

A*68:01 1805 149AH+161T

A*68:02 1855 149AH+161T

A*69:01 2391 149AH+161T

A*03:01 159 149AH+161D

A*23:01 69

A*25:01 43

A*26:01 22

A*29:01 20

A*29:02 52

A*30:01 9

A*30:02 8

A*31:01 self 13

A*32:01 self 10

A*33:01 64

A*33:03 22

A*34:01 31

A*34:02 40

A*43:01 28

A*66:01 36

A*66:02 19

A*74:01 15

A*80:01 1

151AHA (confirmed) on HLA-ABC

Human monoclonal antibody MUL6D1 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A24; B18, B51. Immunizing haplotype is HLA-A11; B55; Cw3.

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Alloserum 2002-00323 positive with HLA-A*11:01, *11:02 Equivalent to TerEp #404.

156DA (provisional) on HLA-ABC

Lomago et al, Human Immunology 71: 176-178, 2010: Post renal transplant alloserum 2010-156DA with antibody towards alleles that share epitope on mismatched donor allele C*07:04. Antibody producer types as HLA- A*01:01, A*66:01; B*44:03, B*58:01; C*04:01, C*06:02. Donor typed as HLA- A*01:01, A*03:01; B*15:01, B*57:01; C*06:02, C*07:04.

Serum had also reactivity towards other mismatched epitopes shared by donor HLA-A*03:01 and B*15:01 alleles.

158T (confirmed) on HLA-ABC

Ge and Hannestad, Human Immunology 36: 168-171, 1993: Human monoclonal antibody TrJ5 (IgM) positive with HLA-B38, B39 (no B67 cells tested) in CDC assays using B cell lines. Weaker reactions observed for CDC with purified T- and B-cells. Sensitization due to pregnancy El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody Z7567.RO positive with HLA-B*38:01, *39:01, *67:01 Equivalent to TerEp #9.

161D (confirmed) on HLA-ABC

Human monoclonal antibody OK2F3 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A28; B7, B27; Cw2, Cw7. Immunizing haplotype is HLA-A3; B70.

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Mouse monoclonal antibody X8341.EO positive with HLA-A*03:01 Equivalent to TerEp #6. Epitope is shared also by A*32:04. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: OK2F3 (13-WS 0038) reacts with HLA-A*03:01, *03:02, *03:09, *32:04 in CDC assays in 13th IHWS. In ELISA assays, reacts also with HLA-B13 (see Mulder et al, Human Immunology 56: 106-113, 1997). Mouse monoclonal antibodies X5510, Z5162, X2635, 361-1 (13-WS 0035), MRE2 (13-WS 0034), UL101 0912-12 (13-WS 0033), 160-3 (13-WS 0036), 3E11 (13-WS 0036), 129-2-47 (13-WS 0039) positive with HLA-A*03:01, *03:02, *03:09, *32:04 in CDC assays in 13th IHWS. X2635, MRE2, 3E11, 129-2-47 also react with A*03:06, which has residue 162A; other A3 alleles and A*32:04 have 162G. Tongio et al, in Genetic Diversity of HLA - Functional and Medical Implication, D. Charron (Ed), pp.7-11, 1997: Monoclonal antibodies OK2F3 (12w021), MP9 (12w022), 361-1 (12w024), UL-101 (12w025), 3E11DS (12w028) and MRE2 (12w029) positive with HLA-A3 in CDC assays in 12th IHWS, with r values of 0.80, 0.80, 0.89, 0.93, 0.94 and 0.93, respectively. Nelson et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies GAP.A3 (10w2005), XI.23 (10w2009), GSP55.2 (10w2013) positive with HLA-A3 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Antibody XI.23 is weak with PBL. Kennedy et al, in Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies GAP.A3 (10w2005), XI.23 (10w2009), XI15.4 (10w2010), GSP55.2 (10w2013) positive with HLA-A3 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.

163EW (confirmed) on HLA-ABC

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X3245.AO (absorbed with HLA-B*73:01 cells) positive with HLA-A*66:02, B*07:02, B*13:01, B*27:05, B*27:08, B*47:01, B*48:01, B*40:01, B*40:02, B*73:01, B*81:01 Equivalent to TerEp #222. Epitope is not shared by A*66:01.

163EW pairs on HLA-ABC

163EW+66I (provisional) cross-reacts with 163EW+66N on A*66:02 This pregnancy serum had also antibodies against 41T.



First Pregnancy Serum 1stP#233



MFI

Allele Ep Ep

B*40:02 Immunizer 9647 41T 163EW+s66I

B*47:01 5358 41T 163EW+s66I

B*40:01 10547 41T 163EW+s66I

B*40:06 10787 41T 163EW+s66I

B*13:02 8552 41T 163EW+s66I

B*13:01 5221 41T 163EW+s66I

B*41:01 7579 41T

B*44:03 6717 41T

B*44:02 6513 41T

B*45:01 10001 41T

B*49:01 8509 41T Distance from 163EW

B*50:01 8242 41T 66I 8 Ang

B*07:02 Informative 11608 163EW+s66I






A*66:02 Informative 7976 163EW+s66N Cross-reactive

Mean+SD 8306+1956 163EW+s66I/N

C*02:02 430 163EW+66K Non-reactiveC*17:01 67 163EW+66K Non-reactive

Others N=76 164+178


Negative Control 0

Self Alleles 86+39

163EW+73TE (provisional) El Awar N et al, Human Immunology 68: 170-180, 2007: Alloserum RGF37 (absorbed with B*07:03 cells) was positive with beads bearing B*07:02, B*13:01, B*27:05, B*27:08, B*47:01, B*48:01, B*40:01, B*40:02, B*81:01 in Luminex single antigen assay. Equivalent to TerEp #223. Marrari M et al, Transplantation 90: 1468-72, 2011 Human IgG monoclonal antibody WK1D12 is positive with HLA-B alleles that share the nonself eplet 163EW paired with self eplet 73TE. The antibody producer types as HLA-A1; B8; C7 and the immunizing allele is HLA-B27, on which eplet 163EW is found; the antibody producer’s HLA-B8 shares the self eplet 73TE. The two eplet configurations are approximately 16 Ångstroms apart from each other, sufficient distance for contact by two different CDRs of antibody. Reactivity of WK1D12:


Mother A*02:01 A*23:01 B*15:18 B*51:01


B*40:02 IMM 9647 41T 163EW+66I/N

B*40:06 10787 41T 163EW+66I/N

B*40:01 10547 41T 163EW+66I/N

B*13:02 8552 41T 163EW+66I/N

B*47:01 5358 41T 163EW+66I/N

B*13:01 5221 41T 163EW+66I/N

B*45:01 10001 41T

B*49:01 8509 41T

B*50:01 8242 41T

B*41:01 7579 41T

B*44:03 6717 41T

B*44:02 6513 41T

B*27:05 Informative 7995 163EW+66I/N

A*66:02 Informative 7976 163EW+66I/N







163LS/G (confirmed) on HLA-ABC

163LS and 163LG have a Landsteiner-type cross-reactivity


Mother A*24:02, A*32:01 B*07:02 B*41:02

Allele MFI Epitope

B*44:02 Imm 6742 163LS/G

B*44:03 6927 163LS/G

B*45:01 12019 163LS/G

B*82:01 5607 163LS/G

B*15:12 8306 163LS/G


Post 3rd Pregnancy serum (Schaub, Basel)

Mother A*02:01 A*31:01 B*08:01 B*27:05

MFI Epitope

Pos Cont 10659 -

Neg Cont 14 -

B*44:03 Imm 3447 163LS/G

B*15:12 8531 163LS/G

B*44:02 3207 163LS/G

B*45:01 7155 163LS/G

B*82:01 4204 163LS/G


Post -allograft nephrectomy

serum DEMERI, Cesbon (Nantes, France)

Patient A*02:01A*11:01

Patient B*18:01B*51:01

Patient C*07:01C*04:01

Immunizer Unknown

B*15:12 10360 163LS/G

B*44:02 5686 163LS/G

B*44:03 3315 163LS/G

B*45:01 9793 163LS/G

B*82:01 8447 163LS/G

Self Alleles 129+92

40 Other HLA-B 130+35

Post allograft nephrectomy case Pt#2 (Adams)

HLA-AB type of patient

A*32:01 A*68:02 B*35:01 B*53:01B*57:01 8742 62GE induced by A*02:01

B*57:03 8197 62GE induced by A*02:01

B*58:01 7060 62GE induced by A*02:01

Epitope

B*44:02 Imm 10358 163LS/G

B*15:12 12947 163LS/G

B*44:03 7870 163LS/G

B*45:01 14998 163LS/G

B*82:01 14008 163LS/G

B*35:01 self 184

B*53:01 self 195

39 HLA-B alleles 641+697

163LW (confirmed) on HLA-ABC

Human monoclonal antibody VDe1F11 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A1, A3; B7, B8; Cw7; immunizer HLA type is unknown. Duquesnoy R, Marrari M, Mulder A, Claas F, Mostecki J, Balazs I. 2012. Structural Aspects of HLA Class I Epitopes Detected by Human Monoclonal Antibodies. Human Immunology 73: 267-77

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Serum eluate A6 (absorbed with B*15:01/B35 cells, Equivalent to TerEp #245.

Mulder et al, Human Immunology 56: 106-133, 1997: VDe1F11 reacts with HLA-B15, B17, B21, B35, B46, B56, B51, B52, B72, B60, B55 in CDC assays; it reacts with HLA-B15, B17, B49 and B13 in ELISA assays (B46, B56 and B72 not tested by ELISA). Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: VDe1F11 (13-WS 0147) positive with HLA-B*13:04, *15:01, *15:02, *15:03, *15:04, *15:05, *15:07, *15:08, *15:09, *15:10, *15:11, *15:13, *15:16, *15:17, *15:18, 15:20, *15:21, *15:23, *15:24, *15:25, *15:27, *15:29, *15:30, *15:31, *15:32, *15:35, *15:39, *15:65, *15:70, *35:01, *35:02, *35:03, *35:05, *35:08, *35:10, 35:12, *35:17,


Mother A*26:01 A*30:01 B*18:01 B*38:01

MFI Epitope Epitope

B*15:01 Imm 12245 44RMA 163LW

B*15:02 11877 44RMA 163LW

B*15:13 9703 44RMA 163LW

B*15:11 5869 44RMA 163LW

B*46:01 5794 44RMA 163LW

B*15:16 9345 44RMA 163LW

B*57:03 8781 44RMA 163LW

B*57:01 9117 44RMA 163LW

B*13:01 6347 44RMA

B*15:12 11921 44RMA

B*13:02 6898 44RMA

B*15:03 Informative 10973 163LW












C*03:03 Informative 3075 163LW



41 remaining HLA-B,C alleles 76+117

*35:19, *35:20, *35:23, *46:01, *49:01, *49:03, *50:01, *51:01, *51:02, *51:04, *51:06, *51:07, *51:08, *51:24, *51:28, *52:01, *53:01, *53:06, *55:08, *56:01, *56:02, *56:03, *56:04, *56:05, *56:07, *57:01, *57:02, *57:03, *57:04, *58:01, *58:02, C*03:02, C*03:03, C*03:04 in CDC assays in 13th IHWS.

163LW pairs on HLA-ABC

163LW + 65QIT (provisional) Duquesnoy R, Int J Immunogenetics 39, p 1-9, 2012: Human monoclonal antibody HDG11G12 (A. Mulder) is produced by a woman who types as HLA-A2, A24; B7, B60; Cw7 and was immunized through pregnancy to HLA-B35. The antibody reacts with only those HLA-B alleles that share eplet 163LW in combination with 65QI:


Mother A*01:01, A*68:01 B*40:01 B*44:02 C*03:04' C*07:04

MFI Epitope Epitope

B*40:01 Self 3 65QIT

B*44:02 Self 1 65QIT

B*35:01 Imm 6814 163LW+65QIT 44RT+65QIT

B*51:01 4787 163LW+65QIT 44RT+65QIT

B*51:02 6951 163LW+65QIT 44RT+65QIT

B*52:01 3266 163LW+65QIT 44RT+65QIT

B*53:01 6097 163LW+65QIT 44RT+65QIT

B*78:01 5893 163LW+65QIT 44RT+65QIT

B*18:01 3618 44RT+65QIT

B*37:01 2759 44RT+65QIT

B*58:01 566 163LW+65RNA 44RT+65RNA

B*15:01 Informative 1843 163LW+65QIT








B*56:01 704 163LW+65QIA

B*57:01 593 163LW+65RNA

B*57:03 504 163LW+65RNA

B*15:16 689 163LW+65RNA

C*03:02 9 163LW+65QKR

C*03:03 7 163LW+65QKR

C*03:04 Self 2 163LW+65QKR

163R (provisional) on HLA-ABC

El-Awar N et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate AS264 (absorbed with A*25:01 cells) positive with HLA-A*01:01, A*11:01, A*11:02, A*25:01, A*26:01, A*43:01, A*66:01 Equivalent to TerEp #12. Epitope is not shared by HLA-A*66:02. Laundy GJ et al, Transfusion 44: 814-25, 2004: Serum from multiparous female patient KG186, with acquired aplastic anemia following transfusions of WBC-poor red blood cells, showed pattern of IgG reactivity towards HLA-A1, A11, A25, A26, A43, A*66:01.

163RG (confirmed) on HLA-ABC

Human monoclonal antibody GV2D5 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A2, A29; B44, B57; Cw6. Immunizer types as HLA-A1; B8, B56; Cw1, Cw7.

Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibodies X7993, X8894 positive with HLA-A*01:01, *01:03 in CDC assays in 13th IHWS.

163RW (confirmed) on HLA-ABC

Human monoclonal antibody VP5G3 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-A24, 32; B18, B60; Cw10. Immunizing haplotype is HLA-A26; B55; Cw1.

El-Awar et al, Human Immunology 68: 170-180, 2007: Serum eluate Z2076.@0 (absorbed with A*25:01 cells), Equivalent to TerEp #209. Epitope is not shared by HLA-A*66:02, but is shared by *24:10, which was positive in CDC assays.

Mulder et al, Tissue Antigens 52: 393-396, 1998: VP5G3 reacts with HLA-A11, A25, A26, A66 in CDC assays; A43 not tested. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: VP5G3 (13-WS 0061) positive with HLA-A*11:01, *11:02, *11:03, *24:10, *25:01, *25:02, *26:01, *26:02, *26:03, *26:08, *26:15, *66:01 in CDC assays in 13th IHWS. No HLA-A43-positive cells were tested.

Post allograft nephrectomy serum MERFAT, Cesbron (Nantes, France)

Patient A*29:02 A*30:01 B*07:02 B*51:01C*07:02

Allele Self MFI Ep1 Ep2

A*11:01 Imm 3203 163RW

A*25:01 3780 163RW

A*26:01 2329 163RW

A*43:01 2180 163RW

A*66:01 2511 163RW

A*11:02 3140 163RW

A*30:02 Imm 8825 76EG

A*30:01 Self 706

A*29:02 Self 703

All Self Alleles 646+72

Remaining HLA-A (N=22) 818+259

Neg Cont 611

Pos Cont 11611

mailto:Z2076.@0

163TW pairs on HLA-ABC

163TW+65QI (preliminary) El Awar N et al, Human Immunology 68: 170-180, 2007: Serum eluate Z6895.00 (absorbed with B*18:01 cells) was positive with beads bearing B*08:01, B*14:01, B*14:02, B*18:01, B*37:01, B*38:01, B*39:01, B*39:05, B*41:01, B*41:02, B*42:01, B*54:01, B*55:02, B*59:01, B*67:01 in Luminex single antigen assay. Equivalent to TerEp #226. Duquesnoy R and Marrari M, Tissue Antigens 74: 117-33, 2009: This eplet pair consists of two amino acid residue configurations located approximately 13 Ångstroms apart, sufficient distance for contact by two different complementarity-determining regions (CDRs).

163TEW+103L (preliminary) El Awar N et al, Transplantation 84: 532-40, 2007: Mouse monoclonal antibody Z2611.R0 was positive with beads bearing B*54:01, B*55:02, B*59:01, C*01:02, C*04:01, C*05:01, C*06:02, C*07:02, C*08:01, C*12:03, C*14:02, C*15:02, C*16:01, C*18:02 in Luminex single antigen assay. Equivalent to TerEp #232. Duquesnoy R and Marrari M, Tissue Antigens 74: 117-33, 2009: The distance between the two configurations making up this eplet pair is 7 Ångstroms, sufficient for contact by two different complementarity-determining regions (CDRs) of antibody.

166DG (confirmed) on HLA-ABC

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate X9288.OO (absorbed with A*24:02 cells) positive with HLA-A*01:01, A*23:01, A*24:02, A*80:01, B*15:12 Equivalent to TerEp #14. Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: Mouse monoclonal antibody 384-5 (13-WS 0006) reacts with A*01:01, *01:03, *23:01, *24:02, *24:06, *24:07, *24:17, *24:20, *24:27, *80:01 in CDC assays in 13th IHWS.


Mother A*02:01 A*30:01 B*07:02 B*13:02


A*24:02 Imm 11126 80I 166DG

A*23:01 11803 80I 166DG

A*25:01 11978 80I

A*32:01 11321 80I

A*24:03 11907 80I

A*01:01 Informative 4653 166DG


B*15:12 Informative 5078 166DG


Post Allograft Nephrectomy Serum KJ Chrenova (Bratislava, Slovakia)

Patient A*26:01 A*03:01B*41:01 B*35:01 C*04:01

Imm B*57:01


A*01:01 Imm 13718 44KM3 166DG

A*36:01 9784 44KM3





A*02:01 4139 62GE

A*02:02 1232 62GE

A*02:03 4804 62GEA*02:05 2272 62GE

18 reamaining HLA-A alleles 676+165


Mother A*03:01, A*33:01 B*14:02 B*15:18 C*07:04 C*08:02


Pos cont 8644

Neg cont 9

A*24:02 IMM 6122 127K 82LR 167DG

A*23:01 8354 127K 82LR 167DG

A*24:03 6704 127K 82LR

A*02:01 3246 127K

A*02:03 7376 127K

A*02:06 3227 127K

A*68:01 8802 127K

A*68:02 6659 127K

A*69:01 2860 127K

A*25:01 7549 82LR

A*32:01 7947 82LR






Mother A*02:01, A*03:01:B*07:02 B*18:01 C*07:01 C*07:02


A*24:02 Imm 8916 82LR 166DG

A*25:01 11850 82LR

A*32:01 11570 82LR

A*23:01 10483 82LR

A*24:03 8966 82LR




24 remaning HLA-A alleles 36+69

173K (confirmed) on HLA-ABC

Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki P, Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki Pl. 2006. HLA class I epitopes: C-locus. Clinical Transplants: 95-102 This eplet corresponds to Terasaki epitope #5081. Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71 Antibody reactivity towards this eplet was seen in five renal transplant patients whose post-nephrectomy sera were submitted to the 15th International Histocompatibility Workshop study on HLA epitope immunogenicity. The high antibody frequency (>40%) observed in this small study leads us to believe that eplet 173K has a relatively high immunogenicity among HLA-C eplets.

177KT (provisional) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Alloserum A129 positive with HLA-C*05:01, C*08:01 Equivalent to TerEp #40

Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71 Antibody reactivity towards this eplet was seen in four renal transplant patients whose post-nephrectomy sera were submitted to the 15th International Histocompatibility Workshop study on HLA epitope immunogenicity. The high antibody frequency (>40%) observed in this small study leads us to suspect that eplet 177KT has a relatively high immunogenicity among HLA-C eplets.


156684MA, Doxiadis (Leiden, The Netherlands)

Patient A*29:02 B*45:01 B*50:01 C*06:02

MFI Ep

C*05:01Imm 9296 177KT

C*08:01 6438 177KT

C*01:02 190

C*02:02 268

C*03:02 198

C*03:03 190

C*03:04 152

C*04:01 329

C*06:02Self 183

C*07:02 176

C*12:03 193

C*14:02 254

C*15:02 190

C*16:01 151

C*17:01 307

C*18:01 302

self alleles 114+47

Neg Cont 62

Pos Cont 4312

Post allograft nephrectomy serumDay, Romano (Hershey, PA)

Patient A*25:01A*29:01 B*15:01 B*44:02MFI Ep1 Ep2

C*05:01 Imm 13490 80K 177KT

C*08:01 12121 177KT

C*06:02 Imm 8727 80K

C*18:02 12077 80K

C*17:01 10574 80K

C*15:02 10282 80K

C*02:02 9711 80K

C*04:01 5321 80K

C*01:02 641

C*07:02 541

C*12:03 496

C*03:03 331

C*03:04 Self 295

C*03:02 288

C*14:02 287

C*16:01 Self 200


Neg Cont 48

Pos Cont 9996

180E (provisional) on HLA-ABC

El-Awar et al, Human Immunology 68: 170-180, 2007 (no MFI values): Serum eluate ARCJA (absorbed with B*07:02 cells) positive with HLA-B*07:02, B*08:01, B*40:01, B*41:01, B*42:01, B*48:01, B*81:01 Equivalent to TerEp #20.


Mother A*11:01 A*24:02 B*15:18 B*51:01 C*01:02 C*07:04

Allele MFI Epitope Epitope Epitope Epitope

B*07:02 Imm 10843 163EW 65QIA 69AA 180E

B*27:05 11613 163EW 65QIA 69AA

B*27:08 11677 163EW 65QIA 69AA

B*73:01 12478 163EW 65QIA 69AA

B*81:01 13214 163EW 65QIA 69AA

B*40:01 13932 163EW 180E

B*48:01 12679 163EW 180E

A*66:02 14656 163EW

B*13:01 9904 163EW

B*13:02 13610 163EW

B*40:02 12472 163EW

B*40:06 14220 163EW

B*47:01 7729 163EW

B*42:01 12333 65QIA 69AA 180E

B*54:01 13471 65QIA 69AA

B*55:01 13379 65QIA 69AA

B*56:01 11247 65QIA 69AA

B*67:01 11606 65QIA 69AA

B*82:01 13599 65QIA 69AA

B*15:16 3803 69AA

B*57:01 5353 69AA

B*57:03 5040 69AA

B*58:01 2319 69AA

B*08:01 Informative 6634 180E




Mother A*24:02,- B*15:01 B*57:01 C*03:03 C*06:02


B*07:02 Imm 12482 163EW 65QIA 180E

B*81:01 11812 163EW 65QIA 180E

B*27:05 11800 163EW 65QIA

B*27:08 12473 163EW 65QIA

B*73:01 6675 163EW 65QIA

B*40:01 12546 163EW 180E

B*48:01 10894 163EW 180E

B*13:01 5462 163EW

B*13:02 12395 163EW

B*40:02 12622 163EW

B*40:06 11634 163EW

B*47:01 5625 163EW

B*42:01 10811 65QIA 180E

B*54:01 2238 65QIA

B*55:01 8599 65QIA

B*56:01 2630 65QIA

B*67:01 8835 65QIA

B*82:01 7000 65QIA




193PL3 (provisional) on HLA-ABC

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Serum eluate A132 (absorbed with C*07:02 cells) positive with HLA-C*07:02 Equivalent to TerEp #37. Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki P. 2006. HLA class I epitopes: C locus. Clinical Transplants: 95-102 Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71 Antibody reactivity towards this eplet was observed in five renal transplant patients whose post-nephrectomy sera were submitted to the 15th International Histocompatibility Workshop study on HLA epitope immunogenicity.

193PV (provisional) on HLA-ABC

Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71 Adeyi OE, Girnita A, Awadalla Y, Askar M, Shapiro R, Howe J, Martell J, Zeevi A, Nalesnik M, Rhandawa P, Demetris AJ, Duquesnoy RJ. 2005. Serum Analysis After Kidney Transplant Nephrectomy Reveals Restricted Antibody Specificity Patterns Against Donor HLA Class I Antigens. Transpl. Immunol 14: 53-62 Antibody reactivity with specificity against this epitope was observed in four patients who underwent nephrectomy following a failed kidney transplant. All four cases involved donors mismatched for HLA-B51 and eplet 193PV. In three cases, no antibody was detected prior to allonephrectomy, while in one case, the antibody reactivity was essentially identical pre- and post-nephrectomy.

219W (confirmed) on HLA-ABC

Human monoclonal antibody TRA2G9 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA- A2, A24; B14, B38; Cw7, Cw8. Immunizing haplotype is HLA-A2; B62 (B*15:01); Cw3.

Fernandez-Vina et al, in Immunobiology of the Human MHC vol. I, J.A. Hansen (Ed), pp 890-931, 2006: TRA2G9 (13-WS 0143) shows correlation with HLA-B alleles, but reactivity is actually against HLA-C alleles that share epitope 219W in CDC assays in 13th IHWS. Duquesnoy R, Marrari M. 2011. Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants. Transplant Immunol. 24: 164-71 REMOVE THIS REFERENCE? Only one case with antibody to 219W, and that is in (), indicating that the positives could be due to other eplets shared by reactive alleles!!

253Q (provisional) on HLA-ABC

This serum reacted with all HLA-A alleles except those two of the patient. Nevertheless, it was possible to four likely epitopes. One of them is defined by 253Q. Informative alleles are highlighted in yellow. The other epitopes discussed in the EpiPedia are 76VD and 144K.

El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Multiple serum eluates (absorbed with A*25:01, A*02:01 cells, no information on HLA types of antibody producers or immunizers). Equivalent to TerEp #38.

Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki P, Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki Pl. 2006. HLA class I epitopes: C-locus. Clinical Transplants: 95-102


Patient A*23:01 A*30:02 B*53:01 C*04:01

Allele MFI Ep1 Ep 2 Ep3 Ep4

A*02:01 Imm 15936 62GE 76VD 144K 253Q

A*02:03 13398 62GE 76VD 144K 253Q

A*02:06 16421 62GE 76VD 144K 253Q

B*57:01 6889 62GE

B*57:03 8468 62GE

B*58:01 6921 62GE

A*68:01 13787 76VD 144K 253Q

A*68:02 12591 76VD 144K 253Q

A*69:01 9676 76VD 144K 253Q

A*03:01 4478 76VD 144K

A*11:01 6996 76VD 144K

A*11:02 11269 76VD 144K

A*24:03 8525 144K

A*24:02 6623 144K

A*01:01 1790 144K

A*36:01 1523 144K

A*80:01 1051 144K

A*31:01 4949 76VD 253Q

A*33:01 2826 76VD 253Q

A*33:03 5127 76VD 253Q

A*34:01 4615 76VD 253Q

A*34:02 5590 76VD 253Q

A*66:01 3830 76VD 253Q

A*66:02 4128 76VD 253Q

A*74:01 5105 76VD 253Q

A*30:01 3815 76VD

A*30:02 Self 278

A*32:01 2317 253Q

A*25:01 3551 253Q

A*26:01 2563 253Q

A*29:01 4003 253Q

A*29:02 3532 253Q

A*43:01 2556 253Q

B*73:01 2312 253Q

C*07:02 4181 253Q

C*17:01 4956 253Q

A*23:01 Self 345



Neg Cont 194

Pos Cont 10399

267QE (provisional) on HLA-ABC

Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki P, Akaza T, El-Awar N, Nguyen A, Kitawaki J, Terasaki Pl. 2006. HLA class I epitopes: C-locus. Clinical Transplants: 95-102 El-Awar et al, Transplantation 84: 532-540, 2007 (no MFI values): Serum eluate A61 (absorbed with C*17:01 cells) was positive with HLA-B73, Cw7 and Cw17 in Luminex single bead assays. Equivalent to TerEp #41.

EpiPedia of HLA-DR

4Q (provisional) on DRB

Knowles, R. W., N. Flomenberg, et al. (1986). "Complexity of the supertypic HLA-DRw53 specificity: two distinct epitopes differentially expressed on one or all of the DR beta-chains depending on the HLA-DR allotype." Journal of Immunology 137(8): 2618-2626. Mouse mAb PL3 recognizes 4Q and mAb 109d6 is DR53 specific. Knowles, R. W. (1989). Structural polymorphism of the HLA class II alpha and beta chains: Summary of the 10th Workshop 2-D gel analysis. Immunobiology of HLA. B. Dupont. New York, Springer-Verlag. I. Immunoprecipitation studies and amino acid sequence comparisions suggest the involvement of 4Q in the epitope recognized by mAb PL3 Lardy, N., A. van der Horst, et al. (1991). "Fine Specificity of the Alloantiserum MSD-51: Epitope Mapping of HLA-DR53 Determinants." Hum Immunol 32: 65-71. Immunoprecipitation studies with mAb PL3 demonstrated epitope shared between DR7, DR9 and DR53 Fu XT, Yu WY, Alber C, Benson C, Watts R, Nordwig H, Johnson JP, Knowles RW, Karr RW. 1992. Identification of residues involved in polymorphic antibody binding epitopes on HLA-DR molecules. Human Immunology. 33: 47-56 Mutated DR7 molecules with a Q4R substitution lose their reactivity with mAb PL3 whereas mutated DR4 molecules with a R4Q substitution gain reactivity. Cai et al, Clinical Transplants 2006, pp 103-114 Mouse mAbs reacting with HLA-DR7, DR9, DR53. Equivalent to Terasaki’s Epitope #1001 Cai, J., P. I. Terasaki, et al. (2006). "Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens." American Journal of Transplantation 6(12): 2947-2954. Four DR7-Induced donor-specific antibodies reacted with 4Q-carrying alleles

4R (provisional) on DRB

Marsh SG, Bodmer JG. 1989. HLA-DR and -DQ epitopes and monoclonal antibody specificity. Immunology Today 10: 305-12Mouse mAb HU-26 (10W3057) detects a postulated 4R-defined epitope shared by all DRB antigens except DR7, DR9, and DR53 Fu XT, Yu WY, Alber C, Benson C, Watts R, Nordwig H, Johnson JP, Knowles RW, Karr RW. 1992. Identification of residues involved in polymorphic antibody binding epitopes on HLA-DR molecules. Human Immunology. 33: 47-56 Mutated DR4 molecules with R4Q substitutions lose their reactivity with mAbs I-2 and HU-26 whereas mutated DR7 molecules with Q4R substitutions gain reactivity. Fu XT, Karr RW. 1994. HLA-DR chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Human Immunology 39: 253-60 Antibody binding to DRB1*07:01 transfectants with DRA mutations indicate that some residues on the outer loops of DRA are critical for epitopes recognized by mAbs, HU-26 and I-2. (Editor’s note: since DRA chains are primarily monomorphic, these residues are not relevant to the polymorphisms of DR epitopes)

11STS (provisional) on DRB

Post 1st pregnancy serun #235 (Schaub, Basel)

Mother DRB1*07:01 DRB1*09:01DRB4*01:01DRB4*01:01

Allele MFI Epitope Epitope Influence Epitope

DRB1*11:01 Imm 4356 11STS 28D 32Y

DRB1*11:04 5029 11STS 28D 32Y

DRB1*03:01 8005 11STS 28D

DRB1*13:01 5967 11STS 28D

DRB1*13:03 7184 11STS 28D 32Y

DRB1*14:01 5102 11STS 28D

DRB1*03:02 Informative 3721 11STS

DRB1*04:01 2512 28D 32Y

DRB1*04:02 2010 28D 32Y

DRB1*04:03 2165 28D 32Y

DRB1*04:04 2525 28D 32Y

DRB1*04:05 2467 28D 32Y

DRB1*08:01 1558 28D 32Y

DRB1*15:01 5434 28D 32Y

DRB1*15:02 4166 28D 32Y

DRB1*15:03 2915 28D 32Y

DRB1*16:01 3509 28D 32Y

DRB1*16:02 3133 28D 32Y

DRB3*01:01 864 28D 32H

DRB3*02:02 Imm 982 51R

DRB3*03:01 74


Post 2nd pregnancy serum #102 (Schaub,Basel)

Antibody producer DRB1*08:01 DRB1*15:01DRB5*01:01


DRB1*13:02 Imm nd 11STS

DRB1*03:01 12387 11STS

DRB1*03:02 12499 11STS

DRB1*11:01 11579 11STS

DRB1*11:04 11429 11STS

DRB1*13:01 10626 11STS

DRB1*13:03 11481 11STS

DRB1*14:01 11754 11STS

DRB3*01:01 Imm 7860 98Q 57V 104AK

DRB3*03:01 6137 98Q 57V 104AK

DRB3*02:02 10788 98Q 104AK

DRB1*07:01 5475 57V 104AK

DRB1*09:01 3967 57V 104AK

DRB1*12:02 4040 57V

DRB1*12:01 3741 57V

DRB1*09:02 weak 1030 104AK

DRB1*04:01 weak 251 104AK

DRB1*04:02 weak 247 104AK

DRB1*04:05 weak 238 104AK

DRB1*04:04 weak 266 104AK

DRB1*04:03 weak 121 104AK

self alleles 15+24


Neg cont 1

Pos cont 8918

Note: This epitope is defined solely by the unique 13S which has nearby polymorphic residues 10Y, 11S, 12T in the peptide-binding groove. None of them appear accessible for direct contact with antibody and it possible that they influence the conformation of nearby surface residues such 14E and 25R thereby giving rise to 11STS epitope. Heyes, J. M., H. Inoko, et al. (1992). Fine mapping of Eleventh International Histocompatibility Workshop HLA class II monoclonal antibodies using transfectants. HLA 1991 - Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, Oxford University Press. 2: 400-404. Mouse mAb TAL8.1 (11W0706/11W1443) reacts with transfectants expressing DRB1*03:01, 11:01 and 14:02 according to the serologically assigned DR3,11,6 specificity. Navarrete et al, Genetic Diversity of HLA – Functional Medical Implications vol. 1, D. Charron (Ed), pp 11-17, 1997: Mouse mAb M5210 (12w558) reacts with HLA-DRB1*03:01, *03:02, *03:04, *11, *13:01/*13:02, *13:03, *14:01, *14:03 in CDC assays in 12th IHWS (r=0.82) Cai, J., P. I. Terasaki, et al. (2006). "Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens." American Journal of Transplantation 6(12): 2947-2954. DR13-induced donor-specific antibodies in a patient who typed as DR1, DR12 reacted only with 11S12T13S-carrying alleles DRB1*03:01, *03:02,*11:01,*13:01, *13:03 and *14:01. Eluates after absorptions with DRB1*13:01 or DRB1*14:01 had the same reactivity pattern.

13FE (preliminary)

Post allograft nephrectomy serum ECU-1 Rebelleto (Greenville,NC)

Patient: DRB1*11:01 DRB1*13:03 DRB3*02:02 DRB3*01:01

MFI Ep1 Ep2 Ep3

DRB1*01:01 Imm 9939 96EV 13FE 31I

DRB1*01:02 11390 96EV 13FE 31I

DRB1*01:03 7636 96EV 13FE 31I

DRB5*01:01 7320 96EV 13FE 31I

DRB5*02:02 5386 96EV 13FE 31I

DRB1*09:01 2505 13FE 31I

DRB1*10:01 Informative 5250 13FE

DRB4*01:01 4437 31I

DRB4*01:03 6129 31I

Self alleles 509+441


16Y (confirmed) on DRB

Pistillo MP, Mazzoleni O, Kun L, Falco M, Tazzari PL, Ferrara GB. 1991. Production of two human hybridomas secreting antibodies to HLA-DRw11 and--DRw8+w12 specificities. Human Immunology 31: 86-93 Human mAb HMP14 (IgM) induced by planned immunization with cells from HLA-DR8-positive donor; antibody reacts with HLA-DR8, DR12 in cytofluorometry and CDC assays. Epitope originally described as 13G14E15C16Y. Navarrete C, Brown C, De Lange P, Schreuder GMT. 1997. 12th International Histocompatibility Workshop HLA class II monoclonal antibodies study. In HLA Genetic diversity of HLA. Functional and Medical Implication. Vol 1, ed. D Charron, pp. 11-7. Mouse mAbs 294-1 (12w526), 294-5 (12w527) and human mAb MP 14 (12w528) react with HLA-DRB1*08:01, *08:02, *08:03, *08:04, *08:09, *12:01, *12:02, *14:04 in CDC assays in 12th IHWS (r values range 0.87-0.90) Cai J, Kohanof S, Terasaki P. 2006. HLA-DR Antibody Epitopes. In Clinical Transplants 2006, pp. 103-14. Los Angeles, CA: Tearasaki Foundation Laboratory Multiple post renal transplant allosera (no information on HLA types of antibody producers/immunizers) and mouse mAb reacting with HLA-DR8, DR12 Epitope equivalent to Terasaki’s Epitope #1407 (Marrari and Duquesnoy. 2009 Tissue Antigens 74: 134-46).


Patient DRB1*15:01 DRB1*09:01 DRB5*01:01 DRB4*01:01

sDRB ImDRB Score MFI Ep

DRB1*12:01 Imm 4886 16Y

DRB1*08:01 2238 16Y

Self alleles 210+64


25Q3 (confirmed) on DRB

Nelson K, Bodmer J, Martin A, Navarrete C, Strong DM. 1989. Micro EIA and Monoclonal Antibodies. In Immunobiology of HLA, ed. B Dupont, pp. 292-301. New York: Springer-Verlag Rat mAb SFR16.DR7M (10w3050) reacts with HLA-DR7 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Kennedy LJ, Marsh SGE, Bodmer J. 1989. Cytotoxic Monoclonal Antibodies. In Immunobiology of HLA, ed.

B Dupont, pp. 301-305. New York: Springer-Verlag Monoclonal antibody SFR16.DR7M (10w3050) and TAL 13.1 react with HLA-DR7 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Fu X-T, Drover S, Marshall WH, Karr RW. 1995. HLA-DR residues accessible under the peptide-binding groove contribute to polymorphic antibody epitopes. Hum Immunol 43: 243-50 Mutated DRB1*07:01 with the K14E substitution did not react with the DR7-specific mAb SFR16-DR7m and TAL13.1 whereas the Q25R substititution partially reduced binding. Mutated DRB1*04:03 with R25Q was nonreactive. Thus 14K is critical for the epitope recognized by these mAbs. Navarrete C, Brown C, De Lange P, Schreuder GMT. 1997. 12Th International Histocompatibility Workshop HLA class II monoclonal antibodies study. In HLA Genetic diversity of HLA. Functional and Medical Implication. Vol 1, ed. D Charron, pp. 11-7. Paris, France: EDK Mouse mAb 291-3 (12w519) reacts with HLA-DRB1*07:01 in CDC assays in 12th IHWS (r=0.80) Cai et al, Clinical Transplants 2006, pp 103-114 Mouse mAb reacts with HLA-DR7. Equivalent to Terasaki’s Epitope #1008, 1405 and 1602.

25R (confirmed) on DRB

Transplant case

Ogasawara, K., M. Kasahara, et al. (1985). "A monoclonal antibody recognizing a polymorphic determinant on HLA-DR antigens except DR7 and DRw9." Tissue Antigens 26(5): 344-347. Mouse mAb HU-26 was shown to recognize a polymorphic determinant on HLA-DR molecules except DR7 and DRw9 by serological and immunochemical analyses. Marsh SG, Bodmer JG. 1989. HLA-DR and -DQ epitopes and monoclonal antibody specificity. Immunology Today 10: 305-12 Mouse mAb 50D6 (10W3054), GSP14.1 (10W3055), HU20 (10W3056) react in CDC with a postulated 25R-defined epitope shared between all HLA-DRB except DR7 and DR53. Nelson K, Bodmer J, Martin A, Navarrete C, Strong DM. 1989. Micro EIA and Monoclonal Antibodies. In Immunobiology of HLA, ed. B Dupont, pp. 292-301. New York: Springer-Verlag Mouse mAbs 50D6 (10w3054), GSP14.1 (10w3055), HU20 (10w3056), HU26 (10w3057) react with all HLA-DRB1 alleles except DR7 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS Kennedy LJ, Marsh SGE, Bodmer J. 1989. Cytotoxic Monoclonal Antibodies. In Immunobiology of HLA, ed. B Dupont, pp. 301-5. New York: Springer-Verlag Mouse mAbs 50D6 (10w3054), GSP14.1 (10w3055), HU20 (10w3056), HU26 (10w3057) react with all HLA-DRB1 alleles except DR7 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930. DRB1*04:03-induced mouse mAb 51WS3 reacts with all DRB except DR7 and DR53 Fu X-T, Drover S, Marshall WH, Karr RW. 1995. HLA-DR residues accessible under the peptide-binding groove contribute to polymorphic antibody epitopes. Hum Immunol 43: 243-50 Four mAbs DA6.164, HU-20, Q5/6 and 50D6 reacted with all DR except DR7. The substitution R25Q on DRB1*04:03 abolished reactivity with these mAbs but the double substitution K14E+Q25R made the mutated DRB1*07:01 to become reactive. Thus, the epitope requires 25R and 14E

25YRL (provisional) on DRB

Post-pregnancy serum #173 from Schaub

Antibody producer DRB1*03:01 DRB1*13:01 DRB3*01:01

ImDRB Score MFI Ep

DRB1*12:01 Imm 6950 25YRL

DRB1*12:02 7278 25YRL

DRB3*02:02 Imm 1

self alleles 3+3

28 Remaining alleles 9+16

Neg cont 1

Pos cont 7787

28D (preliminary)

Post 1st pregnancy serun #235 (Schaub, Basel)

Mother DRB1*07:01 DRB1*09:01DRB4*01:01DRB4*01:01

Allele MFI Epitope Epitope Influence Epitope

DRB1*11:01 Imm 4356 11STS 28D 32Y

DRB1*11:04 5029 11STS 28D 32Y

DRB1*03:01 8005 11STS 28D

DRB1*13:01 5967 11STS 28D

DRB1*13:03 7184 11STS 28D 32Y

DRB1*14:01 5102 11STS 28D

DRB1*03:02 3721 11STS

DRB1*04:01 Informative 2512 28D 32Y











DRB3*01:01 Informative 864 28D 32H

DRB3*02:02 Imm 982 51R

DRB3*03:01 74


28H (provisional) on DRB



MFI Ep1 Ep1var Ep2 Ep3?

DRB5*02:02 Imm 10145 96EV 28H

DRB5*01:01 8014 96EV 28H

DRB1*01:01 8018 96EV

DRB1*01:02 5595 96EV

DRB1*01:03 8273 96EV

DRB1*09:02 informative 5504 28H

DRB1*09:01 informative 3540 28H

DRB1*16:01 Imm 1603 96QV xr ?142M3

DRB1*16:02 1263 96QV xr ?142M3

DRB1*15:03 1393 96QV xr ?142M3

DRB1*15:01 2431 96QV xr ?142M3

DRB1*15:02 1803 96QV xr ?142M3

DRB1*10:01 Informative 2014 96QV xr

Self alleles 33+35


31FYY (provisional) on DRB

Duquesnoy RJ, Honger G, Hosli I, Marrari M, Schaub S. Identification of epitopes on HLA-DRB alleles reacting

with antibodies in sera from women sensitized during pregnancy. Hum Immunol. 77: 214-222, 2016

Two examples (31FYY was previously annotated as 31FY+37Y)

Stefan Schaub Pregnancy Serum #384 Stefan Schaub Pregnancy Serum #178

Antibody Producer: DRB1*13:01,-; DRB3*01:01,- Antibody Producer: DRB1*13:01,15:01; DRB3*01:01,DRB5*01:01

Ep1 Ep2 New Ep1 Ep2 New Other Nearby

DRB Allele MFI AbVer AbVer Ep DRB Allele MFI AbVer AbVer Ep Residues

DRB3*02:02 Immunizer 11468 51R2 DRB3*02:02 Immunizer 13641 51R2

DRB1*11:04 Immunizer 11215 57DE 31FYY DRB1*11:04 Immunizer 15161 57DE 31FYY 10Y 11S 12T 33N

DRB1*11:01 10331 57DE 31FYY DRB1*11:01 14486 57DE 31FYY 10Y 11S 12T 33N

DRB1*13:03 Informative 4704 31FYY DRB1*13:03 Informative 12264 31FYY 10Y 11S 12T 33N

DRB1*08:01 Informative 3140 31FYY DRB1*08:01 Informative 11339 31FYY 10Y 11S 12T 33N

DRB1*04:01 Informative 4806 31FYY DRB1*04:01 Informative 2383 31FYY 10Q 11V 12K 33H





DRB1*07:01 1504 Cross-reactive? 31FY+37F DRB1*13:01 self 25

DRB1*13:01 self 1 DRB1*15:01 self 39

DRB3*01:01 self 1 DRB1*07:01 120

DRB3*03:01 1 DRB1*15:02 29

DRB1*16:01 85 DRB1*15:03 41

DRB1*16:02 1 DRB1*16:01 13

DRB4*01:01 1 DRB1*16:02 1

DRB4*01:03 23 DRB3*01:01 self 1

DRB1*15:01 28 DRB3*03:01 1

DRB1*15:02 21 DRB4*01:01 127

DRB1*15:03 16 DRB4*01:03 67

Negative Alleles (N=23) 13±28 Negative Alleles (N=24) 82±71

Positive Control 6808 Positive Control 6943

31I (preliminary) on DRB



MFI Ep1 Ep2 Ep3

DRB1*01:01 Imm 9939 96EV 13FE 31I

DRB1*01:02 11390 96EV 13FE 31I

DRB1*01:03 7636 96EV 13FE 31I

DRB5*01:01 7320 96EV 13FE 31I

DRB5*02:02 5386 96EV 13FE 31I

DRB1*09:01 2505 13FE 31I

DRB1*10:01 5250 13FE

DRB4*01:01 Informative 4437 31I

DRB4*01:03 Informative 6129 31I



37YV (provisional) on DRB

(Editor’s note: this epitope is defined by hidden residues that cannot make direct contact with antibody. The may alter the conformation of nearby monomorphic 36E, 39R and 50V on the molecular surface thereby creating the TrJ11 epitope. Bunce, M., P. M. Sutton, et al. (1990). "The production of a human monoclonal antibody defining a split of HLA-DRw13 (DRw13b)." Tissue Antigens 36(3): 100-102. The cytotoxic human mAb NDS40 which detects a split of HLA-DRw13 (DRw13b) which is in linkage with HLA-DQw1. In addition, the antibody reacts with cells positive for HLA-DRw8 and DRw11, but does not react with the commonly found split of DRw13 (DRw13a) which is associated with DQw1. Marsh, S. G., J. H. Moses, et al. (1991). HLA class II sequence polymorphism detectable by serology. HLA 1991 Proceedings 11th International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. 1: 610-619. Human mAb NDS40 detects a 37Y38V epitope Ge, J., A. Bratlie, et al. (1995). "A human hybridoma antibody (TrJ11) recognizing a new HLA-DR epitope shared by DR4, DR8, DR11, and DRB1*1303." Hum Immunol. 42: 27-36. Human mAb TrJ11 from a DR1, DR6, DQ1 multiparous woman whose husband typed as DR4, DR8. It reacts in CDC and Flow Cytometry with DR4, DR8, DR11 and DRB1*13:03 on B cell lines but reacts with freshly isolated B-cells only from DR4 donors. The authors propose that 37Y is important to this epitope. However, DR10 which has 37Y is nonreactive. Moreover, this residue is on the floor of the peptide binding groove and therefore not antibody-accessible. (Editor’s note: the underlying 10Q11V12K configuration unique for DR4 may explain the DR4-specific B-cell reactivity through an additional conformational effect on the TrJ11 epitope)

40YD3 (provisional) on DRB

Data from Navarrete et al, Genetic Diversity of HLA – Functional Medical Implications vol. 1, Domenique Charron (Ed), pp 11-17, 1997: Mouse monoclonal antibodies M5426 (12w533) and M2439 (12w534) positive with DRB1*10:01 in CDC assays in 12th IHWS (r values range 0.42-0.52)

47F (provisional) on DRB



Stefan Schaub Pregnancy Serum #46

Antibody Producer: DRB1*04:05, *09:01; DRB4*01:01,-

Ep1 New Ep3 Ep4 Ep5

DRB Allele MFI VerEp Ep Eplet VerEp Eplet Pair

DRB1*13:01 Immunizer 15562 96HK 47F 70DA

DRB1*13:03 15051 96HK 70DA

DRB1*11:01 15022 96HK 47F 70DA

DRB1*11:04 15472 96HK 47F 70DA

DRB1*03:01 14712 96HK 47F

DRB1*03:02 11613 96HK 77N+s85VG

DRB1*14:01 13768 96HK

DRB1*08:01 13788 96HK 70DA

DRB1*12:01 16379 96HK 47F 70DA

DRB1*12:02 16188 96HK 47F 70DA

DRB1*15:01 Informative 7337 47F



DRB1*01:03 14704 70DA

DRB1*04:02 15680 70DA

DRB1*16:02 13765 70DA

DRB1*16:01 12586 70DA

DRB5*01:01 11759 70DA

DRB1*01:01 16

DRB1*01:02 5

DRB1*04:01 1

DRB1*04:03 1

DRB1*04:04 1

DRB1*04:05 Self 23

DRB1*07:01* 1183*

DRB3*02:02 Immunizer 10164 51R2 77N+s85VG

DRB3*01:01 5133 77N+s85VG

DRB3*03:01 1

Negative Alleles (N=13) 9±13


*The weak reactivity with DRB1*07:01 might reflect the presence of

25QR3-specific antibodies induced during a previous pregnancy

48Q6 (confirmed) on DRB

48Q6 has twelve polymorphic residues that are unique for DRB4 (DR53), two of them 11A and 13C are in the peptide-binding groove and cannot make direct contact with antibody. Eight residues 18L, 25W, 26N, 28I, 40Y, 41N, 44L, 48Q and 81Y are in antibody-accessible locations on the top of the DRB molecule. Residue 180M is in the membrane-proximal domain. Altogether, there might be as many as six unique eplets on DRB4 molecules.

Kosinski, S., U. Hammerling, et al. (1986). "A human monoclonal antibody to an HLA-DRw53 (MT3)-like epitope on class II antigens." Tissue Antigens 28(3): 150-162. A human mAb R39.14 cloned from B-LCL was specific for DR53 I cytotoxicity assays on B-LCL and PBL Knowles, R. W., N. Flomenberg, et al. (1986). "Complexity of the supertypic HLA-DRw53 specificity: two distinct epitopes differentially expressed on one or all of the DR beta-chains depending on the HLA-DR allotype." Journal of Immunology 137(8): 2618-2626.

Mouse mAbs PL3 and 109d6 detect DR53-related determinants 109d6 must be DRB4-specific and in contrast to PL3 which did not react with the B57, DR7, DQ3 haplotype which lacks DRB4.

Nelson K, Bodmer J, Martin A, Navarrete C, Strong DM. 1989. Micro EIA and Monoclonal Antibodies. In Immunobiology of HLA, ed. B Dupont, pp. 292-301. New York: Springer-Verlag Mouse mAb GSP65.1 reacts with HLA-DR53 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Kennedy et al, Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 301-305, 1989: Mouse mAb GSP65.1 (10w3051) reacts with HLA-DR53 in CDC assays with PBL and B-lymphoblastoid cell lines in 10th IHWS.


Fuggle, S. V., C. Carter, et al. (1989). "Monoclonal antibody definition of the DRB3 allele, HLA-Dw25." Tissue Antigens 34(3): 149-157. Mouse mAb NDS10 reacts with all DR5(w11) cells,2/3 DRw12 cells, 3/17 DRw13 and 9/10 DRw14 cells.. Two-dimensional gel analyses revealed that the NDS10 molecule precipitated from DR3, DR5(w11) and DRw6(w14) cell lines had identical DRB chain profiles. These data indicate that NDS10 recognizes the Dw25 allele of the DRw52 complex. Berte CC, Gorski J, Reith W, Mach B. 1989. Epitope Mapping of HLA-DR Antigens with the Use of DNA-Transfected Cells. In Immunobiology of HLA, ed. B Dupont, pp. 245-7. New York: Springer-Verlag Mouse mAb (NDS10) reacts only with DRB3*02 (DR52b) but not with DRB3*01 (DR52a) or DRB3*03 (DR52c) transfected mouse cells


Antibody producerDRB1*10:01DRB1*13:03 DRB3*01:01

MFI Ep

DRB3*02:02 Imm 7037 51R

DRB1*03:01 Imm 166

self alleles 30+34

29 remainng alleles 26+26

Neg Cont 1

Pos Cont 7311

57DE (confirmed) on DRB

Human monoclonal antibody (IgG) VR1H5 from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-DRB1*04:01, *16:01; DRB4*01:03; DRB5*02:02. Immunizing haplotype is HLA-DRB1*11:01; DRB3*02:02; DQB1*03:01.

Pistillo, M. P., O. Mazzoleni, et al. (1991). "Production of two human hybridomas secreting antibodies to HLA-DRw11 and--DRw8+w12 specificities." Human Immunology 31(2): 86-93. The DR11-induced human mAb MP12 reacts only with DR11 in cytofluorometry and CDC assays. Knowles, R. W. (1989). Structural polymorphism of the HLA class II alpha and beta chains: Summary of the 10th Workshop 2-D gel analysis. Immunobiology of HLA. B. Dupont. New York, Springer-Verlag. I. Mouse mAb GS88.2 is monospecific for DR11 Marsh SG, Bodmer JG. 1989. HLA-DR and -DQ epitopes and monoclonal antibody specificity. Immunology Today 10: 305-12 Rat mAb SFR.DR5 (10W3037) reacts with a postulated 58E-defined epitope on DRw11. Nelson et al, Immunobiology of HLA, vol I, Bo Dupont (Ed), pp. 292-301, 1989: Mouse mAb GSP88.2 (10w3036) reacts with HLA-DR11 in micro ELISA assays with PBL and B-lymphoblastoid cell lines in 10th IHWS. Extra reactions seen with PBL. Klohe E, Pistillo MP, Ferrara GB, Goeken NE, Greazel NS, Karr RW. 1992. Critical role of HLA-DR beta 1 residue 58 in multiple polymorphic epitopes recognized by xenogeneic and allogeneic antibodies. Human Immunology. 35: 18-28 Mutated DR11 with E58A or E58D lost reactivity with MP12 and GS88.2 but D57A had no effect. Moreover mutated DRB1, DRB3 and DRB5 chains with A58E substitutions became reactive with GS88.2 and to lesser extent with MP12. These findings suggest that 58E plays a dominant role this epitope which must also have another configuration unique on DRB (except DRB4) but absent on DPB. Mutated DR11 chains with E9W, Y10Q, S11L, T12K, S13F, D28E, Y30C, Y37S, F37, F67L, D70Q, D70R, R71E, A74Q, A74E and T77N continued to react with MP12 and GS88.2. (Edit. Our sequence analysis and Cn3D modeling indicate that the additional configuration may include 70R/Q and/or 74A/Q). Navarrete et al, Genetic Diversity of HLA – Functional Medical Implications vol. 1, Domenique Charron (Ed), pp 11-17, 1997: Human mAb HMP (12w538) and mouse mAbs Y2628 (12w535), Y2566 (12w536) and LU6 (12w539) react with HLA-DRB1*11:01, *11:04 in CDC assays in 12th IHWS (r values range 0.71-0.94) Cai et al, Clinical Transplants 2006, pp 103-114: Multiple mouse mAbs react with HLA-DR11. Equivalent to Terasaki’s Epitope #1017

Epitope: 57DEDP (confirmed) on DRB also on DP

Note: The 58EDPepitope on DR11 is the same as the 56EDR11 epitope on DPB Pistillo, M. P., O. Mazzoleni, et al. (1991). "Production of two human hybridomas secreting The DR11-induced human mAb MP4 reacts with HLA-DR11 and 56E-carrying DPB alleles in cytofluorometry and CDC assays. Bodmer JG, Bodmer W, Heyes Jea. 1987. Identification of HLA-DP Polymorphism with DP and DP Probes and Monoclonal Antibodies: Correlation with Primed Lymphocyte Typing. Proc. Nat. Acad. Sci. USA 84: 4596-600 Mouse I-LR1 mAb recognize an epitope on DR11 and 56E-carrying DPB molecules that share 56DEE or DED Klohe E, Pistillo MP, Ferrara GB, Goeken NE, Greazel NS, Karr RW. 1992. Critical role of HLA-DR beta 1 residue 58 in multiple polymorphic epitopes recognized by xenogeneic and allogeneic antibodies. Human Immunology. 35: 18-28 Mutated DR11 with E58A or E58D substitutions lost reactivity with MP4 and I-LR1 but D57A had no effect. Moreover mutated DRB1, DRB3 and DRB5 chains with A58E substitutions became reactive. These findings suggest that 58E plays a dominant role in this epitope but may require another configuration shared between DRB1, DRB3, DRB5 and DPB. Mutated DR11 chains with E9W, Y10Q, S11L, T12K, S13F, D28E, Y30C, Y37S, F67L, D70Q, D70R, R71E, A74Q, A74E and T77N continued to react with MP4 and I-LR2. It was suggested that the additional configuration may include residues 41Q, 44L and/or 48R. Yu, W. Y., R. Watts, et al. (1990). "Identification of amino acids in HLA-DPw4 and -DR5 1 chains that are involved in antibody binding epitopes using site-directed mutagenesis and DNA-mediated gene transfer." Human Immunology. 27(2): 122-135. The E56A substitution of mutated DPB1*04:02 and the E58A substitution of mutated DRB*11 abolished binding with I-LR1. Diaz, G., M. Amicosante, et al. (2003). "Functional analysis of HLA-DP polymorphism: a crucial role for DPB residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding." International Immunology 15: 565-576. The E56A substitution on mutated DRB1*02:01 abolished reactivity with mAb ILR1.

57V (provisional) on DRB

Post 2nd pregnancy serum #102 (Schaub,Basel)

Antibody producer DRB1*08:01 DRB1*15:01DRB5*01:01


DRB1*13:02 Imm nd 11STS

DRB1*03:01 12387 11STS

DRB1*03:02 12499 11STS

DRB1*11:01 11579 11STS

DRB1*11:04 11429 11STS

DRB1*13:01 10626 11STS

DRB1*13:03 11481 11STS

DRB1*14:01 11754 11STS

DRB3*01:01 Imm 7860 98Q 57V 104AK

DRB3*03:01 6137 98Q 57V 104AK

DRB3*02:02 10788 98Q 104AK

DRB1*07:01 Informative 5475 57V 104AK

DRB1*09:01 Informative 3967 57V 104AK

DRB1*12:02 Informative 4040 57V

DRB1*12:01 Informative 3741 57V

DRB1*09:02 weak 1030 104AK

DRB1*04:01 weak 251 104AK

DRB1*04:02 weak 247 104AK

DRB1*04:05 weak 238 104AK

DRB1*04:04 weak 266 104AK

DRB1*04:03 weak 121 104AK

self alleles 15+24


Neg cont 1

Pos cont 8918

Post 2nd Pregnancy serum #61 (Schaub, Basel)

Antibody producer DRB1*11:04 DRB1*16:01 DRB3*02:02 DRB5*02:02

MFI Ep1 Ep2 Ep3 Ep4

DRB1*07:01 Imm 13924 4Q 181M 57V 37FV

DRB4*01:03 16275 4Q 181M

DRB4*01:01 Imm 16010 4Q 181M

DRB1*09:01 14831 4Q 181M 57V

DRB1*09:02 10683 4Q 181M

DRB1*10:01 3758 181M

DRB1*12:01 16074 57V

DRB1*12:02 15344 57V

DRB3*01:01 15325 57V

DRB3*03:01 8935 57V 37FV

DRB1*14:01 1732 37FV

self alleles 5+9


Neg Cont 10

Pos Cont 7290

67LQ pair on DRB

67LQ+60Y (provisional) also a very weak Landsteiner-type cross-reactivity with 67LR+60Y Duquesnoy RJ,

Honger G, Hosli I, Marrari M, Schaub S. Identification of epitopes on HLA-DRB alleles reacting with antibodies in

sera from women sensitized during pregnancy. Hum Immunol. 77: 214-222, 2016

67LQ+73AT (preliminary) has a strong Landsteiner-type cross-reactivity with 67LR+s3AT Note: The nonself-self

paradigm was used to determine this epitopeDuquesnoy RJ, Honger G, Hosli I, Marrari M, Schaub S.

Identification of epitopes on HLA-DRB alleles reacting with antibodies in sera from women sensitized during

pregnancy. Hum Imm. 77: 214-222, 2016


Antibody Producer: DRB1*08:01,*15:01; DRB5*01:01,-

Ep1

DRB Allele MFI Eplet Pair*

DRB1*01:01 Immunizer 10185 67LQ+s60Y

DRB1*01:02 13466 67LQ+s60Y

DRB1*04:01 11168 67LQ+s60Y

DRB1*04:03 5050 67LQ+s60Y

DRB1*04:04 13585 67LQ+s60Y

DRB1*04:05 9535 67LQ+s60Y

DRB1*03:01 6523 67LQ+s60Y

DRB1*03:02 5337 67LQ+s60Y

DRB3*02:02 10496 67LQ+s60Y

DRB3*01:01 1 (67LQ+60S)

DRB3*03:01 1 (67LQ+60S)

DRB1*01:03 1 (67ID+s60Y)

DRB1*04:02 1 (67ID+s60Y)

DRB1*10:01 weak reaction** 309 67LR+s60Y



DRB1*09:02 weak reaction** 433 67FR+s60Y

DRB1*09:01 48 (67FR+60H)

DRB1*14:01 26 (67LR+60H)

Other Negative Alleles (N=21) 11±16

*Non-reactive pairs are between parentheses

** A low degree of cross-reactivity of 67LR+s60Y and 67FR+s60Y


Antibody Producer: DRB1*13:01, *15:01; DRB3*01:01, DRB5*01:01

Ep1 Ep2 New Ep 3 Other Residues

DRB Allele MFI AbVer Eplet Eplet Pair* in Ep3

DRB1*01:01 Immunizer 10020 96ES2 13FE s67LQ+s73AT 71R 74A

DRB1*01:03 16163 96ES2 13FE

DRB1*01:02 12638 96ES2 13FE s67LQ+s73AT 71R 74A

DRB1*10:01 10967 13FE 67LR+s73AT 71R 74A

DRB1*09:02 4164 13FE

DRB1*09:01 2834 13FE

DRB1*04:04 Informative 15120 s67LQ+s73AT 71R 74A

DRB1*04:05 Informative 12569 s67LQ+s73AT 71R 74A

DRB1*04:01 Informative 5152 s67LQ+s73AT 71K 74A

DRB1*04:03 Informative 4223 s67LQ+s73AT 71R 74E

DRB1*13:01 Self 1 s67ID+s73AT

DRB1*15:01 Self 28 s67IQ+s73AT

DRB3*01:01 Self 1 s67LQ+s73GN

DRB5*01:01 Self 1 s67FD-s73AT

DRB1*04:02 1 (67ID+s73AT)

DRB1*03:01 65 (s67LQ+73GN)

DRB1*03:02 93 (s67LQ+73GN)

DRB3*02:02 1 (s67LQ+73GN)

DRB3*03:01 1 (s67LQ+73GN)

DRB1*14:01 7776 67LR+s73AT** 71R 74E

DRB4*01:01 7412 67LR+s73AT** 71R 74E

DRB4*01:03 8625 67LR+s73AT** 71R 74E

DRB5*02:02 702



*Non-reactive pairs are between parentheses

** 67LR+s73AT cross-reacts with 67LQ+s73AT

67LR (preliminary) on DRB


Besides Ep1 70R antibodies appeared to recognize Ep2 67LR defined by 67L and 71R and influenced by 3 nearby residues

Patient DRB1*13:01 DRB1*15:01 DRB3*01:01 DRB5*01:01 Influence of

MFI Ep1 Ep 2 nearby residues

DRB1*10:01 Imm 11214 70R 67LR 13F 26L 28E

DRB4*01:03 9534 70R 67LR 13C 26N 28I

DRB4*01:01 8715 70R 67LR 13C 26N 28I

DRB1*14:01 2774 70R 67LR 13S 26F 28D

DRB1*09:01 2041 70R

DRB1*09:02 2930 70R

DRB1*01:01 Informative 6252 67LR 13F 26L 28E

DRB1*01:02 Informative 2832 67LR 13F 26L 28E

DRB1*04:03 380 67LR 13H 26F 28D

DRB1*04:05 59 67LR 13H 26F 28D

Self alleles 13+14


Pos Control 5529

70D (provisional) on DRB




Antibody Prodcer: DRB1*01:01,*03:01; DRB3*01:01,- Ep1 Ep2 Ep3 New

DRB Allele ImDRB MFI VerEp VerEp Eplet Ep

DRB1*15:01 Immunizer 8962 142M3

DRB1*15:02 9726 142M3

DRB1*15:03 10559 142M3

DRB1*16:02 13492 142M3 70D

DRB1*16:01 12963 142M3 70D

DRB5*01:01 Immunizer 13021 108T 28H 70D

DRB5*02:02 12887 108T 28H

DRB1*09:01 Weak 294 28H

DRB1*09:02 Weak 455 28H

DRB1*01:03 Informative 7608 70D










DRB1*01:01 1

DRB1*01:02 1

DRB1*04:01 16

DRB1*04:03 1

DRB1*04:04 1

DRB1*04:05 43

Other negative Alleles (N=14) 36±47


70DA (provisional) on DRB





Ep1 Ep2 New Ep4 Ep5

DRB Allele MFI VerEp Eplet Ep VerEp Eplet Pair


DRB1*13:03 15051 96HK 70DA

DRB1*11:01 15022 96HK 47F 70DA

DRB1*11:04 15472 96HK 47F 70DA

DRB1*03:01 14712 96HK 47F

DRB1*03:02 11613 96HK 77N+s85VG

DRB1*14:01 13768 96HK

DRB1*08:01 13788 96HK 70DA

DRB1*12:01 16379 96HK 47F 70DA

DRB1*12:02 16188 96HK 47F 70DA

DRB1*01:03 Informative 14704 70DA





DRB1*15:01 7337 47F

DRB1*15:02 5499 47F

DRB1*15:03 3768 47F

DRB1*01:01 16

DRB1*01:02 5

DRB1*04:01 1

DRB1*04:03 1

DRB1*04:04 1

DRB1*04:05 Self 23

DRB1*07:01* 1183*


DRB3*01:01 5133 77N+s85VG

DRB3*03:01 1





70QT (provisional) on DRB

Drover, S., R. W. Karr, et al. (1994). "Analysis of monoclonal antibodies specific for unique and shared determinants on HLA-DR4 molecules." Human Immunology 40(1): 51-60. mAb NFLD.D10 binds to DRB1*01:01, 04:01, 04:03, 04:04, 04:05, 04:06,14:02, 15:01, 15:02 and DRB5*02:01. Studies on transfectants expressing hybrid DR4/DR7 chains suggest that the epitope is located in amino acid sequence 41-97. (Editor’s note: our analysis suggests that the epitope is defined by 70Q and 77T 4.8 Angstroms apart.

Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930. NFLD.D10 reactivity consensus specificity: DRB1*01:01, 01:02, DR4 except 04:02, weak DR9, DR10, 14:01, 14:02, 15:01, 15:02 and DRB5*02:01, 02:02. Drover, S., W. Marshall, et al. (1991). Contribution of residues 70 and 73 of HLA-DR 1 chains to the binding of monoclonal antibody NFLD.D10. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference., Oxford University Press. I: . K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. 2: 408-410 As shown in the figure below the Q70D substitution on mutated DRB chains affected the reactivity with NFLD.D10.

Moreover, the D70Q substitution on DRB1*04:02 and on Dw5 (Dr11) induced these alleles to become reactive and this provides further support of the critical role of 70Q. However, DR3 which has 70Q does not react with NFLD.D10 but the G73A substitution induced reactivity. Since all the NFLD.D10-reactive 70Q-carrying alleles (including the mutants) have 73A, it seems that the epitope needs 70Q+73A. Interestingly, the D70R mutation of Dw5 also induced reactivity with NFLD.D10. This finding is consistent with the NFLD.D10 reactivity with DRB1*04:04 and 04:05 which have 70R thereby suggesting that 70R might be an acceptable residue variation of this epitope which can be defined as 70Q(R)A. These studies by Karr’s group indicate that other mAbs NFLD.D2, NFLD.D8 and NFLD.D9 have similar reactivity patterns but as the figures below show there are weaker reactions with some alleles. These mAbs may recognize structurally related epitopes which might be influenced by the nearby peptides bound to the groove.

Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930.

Workshop studies have shown that NFLD.D2, NFLD.D8 and NFLD.D9 have the following consensus specificity: DRB1*01:01, 01:02, 04:01, weak 04:03, 04:04, 04:05, weak 04:06, weak 04:07, 14:02, weak 15:02 and DRB5*02:01, 02:02.

70R (provisional) on DRB


Antibodies appeared to recognize Ep1 70R and 3 nearby residues influenced reactivity

Patient DRB1*13:01 DRB1*15:01DRB3*01:01DRB5*01:01

MFI Ep1 nearby residues Ep 2

DRB1*10:01 Imm 11214 70R 37Y 38A 40Y 67LR

DRB4*01:03 9534 70R 37Y 38A 40Y 67LR

DRB4*01:01 8715 70R 37Y 38A 40Y 67LR

DRB1*14:01 2774 70R 37F 38V 40F 67LR

DRB1*09:01 2041 70R 37N 38V 40F

DRB1*09:02 2930 70R 37N 38V 40F

DRB1*01:01 6252 67LR

DRB1*01:02 2832 67LR

DRB1*04:03 380 67LR

DRB1*04:05 59 67LR

Self alleles 13+14


Pos Control 5529

71A (provisional) on DRB


Antibody producer DRB1*01:01DRB1*13:01DRB3*01:01

MFI Ep1 Ep2 Ep3

DRB5*02:02 Imm 14708 108T 71A

DRB5*01:01 13215 108T

DRB1*15:02 14119 71A 142M2

DRB1*15:03 11405 71A 142M2

DRB1*15:01 15418 71A 142M2

DRB1*16:01 Imm 2205 low 142M2

DRB1*16:02 1975 low 142M2

Self alleles 26+43


Neg cont 10

Pos cont 6501


Cayrol, C., F. Moro, et al. (1992). "New polymorphic HLA-DR epitopes recognized by three monoclonal antibodies produced against DR103 transfected L cells." Tissue Antigens 40(4): 197-203. The DRB1*01:03 induced mouse mAb TM903 reacts with all DR types except DR3 (DR301, 302), DR7 (DR701, 702) and DR52. Fu, X. T., W. Y. Yu, et al. (1992). "Identification of residues involved in polymorphic antibody binding epitopes on HLA-DR molecules." Human Immunology. 33(1): 47-56. Mouse mAb AC.BM.50 reacts with all DR types except DR3 and DR7. Studies with mutated DR4 and DR7 molecules with hybrid DR4/7 chains have shown that the epitope detected by mAb AC.BM.50 reside in sequence position 41-97. They suggest that 73A is involved with this epitope


Human monoclonal antibody BVK3D6 (IgM) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA- DRB1*11:01, *15:01; DRB3*02:02; DRB5*01:01; DQB1*03:01, *06:02. Immunizer HLA type is unknown

BVK3D6 reacts weakly with other DRB3-positive alleles in the One Lambda kit: DRB3*02:02 (self allele, MFI=1417), DRB3*03:01 (MFI=1180) Berte CC, Gorski J, Reith W, Mach B. 1989. Epitope Mapping of HLA-DR Antigens with the Use of DNA-Transfected Cells. In Immunobiology of HLA, ed. B Dupont, pp. 245-7. New York: Springer-Verlag Mouse mAb NDS9 reacts with DRB1*03 (DR3) and DRB3*01 (DR52a) transfected mouse cells Marsh SG, Bodmer JG. 1989. HLA-DR and -DQ epitopes and monoclonal antibody specificity. Immunology Today 10: 305-12 The mouse mAb 16.23 (9W929) reacs with a postulated epitope 74R75V76D77N shared between DR3 and DR52a (Dw24).

77N (confirmed) on DRB

Berte CC, Gorski J, Reith W, Mach B. 1989. Epitope mapping of HLA-DR antigens with the use of DNA-transfected cells. In Immunology of HLA, ed. B. Dupont, pp. 245-7. New York: Springer-Verlag Mouse mAb SJ1.6B1 reacts with all DR3 and DRB3 (DR52a,b,c) on transfected mouse cells Ballas, M., T. H. Eiermann, et al. (1990). "Mapping of an HLA-DRw52-associated determinant on DR beta 1 molecules." Tissue Antigens. 36(5): 187-193. The DR52-specific mAb 7.3.19.1 reactivity correlates with the expression of DRB residues 71K, 73G and 77N. Klohe E, Fu X-T, Ballas M, Karr RW. 1993. HLA-DR beta chain residues that are predicted to be located in the floor of the peptide-binding groove contribute to antibody-binding epitopes. Hum Immunol 37: 51-8 Mouse mAb 7.3.19.1 recognizes a 77N-defined epitope; the N77T mutation of DRB1*03:01 abolishes reactivity and the T77N mutation of DRB1*11:01 generates reactivity with 7.3.19.1. Since this DR11 mutant has the nearby 71R and 73A residues it seems that these sequence positions are not important for the 7.3.19.1 epitope. Heyes, J. M., H. Inoko, et al. (1992). Fine mapping of Eleventh International Histocompatibility Workshop HLA class II monoclonal antibodies using transfectants. HLA 1991 - Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, Oxford University Press. 2: 400-404 Mouse mAb 7.3.19.1 (11W0704/11W1444) has similar reactivity with TAL8.1 tested on lymphoid cell lines but on transfectants it binds to DR52 product Cai et al, Clinical Transplants 2006, pp 103-114: Mouse mAb Y5543.JO positive with HLA-DR17, DR18, DR52.

77N pair on DRB

77N+85sVG (provisional) Duquesnoy RJ, Honger G, Hosli I, Marrari M, Schaub S. Identification of epitopes on

HLA-DRB alleles reacting with antibodies in sera from women sensitized during pregnancy. Hum Immunol. 77:

214-222, 201



Ep1 Ep2 Ep3 Ep4 New

DRB Allele MFI VerEp Eplet Eplet VerEp Eplet Pair


DRB1*13:03 15051 96HK 70DA

DRB1*11:01 15022 96HK 47F 70DA

DRB1*11:04 15472 96HK 47F 70DA

DRB1*03:01 14712 96HK 47F

DRB1*03:02 11613 96HK 77N+s85VG

DRB1*14:01 13768 96HK

DRB1*08:01 13788 96HK 70DA

DRB1*12:01 16379 96HK 47F 70DA

DRB1*12:02 16188 96HK 47F 70DA

DRB1*01:03 14704 70DA

DRB1*04:02 15680 70DA

DRB1*16:02 13765 70DA

DRB1*16:01 12586 70DA

DRB5*01:01 11759 70DA

DRB1*15:01 7337 47F

DRB1*15:02 5499 47F

DRB1*15:03 3768 47F

DRB1*01:01 16

DRB1*01:02 5

DRB1*04:01 1

DRB1*04:03 1

DRB1*04:04 1

DRB1*04:05 Self 23

DRB1*07:01* 1183*


DRB3*01:01 Informative 5133 77N+s85VG

DRB3*03:01 Informative 1 77N+85VV





77T (confirmed) on DRB

Madrigal JA, Ikeda H, Marsh SG, Heyes JM, Kennedy LJ, Trowsdale J, Bodmer JG. 1989 Epitope mapping of an HLA-DR-specific monoclonal antibody produced by using human-mouse transfectant cells. Journal of Immunology 143: 4084-9 A mouse DR8-induced mAb TAL15.1 reacted with all DR except DR3 and DRw52 (which have 77N rather than 77T). In Western blots the antibody reacted with the DR dimer but not with free chains. Two-dimensional gel analysis of a DR11, DR52 cell line showed that TAL15.1 immunoprecipitates DR products. Although it also co-precipitated the DQB products (they share 77T with DR8), flow fluorimetric analysis with various transfectant cell lines showed that TAL15.1 failed to bind the DQ or DP products tested. Maurer D, Madrigal JA, Gorski J. 1992. Thr77 controls a public antibody epitope on DRB1. In HLA 1991 - Proceedings of the Eleventh International Histocompatibility Workshop and Conference, ed. K Tsuji, M Aizawa, T Sasazuki, pp. 404-6. Oxford: Oxford University Press A site-directed DR4x52 mutant which has 77N rather than 77T failed to react with mAb TAL15.1 Klohe E, Fu XT, Ballas M, Karr RW. 1993. HLA-DR beta chain residues that are predicted to be located in the floor of the peptide-binding groove contribute to antibody-binding epitopes. Human Immunology. 37: 51-8 Mouse mAb 21r5 recognizes an epitope in which T77 plays an important role. However, the single amino acid substitution T77N in DRB1*11:01 chains reduces but does not abolish 21r5 binding, which suggests the contribution of other polymorphic residues to this epitope.

Cai, J., P. I. Terasaki, et al. (2006). "Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens." American Journal of Transplantation 6(12): 2947-2954. A DR15-induced alloserum and eluates after DRB1*15:01, DRB1*01:01 and DRB*07:01 absorptions reacted exclusively with 77T-carrying alleles in Luminex assays.

96EV (confirmed) on DRB

Marrari M, Duquesnoy R. 2009. Why can sensitization by a HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1? Hum Immunol 70: 403-9 Studies of post-allograft nephrectomy cases contributed by 13 laboratories worldwide showed that 9/11 DR51 mismatches had induced antibodies that reacted with DR1 and that 8/8 DR1 mismatches induced antibodies that reacted also with DR51. These findings demonstrate that 96EV which is uniquely shared between DR1 and DR51 represents a highly immunogenic epitope that can induce cross-sensitization between antigens encoded by the different DRB loci

Loh, M. T., S. H. Chan, et al. (1993). "A monoclonal antibody with specificity to the HLA-DR1 and -DR51 antigens." Tissue Antigens. 42(2): 100-104.

A mouse mAb 137BL7 raised against purified DR1 protein was shown to bind specifically to 5/5 DR1, 18/18 DR2 cells and 0/23 non-DR1,2 cells by cell-EIA. Further analysis by FACS using HLA-transfectants revealed that 137BL7 also bound specifically to the DRB5 transfectants in addition to the expected DR1 transfectants. However, it did not bind to the DR2 (DR15) transfectants, showing that cross-reactivity with DR2 cells lies with the DRB5 (DR51) rather than the DRB1 gene product. A comparison of the HLA-DR amino acid sequences of DR1 and DR51 antigens revealed a common glutamic acid residue at position 96, which may form the putative binding epitope of this mAb.

Cai, J., P. I. Terasaki, et al. (2006). "Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens." American Journal of Transplantation 6(12): 2947-2954. DR1-induced donor-specific antibodies reacted with 96EV-carrying alleles



MFI ep1 ep2 ep3 ep4

DRB1*16:01 IMM 12472 142M2

DRB1*16:02 11891 142M2

DRB1*15:03 11631 142M2

DRB1*15:01 11236 142M2

DRB1*15:02 11780 142M2

DRB5*02:02 IMM 7436 108T 96EV 28H

DRB5*01:01 6056 108T 96EV 28H

DRB1*01:02 2148 96EV

DRB1*01:01 3013 96EV

DRB1*01:03 3132 96EV

DRB1*09:02 very weak 922 28H


self alleles 1+1


Neg cont 1

Pos cont 6083



MFI Ep1 Ep2 Ep3

DRB1*01:01 Imm 9939 96EV 13FE 31I

DRB1*01:02 11390 96EV 13FE 31I

DRB1*01:03 7636 96EV 13FE 31I

DRB5*01:01 7320 96EV 13FE 31I

DRB5*02:02 5386 96EV 13FE 31I

DRB1*09:01 2505 13FE 31I

DRB1*10:01 5250 13FE

DRB4*01:01 4437 31I

DRB4*01:03 6129 31I



96HK (confirmed) on DRB

Human monoclonal antibody RTLK1E2 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-DRB1*04:05, *15:01; DRB4*01:03; DRB5*01:01, DQB1*03:02, *06:02; immunizing haplotype is HLA-DRB1*03:01; DQB1*02:01. Duquesnoy RJ, Honger G, Hosli I, Marrari M, Schaub S. Identification of epitopes on HLA-DRB alleles reacting with antibodies in sera from women sensitized during pregnancy. Hum Immunol. 77: 214-222, 2016

Navarrete C, Brown C, De Lange P, Schreuder GMT. 1997. 12Th International Histocompatibility Workshop HLA class II monoclonal antibodies study. In HLA Genetic diversity of HLA. Functional and Medical Implication. Vol 1, ed. D Charron, pp. 11-7. Paris, France: EDK Mouse mAb EIII15/4 (12w517) reacts with HLA-DRB1*03:01, *03:02, *03:04, *08, *11, *12, *13:01/*13:02, *13:03, *14:01, *14:03 in CDC assays in 12th IHWS (r=0.87) Cai et al, Clinical Transplants 2006, pp 103-114 (no MFI values): Mouse mAbs reacting with HLA-DR8, DR11, DR12, DR13, DR14, DR17, DR18. Equivalent to Terasaki’s Epitope #1601

Serum #167

Antibody producer: DRB1*10:01,*15:01; DRB5*01:01,-

Ep1 Ep2

DRB Allele MFI Abver

DRB1*11:04 Immunizer 14939 96HK

DRB1*11:01 14562 96HK 96H+s86G

DRB1*03:02 13612 96HK 96H+s86G

DRB1*08:01 13283 96HK 96H+s86G

DRB1*03:01 Informative 15507 96HK





DRB1*14:01 Informative 15105 96HK 96H+s86G

DRB3*02:02 Immunizer 5638 96H+s86G

DRB3*01:01 2960 96H+s86G

DRB1*07:01 5625 96H+s86G

DRB1*09:01 4289 96H+s86G

DRB1*09:02 7178 96H+s86G

DRB3*03:01 1 96H+86V

Other negative Alleles (N=18) 23+33


96H+86G pair on DRB

96H+s86G (preliminary)



Serum #167

Antibody producer: DRB1*10:01,*15:01; DRB5*01:01,-

Ep1 Ep2

DRB Allele MFI Abver

DRB1*11:04 Immunizer 14939 96HK

DRB1*11:01 14562 96HK 96H+s86G

DRB1*03:02 13612 96HK 96H+s86G

DRB1*08:01 13283 96HK 96H+s86G

DRB1*03:01 15507 96HK

DRB1*12:01 9370 96HK

DRB1*12:02 10286 96HK

DRB1*13:01 15013 96HK

DRB1*13:03 15685 96HK

DRB1*14:01 15105 96HK 96H+s86G

DRB3*02:02 Immunizer 5638 96H+s86G

DRB3*01:01 informative 2960 96H+s86G




DRB3*03:01 1 96H+86V

Other negative Alleles (N=18) 23+33


96Y2 (confirmed)

96Y2 has two surface-exposed polymorphic residues that are unique on DR4. The membrane-proximal domain has 96E and 182L. These residues are 4.3 Angstroms apart and they may reflect two separate eplets. Residue 13H is in the peptide-binding groove and cannot make direct contact with antibody.

Maurer D, Gorski J. 1991. Transfer of polymorphic monoclonal antibody epitopes to the first and second domains of HLA-DR beta chains by site-directed mutagenesis. J. Immunol. 146: 621-7 The DR4-reactive mAb GS359-13F10 is specific for an epitope which has been been mapped to 96Y Drover S, Karr RW, Fu XT, Marshall WH. 1994. Analysis of monoclonal antibodies specific for unique and shared determinants on HLA-DR4 molecules. Human Immunology 40: 51-60 The DRB1*04:03-induced mouse mAb NFLD.D1 reacted with all DRB1*04:01-06 alleles in immunofluorescence and flow cytometry assays. Studies on transfectants expressing hybrid DR4/DR7 chains that the epitope does not

involve 96Y98E but more likely 180L. Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930. NFLD.D1 reactivity consensus specificity: all DR4 Cai et al, Clinical Transplants 2006, pp 103-114 Mouse mAbs reacting with HLA-DR4. Equivalent to Terasaki’s Epitopes #1034, #1042, 1406 and #1605

98E (provisional) on DRB



DRB Allele MFI Ep1 Ep2?

DRB1*04:03 Imm 10554 98E 96Y2

DRB1*04:01 11700 98E 96Y2

DRB1*04:02 11741 98E 96Y2

DRB1*04:04 11291 98E 96Y2

DRB1*04:05 11069 98E 96Y2

DRB1*07:01 Informative 9800 98E



DRB1*01:01 Imm 1

DRB3*02:02 weak 592 51R?


Neg Cont 1

Post Cont 11904

98ES (provisional) on DRB



MFI Ep1 Ep2

DRB1*07:01 IMM 14537 98ES

DRB1*09:01 11016 98ES

DRB1*09:02 14016 98ES

DRB4*01:01 IMM 2881 48Q6

DRB4*01:03 3478 48Q6

self alleles 1


Neg Cont 1

Pos Cont 7744

Post-pregnancy serum #387 from SchaubAntibody producer DRB1*15:01 DRB1*04:03 DRB5*01:01 DRB4*01:01

MFI Ep1 Ep2

DRB1*07:01 Imm 12251 25Q3 98ES

DRB1*09:01 4214 98ES

DRB1*09:02 6295 98ES

self alleles 1+0


Neg Cont 1

Pos Cont 7399

98Q (confirmed) on DRB

Note: DR52 alleles have also a unique 10Q in the peptide-binding groove which cannot make direct contact with antibody. Taylor, C. J., L. Ugozolli, et al. (1987). "Antigen Sociey #29 Report (DRw52)." (B. Dupont, Edit.) Immunobiology of HLA. Volume I: Histocompatibility Testing 1987: 273-275. DRw52 was clearly defined on both the Antigen Society and Core serology typing trays Kolstad A, Hansen T, Hannestad K. 1988. A cytotoxic human-human hybridoma antibody (TrH6) specific for HLA-DRw52. Tissue Antigens 31: 90-7 This is the first human mAb specific for DR52; its reactivity with a cell panel was comparable to mouse mAb 7.31.19.1 Cai et al, Clinical Transplants 2006, pp 103-114 (no MFI values): Mouse mAb Y5440.MX positive with HLA-DR52. Equivalent to Terasaki’s Epitope #1036


Cai et al, Clinical Transplants 2006, pp 103-114 (no MFI values): Mouse mAb Y5234.L0 reacts with HLA-DR4, DR7, DR9, DR51, DR52. Equivalent to Terasaki’s Epitope #1037 (Marrari and Duquesnoy. 2009 Tissue Antigens 74: 134-46). Cai, J., P. I. Terasaki, et al. (2006). "Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens." American Journal of Transplantation 6(12): 2947-2954. DR4-induced donor-specific antibodies reacted with 104A-carrying alleles

108T (provisional) on DRB

Van den Berg Loonen, E., J. D. Bignon, et al. (1997). AHS#11: DR2 (DR15, DR16), DR15. HLA Proc. twelfth International Histocompatibility Workshop and Conference. D. Charron. Sevres, France, EDK Medical and Scientific International publisher. 1: 91-95. Two allosera #22 and #23 were monospecific for DRB5 gene products Cai et al, Clinical Transplants 2006, pp 103-114 (no MFI values): Multiple mouse mAbs react with DR51 Equivalent to Terasaki’s Epitope #1402 (Marrari and Duquesnoy. 2009 Tissue Antigens 74: 134-46).


Antibody producer DRB1*01:01DRB1*13:01DRB3*01:01

MFI Ep1 Ep2 Ep3

DRB5*02:02 Imm 14708 108T 71A

DRB5*01:01 informative 13215 108T

DRB1*15:02 14119 71A 142M3

DRB1*15:03 11405 71A 142M3

DRB1*15:01 15418 71A 142M3

DRB1*16:01 Imm 2205 142M3

DRB1*16:02 1975 142M3

Self alleles 26+43


Neg cont 10

Pos cont 6501

142M2 (confirmed) on DRB

142M2 has two DR15 and DR16 unique polymorphic residues 142M and 133L in the membrane-proximal domain of DRB. These residues are 9.2 Angstroms apart and would constitute two distinct eplets. DR15 and DR16 have also two unique residues in the peptide-binding groove 11P and 13R which cannot make direct contact with antibody.

Bodmer.J.G., P. Pickbourne, et al. (1977). Histocompatibility Testing 1977, Munksgaard, Copenhagen, p35. DR15 and DR16 are subtypes of the DR2 specificity which was first characterized with allosera during the 7th International International Workshop. Nelson K, Bodmer J, Martin A, Navarrete C, Strong DM. 1989. Micro EIA and Monoclonal Antibodies. In Immunobiology of HLA, ed. B Dupont, pp. 292-301. New York: Springer-Verlag Mouse mAb NDS15.38 (10w3012) reacts with HLA-DR2 in micro ELISA assays with B-lymphoblastoid cell lines only in 10th IHWS. Navarrete C, Brown C, De Lange P, Schreuder GMT. 1997. 12Th International Histocompatibility Workshop HLA class II monoclonal antibodies study. In HLA Genetic diversity of HLA. Functional and Medical Implication. Vol 1, ed. D Charron, pp. 11-7. Paris, France: EDK Mouse mAb 12w636 reacts with HLA-DRB1*15:01, *15:02, *15:021/*15:03, *16:01, *16:02 in CDC assays in 12th IHWS (r=0.84)



MFI ep1 ep2 ep3 ep4

DRB1*16:01 IMM 12472 142M2

DRB1*16:02 11891 142M2

DRB1*15:03 11631 142M2

DRB1*15:01 11236 142M2

DRB1*15:02 11780 142M2

DRB5*02:02 IMM 7436 108T 96EV 28H

DRB5*01:01 6056 108T 96EV 28H

DRB1*01:02 2148 96EV

DRB1*01:01 3013 96EV

DRB1*01:03 3132 96EV



self alleles 1+1


Neg cont 1

Pos cont 6083

181M (confirmed) on DRB

Fu, X. T., W. Y. Yu, et al. (1992). "Identification of residues involved in polymorphic antibody binding epitopes on HLA-DR molecules." Human Immunology. 33(1): 47-56. Mouse mAb LY9 reacts with DR7,

DR9, DR10 and DR53. Studies with mutated DR4 and DR7 molecules with hybrid DR4/7 chains have

shown that the epitope detected by mAb LY9 resides in the 2 domain. They suggest that 181M is involved with this epitope Fu X-T, Drover S, Marshall WH, Karr RW. 1995. HLA-DR residues accessible under the peptide-binding groove contribute to polymorphic antibody epitopes. Hum Immunol 43: 243-50 The M181T substitution on mutated DRB1*07:01 did not react with mAb LY9 whereas the T181M substitution on DRB1*04:03 induced reactivity with LY9. Substitutions in sequence positions 140 and 180 had no effect. Cai, J., P. I. Terasaki, et al. (2006). "Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens." American Journal of Transplantation 6(12): 2947-2954. DR7-or DR10-induced donor-specific antibodies reacted with 181M-carrying alleles

EpiPedia of HLA-DQB

45EV (confirmed) on DQB

Schreuder, G. M., H. Maeda, et al. (1986). "TA10 and 2B3, two new alleles in the HLA-DQ region

recognized by monoclonal antibodies." Human Immunology 16(2): 127-136. Mouse mAb A10/13 detects

the TA10 specificity on PBL. The DQw3 related TA10 and the 2B3-defined specificity appeared to be in

perfect Hardy-Weinberg equilibrium and they are unrelated to the serological DQ specificities.

Kenter, M. J. H., J. D. H. Anholts, et al. (1989). "Umambuous Typing fro HLA-DQ TA10 and 2B3 Specificities

Using Specific Oligonucleotide Probes." Hum Immunol 24: 65-73. Mouse mAb TA10 reacts with DQ3.1

molecules that share the 45E residue

Maeda, H., R. Hirata, et al. (1986). "Multiple epitopes on a single DQ molecule from the DQw3-carrying

haplotypes." Tissue Antigens 28(3): 136-145. Mouse mAb TA10 and IIB3 detect two new DQw3-related

polymorphisms other than the conventional DQw1-w3 alleles. The TA10 specificity is in linkage

disequilibrium with DR5 and weakly associated with DR4. The IIB3 specificity is in linkage disequilibrium

with DR2, DR4, DRw9 and DRw13. Molecular and topological analysis has revealed that both TA10 and IIB3

determinants were expressed on the same DQ3 molecule.

Radka, S. F., K. A. Nelson, et al. (1989). "HLA-DQw3-related determinants: analysis of subunit and spatial

relationships." Human Immunology. 25(4): 225-236. Mouse and rat mAbs induced by DQw3,TA10+ or

DQw3,TA10- antigens were studied by Western blotting and for their ability to inhibit the binding of

fluoresceinated antibodies on either TA10+ or TA10- DQw3 haplotypes. The data suggest multiple epitopes

on DQ3 and that their spatial relationship is influenced by amino acid residues in positions 45 and 57 of DQB

chains. The DQw3+, TA10--induced Gs159.1 was specific for TA10. The DQw3+, TA10--induced GS285-2B6.7

and GS295-3E5 as well as the DQw3+, TA10+-induced SFR20-DQW3 are all specific for DQw3 although the

latter showed weaker reactions with DQw3+, TA10- antigens. The DQ4-induced GS200.1 reacted with

DQw1, DQw3.2, DQw3.3 and DQw4 similar to IIB3.

Navarrete et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 1, D. Charron (Ed), pp

11-17, 1997: Mouse mAb PLM2 (12w619) and TA10 (12w620) react with HLA-DQB1*03:01 in CDC assays in

12th IHWS.

Deng, C. T., J. Cai, et al. (2006). "HLA Class II DQ Epitopes." Clinical Trasnplants 2006: 115-122.Five mouse

mAb positive with HLA-DQB1*03:01 Equivalent to TerEp #2005.

El-Awar, N., A. Nguyen, et al. (2013). "HLA class II DQA and DQB epitopes: Recognition of the likely

binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines." Human

Immunology 74: 1141-1152. Absorption-elution studies on sera from a DQB1*03:01 mismatched transplant

patient who typed as DQB1*03:02, DQB1*05:03 and showed antibodies to a DQB epitope defined by 45E

and corresponding to Terasaki’s epitope # 2005

45GE3 (confirmed) on DQB

45GE5 may represent five distinct eplets defined by

polymorphic residues 46E+47F, 52L+55L and 74A on

the molecular surface (see structural model) Hidden

polymorphic residues 28S+30S and 37I are also unique

on DQ2 (not visible in structural model).

Ge, J., K. Bartnes, et al. (1993). "A human monoclonal hybridoma antibody (TrJ1) specific for HLA-DQ2." Tissue

Antigens 41(2): 81-85. TrJ1 is a cytotoxic human mAb with a reaction pattern with a panel of 42 HLA-defined

lymphoblastoid B-cell lines correlated precisely with expression of DQ2. By flow cytometry it was shown that the

binding of TrJ1 to DQ2 was efficiently blocked by the murine anti-DQ2 mAb 358.4, indicating that the TrJ1 and

358.4 epitopes overlap. TrJ1 reacted much better with EBV-transformed B cells than with B cells freshly isolated

from blood.

Viken, H. D., G. Paulsen, et al. (1995). "Characterization of an HLA-DQ2-specific monoclonal antibody. Influence

of amino acid substitutions in DQ beta 1*0202." Human Immunology. 42(4): 319-327. The DQB1*0201-induced

mouse mAb 2.12.E11 and also 9A3 react only with HLA-DQB1*02:01 and *02:02 with HLA homozygous B-

lymphoblastoid cells; mAb 2.12.E11 reacted with HLA-transfected murine cells expressing

DQB1*02:02/DQA1*02:01 or DQB1*02:02/DQA1*05:01 but not with DQB1)202 alone suggesting a role of DQA in

the 2.12.E11 epitope. Mouse mAb TU39 (Ziegler, A. et al. Immunobiology 171: 77-92) is specific for an epitope

corresponding to aa 59-67 on the helix of class II chains completely blocked 2.12.E11. Mutated DQB1*02:02

with I37Y decreased 2.12.E11 and 9A3 binding somewhat. A triple mutant G45+E46V+F47Y failed to bind 2.12.E11

and 9A3 whereas A57D, K71T and A74E had no effect. mAb 2.12.E11 inhibited also two DQ2-restricted gluten-

specific T-cell clones.

Viken, H. D., G. Paulsen, et al. (1995). "Influence on antibody recognition of amino acid substitutions in the cleft

of HLA-DQ2 molecules. Suggestive evidence of peptide-dependent epitopes." Human Immunology. 44(2): 63-69.

The DQ2-specific human mAbTrJ1 and mouse mAb NFLD.M100 did not react with mutated DQB1*02:02 with the

triple substitution G45+E46V+F47Y with F47Y alone affected TrJ1. S30Y, I37Y, A57D, K71T and A74E had no effect.

DQ2-specific mAbs, NFLD.M71 and NFLD.M102 had similar patterns with mutated DQ2 except that I37Y and to a

lesser extent A57D reduced reactivity. Some DQ2-reactive mAbs may recognize peptide-dependent epitopes.

Navarrete et al, Genetic Diversity of HLA – Functional Medical Implications vol. 1, D. Charron (Ed), pp 11-17,

1997: Multiple mouse and human monoclonal antibodies (12w587, 12w588, 12w589, 12w590, 12w591, 12w592,

12w593) positive with HLA-DQB1*02:01 and *02:02 in CDC assays in 12th IHWS (r values range 0.80-0.97)

Nelson et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies C1A2

(10w3105), XII358 (10w3107), IVD12 (10w3108) positive with HLA-DQ2 on peripheral blood lymphocytes and

lymphoblastoid cell lines in micro ELISA assays in 10th IHWS. C1A2 and IVD12 are weak with PBL.

Kennedy et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 301-305, 1989: Monoclonal antibodies C1A2

(10w3105), MP1 (10w3106), XIII358 (10w3107) positive with HLA-DQ2 on peripheral blood lymphocytes and

lymphoblastoid cell lines in CDC assays in 10th IHWS.

Deng et al, Clinical Transplants 2006, pp 115-122 Six mouse mAbs reacted with HLA-DQB1*02:01, *02:02

Equivalent to TerEp #2001.

El-Awar, N., A. Nguyen, et al. (2013). "HLA class II DQA and DQB epitopes: Recognition of the likely binding sites

of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines." Human Immunology 74:

1141-1152.Absorption-elution studies on sera from two DQB1*02:02 mismatched transplant patients showed

antibodies to a DQB epitope defined by 52L and corresponding to Terasaki’s epitope # 2001

45GV (confirmed) on DQB

Schreuder, G. M., H. Maeda, et al. (1986). "TA10 and 2B3, two new alleles in the HLA-DQ region recognized by

monoclonal antibodies." Human Immunology 16(2): 127-136. Mouse mAb 2B3 detects a specificity on PBL that is

different from the DQw3-related TA10 determinant. The two specificities appeared to be in perfect Hardy-

Weinberg equilibrium and are unrelated to the serological DQ specificities.

Radka, S. F., K. A. Nelson, et al. (1989). "HLA-DQw3-related determinants: analysis of subunit and spatial

relationships." Human Immunology. 25(4): 225-236. Mouse and rat mAbs induced by DQw3,TA10+ or DQw3,TA10-

antigens were studied by Western blotting and for their ability to inhibit the binding of fluoresceinated antibodies

on either TA10+ or TA10- DQw3 haplotypes. The data suggest multiple epitopes on DQ3 and that their spatial

relationship is influenced by amino acid residues in positions 45 and 57 of DQB chains. The DQw3+, TA10--induced

Gs159.1 was specific for TA10. The DQw3+, TA10--induced GS285-2B6.7 and GS295-3E5 as well as the DQw3+,

TA10+-induced SFR20-DQW3 are all specific for DQw3 although the latter showed weaker reactions with DQw3+,

TA10- antigens. The DQ4-induced GS200.1 reacted with DQw1, DQw3.2, DQw3.3 and DQw4 similar to IIB3.

Kenter, M. J. H., J. D. H. Anholts, et al. (1989). "Umambuous Typing fro HLA-DQ TA10 and 2B3 Specificities Using

Specific Oligonucleotide Probes." Hum Immunol 24: 65-73. Mouse mAb 2B3 reacts with DQ1, DQ3.2/3 and DQ-

blank (DQ4?) molecules that share the 45G46V47Y residue combination

Nordwig, H., W. W. Kwok, et al. (1991). "Identification of the amino acid residues contributing to monoclonal

antibody-defined DQw1 epitopes." Human Immunology. 31(2): 81-85. Mouse mAb R1 and S1 react with all DQB1

molecules except DQB1*02:01/02 and DQB1*03:01 on B-LCL in flow cytometry assays. Mutated DQB1*03:02

molecules with G45E did not react with R1 and S1 whereas G13A, L26Yand A57D had no effect.

Viken, H. D., E. Thorsby, et al. (1995). "Characterization and epitope mapping of four HLA class II reactive mouse

monoclonal antibodies using transfected L cells and human cells transfected with mutants of DQB1*0302." Tissue

Antigens 45(4): 250-257. Three HLA-DQ8-induced mAbs, 13B6, 17F8 and 19A1, bound to all DQ1, 4, 8 or 9 positive

B-lymphoblastoid cell lines (B-LCLs) and transfectants tested, i.e. cells carrying the DQB1 genes 0302-3, 0401-2,

0501-3, 0601-4 and 0609 irrespective of the accompanying DQA1 gene. These DQB1 genes code for the shared

amino acids GVY in position 45-47 of the DQ beta chain. DQ1+4+8+9 specific (IIB3) and DQ3 specific (IVD12)

reference mAbs inhibited binding of all three mAbs. Testing with mutated DQB1*0302 with residue substitutions in

various positions indicated involvement of 45G in the epitopes of all three mAbs. This reactivity pattern correlates

with a shared sequence of shared RFDSDVGE in position 39-46 of DQ

Petersen, J. S. and T. Dyrberg (1992). "Production of epitope specific monoclonal IgG antibodies to HLA class II

molecules by combining in vivo and in vitro immunization." Journal of Immunological Methods 151(1-2): 15-26.

Three DQw8 39RFDSDVGVYRAVTP52 sequence-induced mAbs 2B5, 2H3 and 1A1 specifically recognized by

immunoblotting and flow cytometry an epitope on B-LCL in position 45G46V47Y which is shared between all DQB

alleles except DQ7 which has 45G46V47E and DQ2 which has 45G46E47F. They did not react with mutated DQw8

with a G45E substitution. None of these mAbs reacted by immunoblotting and flow cytometry with PBL nor did they

bind to living cells but they reacted partially to denatured DQ molecules on such cells



1141-1152. Absorption-elution studies on sera from two DRB1*06:03 mismatched transplant patients showed

antibodies to a DQB epitope defined by 45G+46V and corresponding to Terasaki’s epitope # 2010

46VY2 (confirmed) on DQB

46VY2 may represent two distinct eplets defined by

polymorphic residues 46E+47F and 52P in separate

locations on the molecular surface (see structural

model). There is also a hidden 28T residue unique on

all non-DQB1*02 alleles

Marsh, S. G. and J. G. Bodmer (1989). "HLA-DR and -DQ epitopes and monoclonal antibody specificity."

Immunology Today 10: 305-312. Mouse mAb HU11 (10W3097) reacts with DQB1 sharing 46V47Y

El-Awar, N., A. Nguyen, et al. (2013). "HLA class II DQA and DQB epitopes: Recognition of the likely binding

sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines." Human

Immunology 74: 1141-1152. Absorption-elution studies on sera from two transplant patients who typed as

DQB1*02:01,- (the mismatch was DQB1*05:03) and DQB1*02:01,DQB1*02:02 (the mismatch was DQB1*03:01).

Both showed antibodies to a DQB epitope defined by 52P and corresponding to Terasaki’s epitope # 2003

Deng et al, Clinical Transplants 2006, pp 115-122: Two mouse mAbs react with HLA-DQB1*03:01, *03:02,

*03:03, *04:01, *04:02, *05:01, *05:02, *06:01, *06:02 Equivalent to TerEp #2003.

Deng et al, Transplantation 86: 452-459, 2008: Case 1 serum eluate (absorbed with DQ7 cells) positive with

DQ4, 5, 6, 7, 8, 9

52PL3 (confirmed) on DQB

52PL3 represents three distinct eplets: 52PL on the top

of the molecule whereas the 140T and 182N defined

eplets are located in the membrane proximal domain.

One might wonder if 140T-specific and 182N-specific

antibodies will react with DQ3 and DQ4 molecules

bound to the cell surface.

Navarrete et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 1, D. Charron (Ed), pp 11-17,

1997: Mouse mAb 178-38 (12w605) and TAL12.1 (12w606) react with HLA-DQB1*03:01, *03:02, *03:03 and DQ4 in

CDC assays in 12th IHWS (r values range 0.74-0.85)



1141-1152. Absorption-elution studies on sera from three DRB1*0301 or *03:02 or *03:03 mismatched transplant

patients and showed antibodies to a DQB epitope defined by 182N and corresponding to Terasaki’s epitope # 2014.

(Editor’s note: The 182N residue is in the 52PL3 eplet)

Deng et al, Transplantation 86: 452-459, 2008: Serum 338 eluate (absorbed with DQ4 cells) positive with DQ4, 7,

8, 9

52PQ2 (confirmed) on DQB

52PQ2 represents two separate

configurations 52P53Q and 84E85V in

opposite locations on the top of the DQB

molecule

Koning, F., J. Raghoebar, et al. (1985). "A monoclonal antibody detecting a DQw1-related determinant."

Tissue Antigens 26: 100-106. Mouse mAb IIB3 reacts with DQw1


Immunology Today 10: 305-312. Mouse mAb TAL4.1 (10W30920 reacts with postulated 53Q54G55R56P,

84E85V, 89G90I on DQ

Dessi, V., B. Sanchez, et al. (1990). "Characterization of three human monoclonal antibodies specific for

polymorphic class I and class II HLA antigens." Human Immunology 27(4): 323-332. Three human mAb 34F11,

RRA7 and RRF9 from a polytransfused patient who typed as A1,A9; B35, B37, DR3, DR4; DR52, DR53, DQ2, DQ3

were specific for DQ1 (DQ5+6) in FACS and CDC with B-LCL and with PBL

Navarrete et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 1, D. Charron (Ed), pp 11-

17, 1997: Mouse mAbs TAL4.1 (12w577) and G2A5 (12w578) positive with HLA-DQB1*05:01, *05:02, *05:03,

*06:01, *06:02, *06:03, *06:04 in CDC assays in 12th IHWS (r values range 0.81-0.84).

Nelson et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 292-301, 1989: Monoclonal antibodies

GENOX3.53 (10w3094), G2A5 (10w3095), GS148.1 (10w3096), 1.2 (10w3100) react with HLA-DQ1 on PBL and B-

LCL in micro ELISA assays in 10th IHWS. All antibodies are weak with PBL.

Kennedy et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 301-305, 1989: Mouse mAbs 4.1 (10w3092),

G2A5 (10w3095), GS148.1 (10w3096) react with HLA-DQ1 on PBL and B-LCL in CDC assays in 10th IHWS. Extra

reactions seen with LCL with G2A5 (DR53-positive cells), GS148.1 (DR7-positive cells).

Deng et al, Clinical Transplants 2006, pp 115-122 Multiple mouse mAbs react with HLA-DQB1*05:01, *05:02,

*06:01, *06:02



Immunology 74: 1141-1152.Absorption-elution studies on sera from three DRB1*05:01 or *05:02 or *06:03

mismatched transplant patients showed antibodies to a DQB epitope defined by 84E and corresponding to

Terasaki’s epitope # 2004. (Editor’s note: 84E is part of the 52PQ2 eplet)

52PR (confirmed) on DQB

Kolstad, A., B. Johansen, et al. (1989). "Two HLA-DQ-specific human-human hybridoma antibodies

(TrG6;TrC5) define epitopes also expressed by a transcomplementing hybrid DQ molecule (DQw7

alpha/DQw4 beta)." Human Immunology 24(1): 15-29.Human mAb TrG6 reacts with DQ1 and DQ4

expressing B-LCL. Residue 55R is important for the TrG6 specificity.


Immunology Today 10: 305-312. mAbs SH1 ((9W901), SH2 (9W927) and KS1 (10W3121) react with

postulated 54G55R on DQw1, w4

Nelson et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 292-301, 1989: Monoclonal antibody KS.11

(10w3091) positive with HLA-DQ1, DQ4 on peripheral blood lymphocytes and lymphoblastoid cell lines in

micro ELISA assays in 10th IHWS.

Kennedy et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 301-305, 1989: Monoclonal antibody

KS.11 (10w3091) positive with HLA-DQ1, DQ4 peripheral blood lymphocytes and lymphoblastoid cell lines

in CDC assays in 10th IHWS.

Navarrete et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 1, D. Charron (Ed),

pp 11-17, 1997: Mouse monoclonal antibodies AL/DQ61 (12w584) and 236-30 (12w585, IgM) positive with

HLA-DQ4, DQB1*05:01, *05:02, *05:03, *06:01, *06:02, *06:03, *06:04 in CDC assays in 12th IHWS (r values

range 0.85-0.87).

Deng et al, Clinical Transplants 2006, pp 115-122 : Mouse mAb reacts with HLA-DQB1*04:01, *04:02,

*05:01, *05:02, *06:01, *06:02


binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines."

Human Immunology 74: 1141-1152. Absorption-elution studies on sera from DQB1*03:03 or *05:01 or

*06:02 mismatched transplant patients showed antibodies to a DQB epitope defined by 55R and

corresponding to Terasaki’s epitope # 2007

55PP (confirmed) on DQB

Marsh, S. G. and J. G. Bodmer (1989). "HLA-DR and -DQ epitopes and monoclonal antibody

specificity." Immunology Today 10: 305-312. MAbs HU18 (11W3111), PLM12 (10W3112) and GSP100.1

(10W3101) react with a postulated 53L54G55P56P epitope on DQw3

Nelson et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 292-301, 1989: Mouse mAbs IVD12

(10w3108), HU18 (10w3111), GS100.1 (10w3114), 17.15 (10w3115), AC60 (10w3118) react with HLA-

DQ3 on PBL and B-LCL in micro ELISA assays in 10th IHWS. IVD12, GS100.1, 17.15 and AC60 are weak

with PBL.

Kennedy et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 301-305, 1989: Mouse mAbs HU18

(10w3111), PLM12 (10w3112), GSP91.1 (10w3113), GS100.1 (10w3114), 17.15 (10w3115), AC60

(1023118) react with HLA-DQ3 on PBL and B-LCL in CDC assays in 10th IHWS. GSP91.1 has extra reactions

with DR3-, DR7-, DR8-positive cells. 17.15 has extra reactions with DR7-positive cells; AC60 has extra

reactions with DR13-positive cells.

Navarrete et al, Genetic Diversity of HLA – Functional Medical Implications vol. 1, D. Charron (Ed), pp

11-17, 1997: Mouse mAbs XIV 466.2 (12w596), 278-5 (12w597), HU18 (12w599), KS13 (12w600), SO4

(12w602), PLM12 (12w603) react with HLA-DQB1*03:01, *03:02, *03:03 in CDC assays in 12th IHWS (r

values range 0.83-0.98)

Viken, H. D., A. B. Thoresen, et al. (1995). "The cytotoxic HLA-DQ3 reactive human hybridoma

antibody 4166 that may distinguish DQ7 + 8 from DQ9." Human Immunology 42(4): 281-288.

Pregnancy-induced human mAb 4166 reacts with HLA-DQ7, DQ8, DQ9 in CDC and FACs assays with B

lymphoblastoid cell lines. However, antibody reacts only with DQ7 and DQ8-positive PBL; DQ9 cells are

negative. No structural explanation for this reactivity difference.

Deng et al, Clinical Transplants 2006, pp 115-122 : Five mouse mAbs react with HLA-DQB1*03:01,

*03:02, *03:03


binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines."

Human Immunology 74: 1141-1152. Absorption-elution studies on sera from three DQB1*03:02 or

*03:03 mismatched transplant patients showed antibodies to a DQB epitope defined by 55P and


56L (confirmed) on DQB

Ishikawa, N., H. Kojima, et al. (1987). "Detection of a novel HLA-DQ specificity: serological and

immunochemical analyses by a monoclonal antibody." Immunogenetics 26(3): 143-149. A mouse mAb

HU-46, reacted with B cells from not only DR4/Dw15-positive individuals but also certain DRw8/Dw8-

positive ones whose DQ phenotypes had not yet been defined. Two-dimensional gel analyses indicated

that the mAb recognized class II HLA-DQ encoded antigens. Furthermore, in genetic analysis, the gene

encoding the class II antigen detected by HU-46 met the Hardy-Weinberg condition as a fourth allele of

the DQ locus. The novel DQWa specificity is now called DQ4.

Marsh, S. G. and J. G. Bodmer (1989). "HLA-DR and -DQ epitopes and monoclonal antibody

specificity." Immunology Today 10: 305-312. MAb HU46 (11W3101) reacts with a postulated

53L54G55R56L,70A71D72R73A74S75V76D epitope on DQw4 epitope

Kennedy et al, Immunobiology of HLA, vol. I, B. Dupont (Ed), pp. 301-305, 1989: Mouse mAb HU46

(10w3101) reacts with HLA-DQ4 on PBL and B-LCL in CDC assays in 10th IHWS.

Navarrete et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 1, D. Charron (Ed),

pp 11-17, 1997: Mouse mAbHU-46 (12w609) positive with HLA-DQ4 in CDC assays in 12th IHWS (r=0.48),

with unexplained false positive reactions.

74SV (provisional) on DQB

Ge, J. and K. Hannestad (1994). "A cytotoxic human hybridoma monoclonal antibody (TrJ6) defining an epitope

expressed by HLA-DQ4 and -DQ5." Human Immunology 39(2): 106-112. Pregnancy-induced human mAb TrJ6

reacts with DQ4 and DQ5 in CDC and flow cytometry assays. They share 74S and 75V. Reactivity was stronger with

DQ4 than DQ5 suggesting that DQ4 residues 56L, 70E and 71D make a minor contribution to this epitope.

Duquesnoy, R., Y. Awadalla, et al. (2008). "Retransplant Candidates Have Donor-Specific Antibodies that React

with Structurally Defined HLA-DR,DQ,DP Epitopes." Transplant Immunology. 18: 352-360. Some transplant

patients have donor-specific 74SV-related antibodies

74SR3 (provisional) on DQB


Immunology Today 10: 305-312. Mouse mAb HU-33 (9W924) reacts with a postulated

71A72R73A74S75V76D77R epitope on DQw5

Deng et al, Clinical Transplants 2006, pp 115-122 : Post renal transplant alloserum 04-08446 reacted with HLA-

DQB1*05:01, *05:02 (Ab producer types as HLA-DQ6; donor DQ5,2)



Immunology 74: 1141-1152 Serum (#30) from a DQB1*05:01 mismatched transplant patient who typed as

DQB1*02:01, DQB1*06:09 and showed antibodies to a DQB epitope defined by 125S and corresponding to

Terasaki’s epitope #2015. DQB1*05:01 and DQB1*05:02 share the 125S-defined epitope but they also share a

unique 71A and 116I and the well exposed 74SR

77R (provisional) on DQB



Immunology 74: 1141-1152.Absorption-elution studies on sera from two transplant patients who typed as

DQB1*03:02. – (mismatch: DQB1*05:02) and DQB1*03:02,DQB1*06:04 (mismatch: DQB1*02:02)and had

antibodies to a DQB epitope defined by 77R and corresponding to Terasaki’s epitope # 2026

77T (provisional) on DQB



Immunology 74: 1141-1152. Absorption-elution studies on sera from a DQB1*03:01/02 mismatched transplant

patient who typed as DQB1*02:02,DQB1*05:02 and had antibodies to a DQB epitope defined by 77T and


Duquesnoy et al, Hum Immunol. In press, 2016

Pregnancy serum #223 from Stefan Schaub This example shows the effect of nearby residues Mother DQB1*02:01 DQB1*05:01 DQA1*01:01 DQA1*05:01 on the antigenicity of the 77T eplet

Child DQB1*06:02 DQA1*01:02

DQB DQB

DQB DQA DQB DQA MFI Ep Other Res

DQB1*03:01 DQA1*05:03 8222 77T 74E+75L

DQB1*03:01 DQA1*06:01 7268 77T 74E+75L

DQB1*03:01 DQA1*05:05 6823 77T 74E+75L

DQB1*03:01 DQA1*02:01 4784 77T 74E+75L

DQB1*03:01 DQA1*03:01 4729 77T 74E+75L

DQB1*03:02 DQA1*03:02 12583 77T 74E+75L

DQB1*03:02 DQA1*02:01 8646 77T 74E+75L

DQB1*03:02 DQA1*03:01 8607 77T 74E+75L

DQB1*03:02 DQA1*01:01 Self 7361 77T 74E+75L

DQB1*03:03 DQA1*03:02 12701 77T 74E+75L t-Test: Two-Sample Assuming Equal Variances

DQB1*03:03 DQA1*02:01 12469 77T 74E+75L

DQB1*03:03 DQA1*03:01 7520 77T 74E+75L Variable 1 Variable 2

DQB1*06:01 DQA1*01:03 12822 77T 74E+75L Mean 9822.388889 1474.5

DQB1*06:02 DQA1*01:01 Imm Self 12793 77T 74E+75L Variance 9197628.84 538420.3333

DQB1*06:02 DQA1*01:02 Imm Imm 10285 77T 74E+75L Observations 18 4

DQB1*06:03 DQA1*01:03 12662 77T 74E+75L Pooled Variance 7898747.564

DQB1*06:04 DQA1*01:02 Imm 13382 77T 74E+75L Hypothesized Mean Difference 0

DQB1*06:09 DQA1*01:02 Imm 13146 77T 74E+75L df 20

Mean+SD 9822+3033 t Stat 5.373440577

DQB1*04:01 DQA1*03:03 2570 77T 74S+75V P(T<=t) one-tail 1.46547E-05

DQB1*04:01 DQA1*02:01 1160 77T 74S+75V t Critical one-tail 1.724718243

DQB1*04:02 DQA1*02:01 1159 77T 74S+75V P(T<=t) two-tail 2.93093E-05

DQB1*04:02 DQA1*04:01 1009 77T 74S+75V t Critical two-tail 2.085963447

Mean+SD 1475+734

DQB1*02:01 DQA1*04:01 Self 27 77R

DQB1*02:01 DQA1*05:01 Self Self 25 77R

DQB1*02:01 DQA1*02:01 Self 22 77R

DQB1*02:01 DQA1*03:01 Self 1 77R

DQB1*02:02 DQA1*02:01 28 77R

DQB1*05:01 DQA1*01:01 Self Self 26 77R

DQB1*05:02 DQA1*01:02 Imm 43 77R

84QL3 (confirmed) on DQB

84QL3 represents two separate

configurations in opposite locations on the

top of the DQB molecule:

84Q8586EL87L89T90T (see left figure; 86E

and 90T are not visible) and 53L (see right

figure). The 125A residue is unique on

DQ2,DQ3,DQ4 and is located in the

membrane proximal domain.

Vitale, M., M. P. Pistillo, et al. (1992). "Production and characterization of murine monoclonal antibodies

recognizing HLA-DQ polymorphisms obtained by immunizing mice with transfected L cells." Human Immunology.

34(2): 126-134. Mouse mAb TM 902 reacted in cytotoxicity assays with B-LCL and by flow cytometry with all DQB1*

alleles except DQB1*0501, *0502, *0503, and DQB1*0601, *0602, *0603, *0604. Comparison of the amino acid

sequences of the DQB chain suggests the involvement of residues 84-90 (QLELRTT) in the formation of TM902

epitope



1141-1152. Absorption-elution studies on sera from two DQB1*02:02 or *03:19 mismatched transplant patients

showed antibodies to a DQB epitope defined by 84Q and corresponding to Terasaki’s epitope # 2013

Deng et al, Transplantation 86: 452-459, 2008 :Two post renal transplant allosera positive with DQB1*02:01,

*02:02, *03:01, *03:02, *03:03, *04:01, *04:02. One serum (case 9) came from an Ab producer who typed as HLA-

Duquesnoy et al, Hum Immunol. In press, 2016

Pregnancy serum #246 from Stefan Schaub Pregnancy serum #178

Mother DQB1*06:02 DQB1*06:04 DQA1*01:02 DQA1*01:02 DQB1*06:02 DQB1*06:03 DQA1*01:02 DQA1*01:03

Child DQB1*03:01 DQA1*05:01 DQB DQB1*03:01 DQA1*05:01

DQB DQA DQB DQA MFI Ep DQB DQA MFI Ep

DQB1*02:01 DQA1*05:01 Imm 13141 84QL3 Imm 12739 84QL3

DQB1*02:01 DQA1*04:01 14226 84QL3 13990 84QL3

DQB1*02:01 DQA1*03:01 13641 84QL3 11637 84QL3

DQB1*02:01 DQA1*02:01 11969 84QL3 8530 84QL3

DQB1*02:02 DQA1*02:01 12694 84QL3 9426 84QL3






DQB1*03:02 DQA1*03:02 10936 84QL3 10913 84QL3

DQB1*03:02 DQA1*03:01 15137 84QL3 15524 84QL3

DQB1*03:02 DQA1*02:01 13739 84QL3 14866 84QL3

DQB1*03:02 DQA1*01:01 13635 84QL3 14006 84QL3

DQB1*03:03 DQA1*03:02 12584 84QL3 12551 84QL3

DQB1*03:03 DQA1*03:01 12930 84QL3 13690 84QL3

DQB1*03:03 DQA1*02:01 10154 84QL3 10275 84QL3

DQB1*04:01 DQA1*03:03 12913 84QL3 13034 84QL3

DQB1*04:01 DQA1*02:01 13536 84QL3 9918 84QL3

DQB1*04:02 DQA1*04:01 13610 84QL3 12777 84QL3

DQB1*04:02 DQA1*02:01 13401 84QL3 10756 84QL3

DQB1*05:01 DQA1*01:01 1 26

DQB1*05:02 DQA1*01:02 Self 1 Self 183

DQB1*06:01 DQA1*01:03 267 Self 38

DQB1*06:02 DQA1*01:01 Self 1 Self 115

DQB1*06:02 DQA1*01:02 Self Self 1 Self 111

DQB1*06:03 DQA1*01:03 1 Self Self 38

DQB1*06:04 DQA1*01:02 Self Self 1 Self 44

DQB1*06:09 DQA1*01:02 Self 1 Self 39

PosCont 7707 6943

NegCont 1 50

DQ5, 6; donor typed as HLA-DQ4,5. Alloserum 16975 and eluate (absorbed with DQ7 cells) show same reactivity

pattern.

125SQ (provisional) on DQB



Immunology 74: 1141-1152. Absorption-elution studies on serum 31 from a DQB1*05:01 mismatched

transplant patient who typed as DQB1*03:01, DQB1*06:02 showed antibodies that reacted only with

DQB1*05:01 (which has 125S+126Q) but not DQB1*05:02 (which has 125S+126H). This eluate seems to

recognize an epitope defined by 125SQ and which is referred to as Terasaki’s epitope #2022. No information

was provided about the reactivity with DQB1*05:03 which has 125SQ or other informative DQB1*05 alleles.

140A (provisional) on DQB

{El-Awar, 2013 #4710} El-Awar, N., A. Nguyen, et al. (2013). "HLA class II DQA and DQB epitopes: Recognition

of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell

lines." Human Immunology 74: 1141-1152.Absorption-elution studies on sera from a DQB1*05:02 mismatched

transplant patient who typed as DQB1*03:02,- showed antibodies to an epitope DQB defined by 140A and

corresponding to Terasaki’s epitope # 2023.

EpiPedia of HLA-DQA

40GR3 (confirmed) on DQA

40G3 may represent three distinct eplets defined by 40G, 47C and 50V51L53Q; their locations are depicted in the molecular model

El-Awar, N., A. Nguyen, et al. (2013). "HLA class II DQA and DQB epitopes: Recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines." Human Immunology 74: 1141-1152. Absorption-elution studies on sera from four transplant patients with mismatches for DQA1*05 or *06 showed antibodies to a DQA epitope defined by 40G and corresponding to Terasaki’s epitope # 2018

Deng, C. T., N. El-Awar, et al. (2008). "Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients." Transplantation 86(3): 452-459. Post renal transplant alloserum 8702 and eluate (absorbed with DQA1*04:01 cells) reacts with HLA-DQA1*04:01, *05:01, *05:05, *06:01

Tambur, A., J. R. Leventhal, et al. (2010). "The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching." Transplantation 90: 1117-1124. Luminex data illustrates antibody specificity for the 40G3-defined epitope

Duquesnoy, R., Y. Awadalla, et al. (2008). "Retransplant Candidates Have Donor-Specific Antibodies that React with Structurally Defined HLA-DR,DQ,DP Epitopes." Transplant Immunology. 18: 352-360. In transplant patients, many DQA-reactive antibodies recognize 40GR3

47KHL (confirmed) on DQA

Clinical example

El-Awar, N., A. Nguyen, et al. (2013). "HLA class II DQA and DQB epitopes: Recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines." Human Immunology 74: 1141-1152. Absorption-elution studies on sera from four transplant patients with DQA1*02:01 mismatches showed antibodies to an epitope DQB defined by 52H and corresponding to Terasaki’s epitope # 2017. (DQA1*02:01 has three unique residues 47K, 52H and 54L in close proximity; see figure)

Deng, C. T., N. El-Awar, et al. (2008). "Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients." Transplantation 86(3): 452-459. Post renal transplant alloserum reactivity in Luminex

Duquesnoy, R., Y. Awadalla, et al. (2008). "Retransplant Candidates Have Donor-Specific Antibodies that React with Structurally Defined HLA-DR,DQ,DP Epitopes." Transplant Immunology. 18: 352-360.

75S3 (confirmed) on DQA

75S3 represents three eplets defined by distinct polymorphic residues on separate molecular

locations: 75S (on the helix) and 161E and 175K in the membrane-proximal domain. The latter might be less antibody-accessible on DQ molecules attached to cellular membranes

Kolstad, A., B. Johansen, et al. (1989). "Two HLA-DQ-specific human-human hybridoma antibodies (TrG6;TrC5) define epitopes also expressed by a transcomplementing hybrid DQ molecule (DQw7 alpha/DQw4 beta)." Human Immunology 24(1): 15-29. Human mAb TrC5 did not react with a DQB epitope as indicated by a lack of blocking competition with DQB-specific antibodies. TrC5 bound to DQw2 of the DQw2+DR3+ haplotype and to DQw7 of the DQw7+DR5+ haplotype. TrC5 recognizes an epitope defined by amino acids at positions 69 and/or 75 of the DQ alpha chain. Tambur, A., J. R. Leventhal, et al. (2010). "The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching." Transplantation 90: 1117-1124.Luminex data shows antibody specificity for the 75S3-defined epitope as illustrated by two informative DQ heterodimers: DQA1*05:03/self DQB1*03:01 and DQA1*05:05/self DQB1*03:01

EpiPedia of HLA-DPB

35FV (confirmed) on HLA-DPB

Marshall, W. H., S. Drover, et al. (1991). Production of a series of monoclonal antibodies to polymorphisms of HLA-DP. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK Oxford University Press. 1: 415-417. Mouse mAb NFLD.M77 recognizes an epitope that appears to be defined by 35F+36V and 11L; these residues are nearly juxtaposed in the peptide-binding groove. Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197. Mouse mAb NFLD.M117 (immunized with HLA-DPA1*01; DPB1*04:02) reacts in CDC, flow cytometry and live cell ELISA assays with HLA-DPB1 alleles that share 35F and 36V.(r value = 1.0 in each case) Youngs, D. (2004). "DP alloantibodies." ASHI Quarterly(2): 60-62. Seven sensitized transplant patients had 35FV-reactive antibodies

Billen, E. V. A., M. H. L. Christiaans, et al. (2010). "HLA-DP antibodies before and after renal transplantation." Tissue Antigens 75(3): 278-285. Two transplant patients (DPB1*04:01, -; donor: DPB1*04:02, *16:01) and (DPB1*04:01,*05:01; donor:DPB1*03:01) had 35PV-reactive antibodies

56A (provisional) on HLA-DPB

Cano, P. and M. Fernandez-Vina (2009). "Two sequence dimorphisms of DPB1 define the immunodominant serologic epitopes of HLA-DP." Human Immunology 70(10): 836-843. Epitopes on HLA-DP molecules were identified with alloantibodies from clinical serum samples and tested with single antigens on a Luminex platform. Residue 56A defines epitope P-001 and was identified by 2 sera.

56E (confirmed) on HLA-DPB

Note: the 55DE eplet includes both 55D56E57D and 55D56E57E; it is not on DR11

Human monoclonal antibody VR1H5 (IgG) from Arend Mulder (Leiden):

Mazzoleni, O., A. Longo, et al. (1989). "Human monoclonal antibody MP8 detects a supertypic

determinant encoded by DPB alleles DP2.1, DP3, DP4.2, DP8, DP9, DP10, and DP14." Immunogenetics 30(6): 502-505 Human mAb MP8 is specific for 56E on DPB only Pistillo, M. P., R. W. Karr, et al. (1991). Use of transfectants to identify polymorphic epitopes recognized by human monoclonal antibodies. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. 2: 413-415. Studies with transfected cells show that human mAb MP8 is specific for a DPB epitope defined by 56E

Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197 Mouse mAb NFLD.M58 (immunizer: HLA-DPA1*01; DPB1*04:02) and NFLD.M60 (immunizer: DPA1*02; DPB1*09:01) react with HLA-DPB1 alleles that share residues DE at positions 55-56 in CDC, flow cytometry and live cell ELISA assays. CDC and Flow cytometry correlations: M58 (r value = 1.0), M60 (r value = 0.78); Live cell ELISA correlations: M58 (r value = 1.0), M60 (r value = 0.65) Billen, E. V. A., M. H. L. Christiaans, et al. (2010). "HLA-DP antibodies before and after renal transplantation." Tissue Antigens 75(3): 278-285. A transplant recipient (DPB1*01:01, 04:01; donor: DPB1*04:02,*06:01) and a pre-transplant patient (DB1*04:01,*04:01) sensitized by pregnancy (husband (DPB1*02:01,*17:01) had antibodies reacting with 56E (DED/DEE) Not clear if there was DR11 reactivity.

56EDR11 (confirmed) on HLA-DPB also on DR11

Note: the 56EDR11 epitope on DPB is equivalent to the 57DEDPepitope on DR11

Bodmer JG, Bodmer W, Heyes Jea. 1987. Identification of HLA-DP Polymorphism with DP and DP Probes and Monoclonal Antibodies: Correlation with Primed Lymphocyte Typing. Proc. Nat. Acad. Sci. USA 84: 4596-600Mouse I-LR1 mAb recognize an epitope on DR11 and 56E-carrying DPB molecules that share 56DEE or DED Pistillo, M. P., O. Mazzoleni, et al. (1991). "Production of two human hybridomas secreting antibodies to HLA-DRw11 and--DRw8+w12 specificities." Human Immunology 31(2): 86-93. The DR11-induced human mAb MP4 reacts with HLA-DR11 and 56E-carrying DPB alleles in cytofluorometry and CDC assays. Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197. The DPB*04:02/DPA1*01-induced mouse mAb NFLD.M58 reacted with all 56E-carrying DPB1 alleles and the 58E-carrying DR11. In both CDC and Flow cytometry r value = 1.0. mAb NFLD.M73 had a similar reactivity pattern. Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930. Same specificity patterns for NFLD.M58 and NFLD.M64

Klohe E, Pistillo MP, Ferrara GB, Goeken NE, Greazel NS, Karr RW. 1992. Critical role of HLA-DR beta 1 residue 58 in multiple polymorphic epitopes recognized by xenogeneic and allogeneic antibodies. Human Immunology. 35: 18-28 Mutated DR11 with E58A or E58D substitutions lost reactivity with MP4 and I-LR1 but D57A had no effect. Moreover mutated DRB1, DRB3 and DRB5 chains with A58E substitutions became reactive. These findings suggest that 58E plays a dominant role in this epitope but may require another configuration shared between DRB1, DRB3, DRB5 and DPB. Mutated DR11 chains with E9W, Y10Q, S11L, T12K, S13F, D28E, Y30C, Y37S, F67L, D70Q, D70R, R71E, A74Q, A74E and T77N continued to react with MP4 and I-LR2. It was suggested that the additional configuration may include residues 41Q, 44L and/or 48R.

Yu, W. Y., R. Watts, et al. (1990). "Identification of amino acids in HLA-DPw4 and -DR51 chains that are involved in antibody binding epitopes using site-directed mutagenesis and DNA-mediated gene transfer." Human Immunology. 27(2): 122-135. The E56A substitution of mutated DPB1*04:02 and the E58A substitution of mutated DRB*11 abolished binding with I-LR1. Diaz, G., M. Amicosante, et al. (2003). "Functional analysis of HLA-DP polymorphism: a crucial role for DPB residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding." International Immunology 15: 565-576. The E56A substitution on mutated DRB1*02:01 abolished reactivity with mAb ILR1. Vaidya, S., B. Hilson, et al. (2007). "DP reactive antibody in a zero mismatch renal transplant pair." Human Immunology 68(12): 947-949. A zero-ABCDRDDQ but a DPB1*06:01 mismatched renal transplant led to antibodies that reacted with 56E-carrying DPB alleles plus the 58E-carrying DR11. Cano, P. and M. Fernandez-Vina (2009). "Two sequence dimorphisms of DPB1 define the immunodominant serologic epitopes of HLA-DP." Human Immunology 70(10): 836-843. Epitopes on HLA-DP molecules were identified with alloantibodies from clinical serum samples and tested with single antigens on a Luminex platform. Residue 56E defines epitope P-002,and was identified by 9 sera. Interlocus DRB1*11/DPB1 reactivity is associated with P-002

56EE (provisional) on HLA-DPB

Note: the 56EE eplet on DPB is equivalent to the eplet 56EEDR11 but there is no antibody reactivity with DR11

Deng C, Cai J, Ozawa M, El-Awar N. 2007. In Clinical Transplants 2007, pp. 195-202. Los Angeles: Terasaki Foundation Laboratory

Post renal transplant alloserum 4-08954 is positive in Luminex single antigen bead assay with alleles that share eplet 56EE (no HLA types of antibody producer/immunizer):

56EEDR11 (confirmed) on HLA-DPB also on DR11

Note: the 56EEDR11 on DPB is equivalent to the 58EEDP eplet on DR11

Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197. DPB1*04:02-induced mouse mAb NFLD.M106 reacts with HLA-DPB1 alleles that share residues DEE at positions 55-57 in CDC, flow cytometry and ELISA assays. Antibody also reacts with DR11 alleles which share residues DE at positions 57-58. CDC and Flow cytometry correlation: r value = 1.0; ELISA correlation: r value = 1.0

Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/ monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930. The DPB*09:01/DPA1*02-induced NFLD.M60 reacted with all 57E (DEE) carrying DPB1 alleles plus DR11 which has DEE. Tongio et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 2, D. Charron (Ed), pp. 135-138, 1997: Mouse mAb M106 positive with EBV cell lines and peripheral B lymphocytes that have HLA-DPB1alleles that share residues 55D-56E-57E (r = 1.0). Antibody reacts also with HLA-DR11 which shares residues DEE at positions 57-59.

57D (confirmed) on HLA-DPB

Note: the 57D epitope is defined by 56E+57D, it is different from 56EE defined by 56E57E present on a different group of 56E-carrying alleles

Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197 DPB1*13:01-induced mouse mAb NFLD.M112 and NFLD.M115 and DPB1*09:01-induced mouse mAb NFLC.M119 react with HLA-DPB1 alleles that share residues DED at positions 55-57 in CDC, flow cytometry (all r values= 1.0) and ELISA assays (r values: 0.84, 0.91 and 1.0) Tongio et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 2, D. Charron (Ed), pp. 135-138, 1997 Mouse monoclonal antibodies M117 , M111, AL/DP234, M119 positive with EBV cell lines and peripheral B lymphocytes that have HLA-DPB1alleles that share residues 55D-56E-57D (r values for each antibody = 1.0). Deng et al, Clinical Transplants 2007, 195-202: Equivalent to TerEp #4002. Post renal transplant alloserum (no HLA types of antibody producer/immunizer)

Billen, E. V. A., M. H. L. Christiaans, et al. (2010). "HLA-DP antibodies before and after renal transplantation." Tissue Antigens 75(3): 278-285. Two transplant patients (DPB1*04:01,-; donor: DPB1*03:01) and (DPB1*04:01,*08:01; donor: DPB1*03:01) had antibodies reactive with 57D (DED)

84DEAV (confirmed) on HLA-DPB

Human monoclonal antibody TL3B6 (IgG) from Arend Mulder (Leiden): Sensitization due to pregnancy. Antibody producer types as HLA-DPB1*02:01, DPB1*04:01; immunizing haplotype is HLA-DPB1*13:01.

Kolstad et al, Human Immunology 25: 247-256, 1989: Human mAb TrB50 and TrE11 react in radioimmunoassay and indirect immunofluorescence assays with cell lines that express DPB1 alleles with DEAV in positions 84-87. Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197. Mouse mAbs NFLD.M66 (immunized with HLA-DPA1*02; DPB1*09:01) and NFLD.M126 (immunized with DPA1*01; DPB1*16:01) react with HLA-DPB1 alleles that share residues DEAV at positions 84-87 in CDC, live cell ELISA and flow cytometry assays. CDC and Flow cytometry correlations: M66 (r value = 1.0), M126 (r value = 1.0); Live cell ELISA correlations: M66 (r value = 0.95), M126 (r value = 1.0) Tongio et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 2, D. Charron (Ed), pp. 135-138, 1997: Mouse mAb M66 and M126 react with EBV cell lines and peripheral B lymphocytes that have HLA-DPB1alleles that share residues 85G-86P-87M (r values = 1.0 and 0.90, respectively). Deng et al, Clinical Transplants 2007, 195-202: TerEp #4001.Post renal transplant alloserum (no HLA types of antibody producer/immunizer)

Youngs, D. (2004). "DP alloantibodies." ASHI Quarterly(2): 60-62. DP-reactive antibodies are often specific for 84DEAV

Duquesnoy, R., Y. Awadalla, et al. (2008). "Retransplant Candidates Have Donor-Specific Antibodies that React with Structurally Defined HLA-DR,DQ,DP Epitopes." Transplant Immunology. 18: 352-360. Most DP-reactive antibodies are specific for 84DEAV

Billen, E. V. A., M. H. L. Christiaans, et al. (2010). "HLA-DP antibodies before and after renal transplantation." Tissue Antigens 75(3): 278-285. Many transplant patients with donor-specific 84DEAV-reactivie antibodies

Cano, P. and M. Fernandez-Vina (2009). "Two sequence dimorphisms of DPB1 define the immunodominant serologic epitopes of HLA-DP." Human Immunology 70(10): 836-843. Epitopes on HLA-DP molecules were identified with alloantibodies from clinical serum samples and tested with single antigens on a Luminex platform. Residues at DPB1 85-87-EAV define the P-003 epitope. In this study, 12 patient sera identified DP-003

85GPM (confirmed) on HLA-DPB

Viken, H. D., G. Gaudernack, et al. (1989). "Characterization of a monoclonal antibody recognizing a polymorphic epitope mainly on HLA-DPw2 and DPw4 molecules." Tissue Antigens 34(4): 250-259. A DPw4 induced mouse mAb 13.3.B4 reacted with DPw2 and DPw4

Marshall, W. H., S. Drover, et al. (1998). "HLA-DP epitope typing using monoclonal antibodies." Human Immunology. 59(3): 189-197 Mouse IgG mAb NFLD.M120 (immunized with HLA-DPA1*01; DPB1*04:02) reacts with HLA-DPB1 alleles that share residue 85G. CDC and Flow cytometry correlation: r value = 0.78; Live cell ELISA correlation: r value = 1.0. Inoko, H., J. G. Bodmer, et al. (1991). Joint report on the transfectant/monoclonal antibody component. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tsuji, M. Aizawa and T. Sasazuki. Oxford, UK, Oxford University Press. I: 919-930. The DP1*04:01 induced mAb 16.15 (MYE TM901) reacts with DPB1*02, *04 and *15

Tongio et al, Genetic Diversity of HLA – Functional and Medical Implications, vol. 2, D. Charron (Ed), pp. 135-138, 1997: Mouse mAbs M66 and M126 react with EBV cell lines and peripheral B lymphocytes that have HLA-DPB1alleles that share residues 85G-86P-87M (r values = 1.0 and 0.90, respectively). Youngs, D. (2004). "DP alloantibodies." ASHI Quarterly(2): 60-62. Four sensitized transplant patients had 85G (GPM)-reactive antibodies

Billen, E. V. A., M. H. L. Christiaans, et al. (2010). "HLA-DP antibodies before and after renal transplantation." Tissue Antigens 75(3): 278-285. Pre-transplant recipient (DPB1*05:01,*16:01) presumably sensitized during pregnancy (husband: DPB1*02:01;*0402) had 85G (or 84GGPM; panel was not informative enough) reactive antibodies

Cano, P. and M. Fernandez-Vina (2009). "Two sequence dimorphisms of DPB1 define the immunodominant serologic epitopes of HLA-DP." Human Immunology 70(10): 836-843. Epitopes on HLA-DP molecules were identified with alloantibodies from clinical serum samples and tested with single antigens on a Luminex platform. Residues at DPB1 85-87-GPM define the P-004 epitope. In this study, one patient serum identified DP-004

96K (provisional) on HLA-DPB

Transplant case serum contributed by Carol Pancosca

Patient DPB1*02:01 DPB1*17:01 DPA1*02:01 DPA1*01:03

ImmunizerDPB1*01:01 DPB1*02:01 DPA1*02:01 DPA1*01:03 DPB

DPB DPA DPB DPA MFI Ep

DPB1*01:01 DPA1*01:03 IM Self,IM 4221 96K

DPB1*01:01 DPA1*02:01 IM Self,IM 2806 96K

DPB1*03:01 DPA1*01:03 Self,IM 4591 96K

DPB1*03:01 DPA1*01:05 2986 96K

DPB1*03:01 DPA1*02:01 Self,IM 2805 96K

DPB1*05:01 DPA1*02:01 Self,IM 3869 96K

DPB1*05:01 DPA1*02:02 2740 96K

DPB1*06:01 DPA1*01:03 Self,IM 2468 96K

DPB1*06:01 DPA1*02:01 Self,IM 3414 96K

DPB1*09:01 DPA1*02:01 Self,IM 3774 96K

DPB1*10:01 DPA1*02:01 Self,IM 1956 96K

DPB1*11:01 DPA1*01:03 Self,IM 3666 96K

DPB1*11:01 DPA1*01:04 2560 96K

DPB1*13:01 DPA1*02:01 Self,IM 1660 96K

DPB1*13:01 DPA1*02:02 2105 96K

DPB1*13:01 DPA1*03:01 1870 96K

DPB1*14:01 DPA1*02:01 Self,IM 2565 96K

DPB1*15:01 DPA1*02:01 Self,IM 2537 96K

DPB1*18:01 DPA1*01:04 3542 96K

DPB1*18:01 DPA1*01:05 3591 96K

DPB1*18:01 DPA1*02:01 Self,IM 7437 96K

DPB1*19:01 DPA1*01:03 Self,IM 2514 96K

DPB1*20:01 DPA1*03:01 3428 96K

DPB1*04:02 DPA1*01:03 Self,IM 57

DPB1*02:01 DPA1*01:03 Self,IM Self,IM 72

DPB1*28:01 DPA1*01:05 74

DPB1*04:01 DPA1*01:03 Self,IM 61

DPB1*17:01 DPA1*02:01 Self,IM 8

DPB1*28:01 DPA1*04:01 18

DPB1*23:01 DPA1*01:03 Self,IM 19

DPB1*28:01 DPA1*01:03 Self,IM 43

EpiPedia of HLA-DPA

EpiPedia of HLA-MICA

MICA Epitope: 14G (confirmed)

Duquesnoy et al, Human Immunology 69: 826-832, 2008 Post-transplant alloserum #2

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT)

Pre-transplant alloserum GP-MIC-1; antibody producer types as MICA*004, *018

Zou, Y., Z. Qin, et al. (2009). "Polymorphisms of MICA recognized by human alloantibodies."

Immunogenetics 61(2): 91-100. Post-transplant alloserum p5-58 reacted with 14G-carrying MICA*002

and MICA*017; absorption with MICA*002 transfected cells removed all reactivity

Cox, S. T. (2011). The relevance and impact of MICA allele mismatching and MICA antibodies on renal

transplantation outcome, University College London (UCL). Ph.D. Dissertation. The 14G specificity

was identified in the sera of 12% of graft recipients positive for MICA antibodies

GP MFI


Negative control 134

14G+ MICA*002 2345

14G+ MICA*011 1671

14G+ MICA*015 1650

14G+ MICA*017 2262

14G+ MICA*030 1969

14G+ MICA*036 1677

14G+ MICA*046 1957

14G+ MICA*050 1925

14G-negative alleles 134 ± 13

MICA Epitope: 14W (confirmed)

Duquesnoy, R. J., J. Mostecki, et al. (2008). "A Structurally Based Epitope Analysis of MICA Antibody

Specificity Patterns." Human Immunol. 69: 826-832. Two transplant cases with sera with anti-14W

associated antibody reactivity

Suarez-Alvarez, B., R. Alonso-Arias, et al. (2009). "Identification of epitopes and immunodominant

regions on the MICA protein defined by alloantibodies from kidney transplant patients."

Transplantation 88(3 Suppl): S68-77. A MICA antibody positive serum reacted with synthetic MICA

peptides which had the 14W residue; this suggested that the 14W-defined epitope might be linear.

Stastny, P. and Y. Zou (2013). "16th IHIW: Report of the MICA project." Int J Immunogenetics 40: 11-

16. MICA exchange post-renal transplant sera S009 and S016 (reacted with all nineteen 14W-carrying

alleles; there were no false positive or false negative reactions with the 28 MICA allele panel

MICA Epitope 14W pair

14W+36C (provisional)

Data from Justin Mostecki (Immucor, LifeCodes) Post-pregnancy serum GP-MIC-3

14W and 36C are located 18 Ångstroms apart on

the molecular surface


16. Serum S010 from a kidney transplant recipient and eluate after MICA*001 absorption had

antibodies that recognized MICA*001, *007, *012 and *018. This reaction pattern was stable for many

years.

GP MFI



14W+36C+ MICA*001 8431

14W+36C+ MICA*007 6186

14W+36C+ MICA*012 7981

14W+36C+ MICA*018 8520

14W+36C+ MICA*029 4992

14W+36C+ MICA*037 5816

14W+36C+ MICA*043 5094

14W+ MICA*004 259

14W+ MICA*005 226

14W+ MICA*006 219

14W+ MICA*008 264

14W+ MICA*009 236

14W+ MICA*016 209

14W+ MICA*019 215

14W+ MICA*024 245

14W+ MICA*028 262

14W+ MICA*033 257

14W+ MICA*042 192

14W+ MICA*051 322

36C+ MICA*002 233

36C+ MICA*011 210

36C+ MICA*015 189

36C+ MICA*017 215

36C+ MICA*030 170

36C+ MICA*036 248

36C+ MICA*041 182

36C+ MICA*046 227

36C+ MICA*050 241

MICA Epitope: 24T (confirmed)

Duquesnoy, R. J., J. Mostecki, et al. (2008). "A Structurally Based Epitope Analysis of MICA Antibody

Specificity Patterns." Human Immunol. 69: 826-832

Post-transplant alloserum #1 results (equivalent to epitope 25TC)

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT) Alloserum GP-MIC-5

El-Awar, N., P. I. Terasaki, et al. (2007). "Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens." Clinical

Transplants: 175-194. Serum eluate URUALB77 (absorbed with MICA*018 cell line) reacted with

MICA*001, *012, *018 The epitope was called #6001.


Immunogenetics 61(2): 91-100. Post-transplant alloserum Abs224E13 reacted with MICA*001, *012, *018;

absorption with MICA*001 transfected cells removed all reactivity.


transplantation outcome, University College London (UCL). Ph.D. Dissertation. MICA antibody recognition

of 24T was observed in 24% of MICA reactive antibodies

GP MFI



24T+ MICA*001 2706

24T+ MICA*012 2069

24T+ MICA*018 2354

24T-negative alleles 341 ± 163

MICA Epitope: 36C (confirmed)


Post-transplant serum eluate Sample #1 after absorption with MICA*037 positive with MICA*001, *002,

*007, *011, *012, *015, *017, *018, *029, *030, *036, *037, *041, *043, *046, *050 (EFI poster, 2009)

Reactivity pattern is similar to previous reports for the “CMGWS supereplet” (Duquesnoy et al, Human

Immunology 69: 826-832, 2008) and MICA group G1 (Zou et al, Immunogenetics 61: 91-100, 2009). In

each of these earlier reports, limited panels were tested, and positive alleles shared residues 36C, 129M,

206G, 210W and 215S; Zou et al. suggested also that G1 includes 173K). The expanded panel tested by

Mostecki showed reactivity directed to 36C; negative reactions were seen with 36Y-carrying MICA*005,

*028, *042 and *051, which share one or more of residues129M, 173K, 206G, 210W and 215S.

GP MFI



36C+ MICA*001 6943

36C+ MICA*002 7311

36C+ MICA*007 7997

36C+ MICA*011 5752

36C+ MICA*012 8141

36C+ MICA*015 6774

36C+ MICA*017 6458

36C+ MICA*018 7367

36C+ MICA*029 7796

36C+ MICA*030 5996

36C+ MICA*036 6204

36C+ MICA*037 9205

36C+ MICA*041 5934

36C+ MICA*043 7465

36C+ MICA*046 8112

36C+ MICA*050 5855

36C_negative alleles 824 ± 344

MICA Epitope: 36Y (confirmed)

Stastny, P. and Y. Zou (2013). "16th IHIW: Report of the MICA project." Int J Immunogenetics 40: 11-16. 16th

Workshop serum S015 reacted with all twelve 36Y-carrying alleles; there were no false positive or false

negative reactions with 28 MICA allele panel.

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT) Eluate of serum GP-MIC-4 after absorption

with MICA*051:

Two additional allosera have similar 36Y-specific antibody reactivity patterns (data not shown)

GP MFI


Negative control 96

36Y+ MICA*004 2613

36Y+ MICA*005 2418

36Y+ MICA*006 2158

36Y+ MICA*008 2552

36Y+ MICA*009 2600

36Y+ MICA*016 2377

36Y+ MICA*019 2635

36Y+ MICA*024 2474

36Y+ MICA*028 1692

36Y+ MICA*033 1971

36Y+ MICA*042 2377

36Y+ MICA*051 1860

36Y-negative alleles 375 ± 296

MICA Epitope: 105R (provisional)

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT) Mouse monoclonal antibody 6D4

GP MFI

Positive control n/t


105R+ MICA*001 12035

105R+ MICA*002 18983

105R+ MICA*004 19245

105R+ MICA*005 18020

105R+ MICA*006 16696

105R+ MICA*007 17768

105R+ MICA*008 17111

105R+ MICA*009 18596

105R+ MICA*011 17270

105R+ MICA*012 17103

105R+ MICA*015 16485

105R+ MICA*016 18558

105R+ MICA*017 17597

105R+ MICA*018 17410

105R+ MICA*019 18848

105R+ MICA*024 16855

105R+ MICA*028 16992

105R+ MICA*029 16566

105R+ MICA*030 16225

105R+ MICA*033 15730

105R+ MICA*037 18110

105R+ MICA*041 16525

105R+ MICA*042 18586

105R+ MICA*043 17662

105R+ MICA*046 18716

105R+ MICA*050 16757

105R+ MICA*051 16861

105R- MICA*036 168

MICA Epitope: 122V (provisional)


Immunogenetics 61(2): 91-100. Post-transplant alloserum p10-64 positive with MICA*004, *006, *009;

Absorption with MICA*009 transfected cells removed antibody reactivity

El-Awar, N., P. I. Terasaki, et al. (2007). "Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens."

Clinical Transplants: 175-194. Called the 122V –defined epitope #6003


transplantation outcome, University College London (UCL). Ph.D. Dissertation. Transplant case 690MO

(Figure 6.5.7) had MICA*004 and MICA*009 antibodies detected and both antigens uniquely express V at

residue 122.

MICA Epitope: 125E (provisional)

Data from Zou et al, Immunogenetics 61: 91-100, 2009: Unnamed post-transplant alloserum tested

against a limited panel, positive with MICA*002, *004, *006, *007, *008, *009, *012, *017, *018, *019


GP MFI



125E+ MICA*002 12320

125E+ MICA*004 20071

125E+ MICA*005 19012

125E+ MICA*006 16154

125E+ MICA*007 14217

125E+ MICA*008 20331

125E+ MICA*009 20241

125E+ MICA*011 7752

125E+ MICA*012 8714

125E+ MICA*015 8901

125E+ MICA*016 20341

125E+ MICA*017 9699

125E+ MICA*018 7168

125E+ MICA*019 20488

125E+ MICA*024 19925

125E+ MICA*028 20107

125E+ MICA*029 13267

125E+ MICA*030 7720

125E+ MICA*033 15175

125E+ MICA*036 8874

125E+ MICA*037 11446

125E+ MICA*041 5143

125E+ MICA*042 17037

125E+ MICA*043 14045

125E+ MICA*046 9558

125E+ MICA*050 5740

125E+ MICA*051 17423

125E- MICA*001 1499

MICA Epitope: 125K (confirmed)

{Zou, 2009 #4225}. Zou, Y., Z. Qin, et al. (2009). "Polymorphisms of MICA recognized by human

alloantibodies." Immunogenetics 61(2): 91-100. Post-transplant alloserum P5-49 positive with

MICA*001, which uniquely carries this epitope


Cox, S. T. (2011). The relevance and impact of MICA allele mismatching and MICA antibodies on

renal transplantation outcome, University College London (UCL). Ph.D. Dissertation. Reported

antibodies specific for 125K on MICA*001

GP MFI



125K+ MICA*001 4722

125K-negative alleles 209 ± 47

MICA Epitope: 129M (provisional)


Alloserum GP-MIC-9

Eluate after MICA*036 absorption of 16th

IHIW MICA exchange serum S006* (see

below)


16. 16th Workshop specimen S006 came from a patient following a second renal transplant who typed

as MICA*004,*008 ; the second donor typed as MICA*009,*018. The recipient and donor had no

mismatches for HLA-A, -B, -DR, but the kidney was rejected one month post-transplant.

GP MFI



129M+ MICA*001 7606

129M+ MICA*002 3472

129M+ MICA*007 10112

129M+ MICA*011 1780

129M+ MICA*012 8258

129M+ MICA*015 3393

129M+ MICA*017 3443

129M+ MICA*018 8500

129M+ MICA*029 8011

129M+ MICA*030 3744

129M+ MICA*036 2297

129M+ MICA*037 8227

129M+ MICA*041 1862

129M+ MICA*042 1768

129M+ MICA*043 9214

129M+ MICA*046 4453

129M+ MICA*050 3576

129M+ MICA*051 2097

129M-negative alleles 563 ± 225

GP MFI



129M+ MICA*001 11219

129M+ MICA*002 8270

129M+ MICA*007 12955

129M+ MICA*011 6890

129M+ MICA*012 11666

129M+ MICA*015 8013

129M+ MICA*017 6982

129M+ MICA*018 11478

129M+ MICA*029 13010

129M+ MICA*030 6859

129M+ MICA*036 6777

129M+ MICA*037 15031

129M+ MICA*041 5206

129M+ MICA*042 1446

129M+ MICA*043 12422

129M+ MICA*046 9962

129M+ MICA*050 6982

129M+ MICA*051 2046

129M-negative alleles 408 ± 153

MICA Epitope: 151V (provisional)

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT) Alloserum GP-MIC-12 positive

with MICA*011, which uniquely carries this epitope

GP MFI



151V+ MICA*011 2155

151V-negative alleles 221 ± 63

MICA Epitope: 156H (provisional)


Pre-transplant alloserum GP-MIC-13 Post-pregnancy serum GP-MIC-14

GP MFI



156H+ MICA*001 7319

156H+ MICA*002 4321

156H+ MICA*004 2918

156H+ MICA*006 1823

156H+ MICA*007 5111

156H+ MICA*008 2628

156H+ MICA*009 2702

156H+ MICA*011 3328

156H+ MICA*015 3217

156H+ MICA*016 1910

156H+ MICA*017 2363

156H+ MICA*018 7330

156H+ MICA*019 3385

156H+ MICA*028 1676

156H+ MICA*029 3455

156H+ MICA*030 2567

156H+ MICA*033 1997

156H+ MICA*036 2350

156H+ MICA*046 1645

156H+ MICA*050 2392

156H-negative alleles 931 ± 159

GP MFI

Positive control

Negative control

156H+ MICA*001 13011

156H+ MICA*002 8424

156H+ MICA*004 8456

156H+ MICA*005 4510

156H+ MICA*006 5556

156H+ MICA*007 7648

156H+ MICA*008 6318

156H+ MICA*009 6861

156H+ MICA*011 7070

156H+ MICA*015 6896

156H+ MICA*016 7791

156H+ MICA*017 5256

156H+ MICA*018 9094

156H+ MICA*019 7521

156H+ MICA*024 5426

156H+ MICA*028 7985

156H+ MICA*029 7602

156H+ MICA*030 5418

156H+ MICA*033 5364

156H+ MICA*036 8463

156H+ MICA*037 7294

156H+ MICA*041 7283

156H+ MICA*042 4402

156H+ MICA*046 5560

156H+ MICA*050 6374

156H+ MICA*051 7780

156H-negative alleles 162 ± 28

MICA Epitope: 156L (provisional)


Immunogenetics 61(2): 91-100. Post-transplant alloserum RJ reacts with MICA*012, which uniquely

carries an epitope reported as 155L

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT)Alloserum GP-MIC-15

GP MFI



156L+ MICA*012 1634

156L-negative alleles 339 ± 64

MICA Epitope: 173E (provisional)

Zou, Y., F. Mirbaha, et al. (2002). "MICA is a target for complement-dependent cytotoxicity with

mouse monoclonal antibodies and human alloantibodies." Hum Immunol 63: 30-39 Mouse

monoclonal antibodies 2.45F5 and 3.2H3 reacted in ELISA assays with MICA*004, *008 and *009

in a small panel. 173E is most likely epitope recognized by these antibodies


Serum was not tested for other 173E-carrying alleles (MICA*024, *027).

GP MFI



173E+ MICA*004 7261

173E+ MICA*006 5980

173E+ MICA*008 14758

173E+ MICA*009 7397

173E+ MICA*016 3550

173E+ MICA*019 8028

173E+ MICA*028 9082

173E+ MICA*033 4139

173E+ MICA*036 2693

173E-negative alleles 1020 ± 411

MICA Epitope: 173K (confirmed)


Immunogenetics 61(2): 91-100. Mapping of 173K-defined epitope detected by antibodies.

Communication from J. Mostecki (Gen-Probe, Stamford, CT:

Eluate after MICA*005 absorption of 16th IHIW

MICA exchange serum S006*

Sample #3, eluate after MICA*005 absorption

(poster, 2009 EFI poster):

Stastny, P. and Y. Zou (2013). "16th IHIW: Report of the MICA project." Int J Immunogenetics 40:

11-16. 16th Workshop specimen S006 came from a patient following a second renal transplant who

typed as MICA*004,*008 ; the second donor typed as MICA*009,*018. The recipient and donor

had no mismatches for HLA-A, -B, -DR, but the kidney was rejected one month post-transplant. All

nineteen 173K-carryting alleles reacted with S006; there were no false positive or false negative

reactions with the 28 MICA allele panel

GP MFI



173K+ MICA*001 3719

173K+ MICA*002 6068

173K+ MICA*005 4953

173K+ MICA*007 5456

173K+ MICA*011 4523

173K+ MICA*012 4588

173K+ MICA*015 5312

173K+ MICA*017 4784

173K+ MICA*018 5341

173K+ MICA*029 4974

173K+ MICA*030 4816

173K+ MICA*037 4978

173K+ MICA*041 3342

173K+ MICA*042 4693

173K+ MICA*043 5012

173K+ MICA*046 5213

173K+ MICA*050 5410

173K+ MICA*051 5156


GP MFI


Negative control 50

173K+ MICA*001 1717

173K+ MICA*002 2416

173K+ MICA*005 1935

173K+ MICA*007 2239

173K+ MICA*011 1848

173K+ MICA*012 1770

173K+ MICA*015 1885

173K+ MICA*017 1794

173K+ MICA*018 2007

173K+ MICA*029 1951

173K+ MICA*030 1869

173K+ MICA*037 1801

173K+ MICA*041 1353

173K+ MICA*042 1957

173K+ MICA*043 1815

173K+ MICA*046 1962

173K+ MICA*050 2053

173K+ MICA*051 2044


MICA Epitope: 175S


Immunogenetics 61(2): 91-100. Post-transplant alloserum p5-31 reactivity. Mapping of 175S-

defined epitope detected by antibodies.

Absorption with MICA*009 removed all reactivity; serum was not tested for other 175S-carrying

alleles (MICA*016, *033, *036).

MICA Epitope: 176I (provisional)


Immunogenetics 61(2): 91-100. Post-transplant alloserum p7-47 reacts only with MICA*006,

which uniquely carries this epitope. Mapping of 176I-defined epitope detected by antibodies.

MICA Epitope: 181R (provisional)


Immunogenetics 61(2): 91-100. Post-transplant alloserum G-495 reacts with MICA*004, which

uniquely carries this epitope. Mapping of 181R-defined epitope detected by antibodies.


Clinical Transplants: 175-194. The 181R-defined epitope was called #6006

Cox, S. T. (2011). The relevance and impact of MICA allele mismatching and MICA antibodies on

renal transplantation outcome, University College London (UCL). Ph.D. Dissertation.Transplant

case 194AH. The patient was MICA*008,- and serum reacted only with MICA*004 in Stastny and

Gen-probe kits. Antibodies may be specific for R at residue 181.

MICA Epitope: 206 GWS (provisional)


Immunogenetics 61(2): 91-100. Mapping of epitope defined by 206G,and 209W with MICA antibodies

in sera from transplant patient

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT) Sample #2, eluate after absorption

with MICA*028 (poster, 2009 EFI meeting)

GP MFI


Negative control 50

206GWS+ MICA*001 954

206GWS+ MICA*002 1618

206GWS+ MICA*007 1401

206GWS+ MICA*011 1111

206GWS+ MICA*012 1100

206GWS+ MICA*015 1436

206GWS+ MICA*017 1309

206GWS+ MICA*018 1230

206GWS+ MICA*028 1137

206GWS+ MICA*029 1196

206GWS+ MICA*030 1229

206GWS+ MICA*036 927

206GWS+ MICA*041 1343

206GWS+ MICA*043 1343

206GWS+ MICA*050 1374

206GWS+ MICA*051 1448

206GWS-negative alleles 90 ± 101

MICA Epitope: 206S2 (provisional)


Immunogenetics 61(2): 91-100.Post-transplant alloserum 226E03; absorption with MICA*008 and *009

transfected cells removed all reactivity. Mapping of an epitope defined by 206S and 210R with MICA

antibodies in sera from transplant patients

This reactivity pattern was named MICA group 2 (MICA-G2) by Zou et al, defined by residues 36Y, 129V,

173E, 206S, 210R and 215T. To identify the specific epitopes required for a MICA-G2 antibody to react,

hybrid recombinants of MICA*002 and MICA*008 were made by replacing residues at positions 173,

206, 210, 215 with residues of the other allele. The hybrid MICA*002 molecule carrying residues

173E/206S/210R/215T reacted with an eluate from MICA-G2-specific serum after absorption with

MICA*009 transfected cells, while the hybrid MICA*008 molecule carrying residues of MICA*002 did not,

showing that 36Y and 129V were not required for binding. No reactivity was seen with a hybrid

recombinant MICA*002 that had 173E substituted for 173K, showing that this position also was not

required for binding of that antibody.

MICA Epitope: 213I (confirmed)


Immunogenetics 61(2): 91-100. Antibodies reacted specifically an epitope shared by MICA*008 and

MICA*019, absorption with MICA*008 removed antibody activity. Mapping of a 213I-defined epitope

with MICA antibodies in sera from transplant patients


Clinical Transplants: 175-194. This epitope had possible 215I and/or 251R and was called #6007


16. 16th IHIW exchange serum S011 came from a transplant recipient who typed as MICA*002, *009;

donor typed as MICA*002:01, *08:01 . All six 213I-carrying MICA alleles reacted with S011, there were

no false positive or false negative reactions with the 28 MICA allele panel

Data from Justin Mostecki (Immucor, LifeCodes, Stamford, CT) Eluate after absorption with MICA*037

of 16th IHIW exchange serum S011


transplantation outcome, University College London (UCL). Ph.D. Dissertation.

GP MFI



213I+ MICA*008 3325

213I+ MICA*016 2922

213I+ MICA*019 2910

213I+ MICA*033 2530

213I+ MICA*037 2690

213I+ MICA*042 3202

213I-negative alleles 275 ± 44

EpiPedia of HLA - epregistry.com.br · 17RS (preliminary) on HLA-ABC El-Awar et al, Transplantation...

Documents

Transcript of EpiPedia of HLA - epregistry.com.br · 17RS (preliminary) on HLA-ABC El-Awar et al, Transplantation...